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SUMMARY 
With the exponential growth of genomic data, the pharmaceutical industry enter the 
post-genomic era and adopts a multi-disciplinary strategy is increasingly used to 
advance drug discovery. A large variety of specialties and general-purpose 
bioinformatics databases have been developed to store, organize and manage vast 
amounts of biomedical and genomic data. The first aim of this thesis is to develop or 
update three pharmainformatics databases: Therapeutic Target Database (TTD), 
Therapeutically Relevant Multiple Pathways (TRMP) database, and 
ADME-Associated Proteins (ADME-AP) database. These databases may serve as the 
basis for further knowledge discovery in drug target search analysis; drug 
pharmacokinetics and pharmacogenetics studies; and drug design and testing. 
TTD (http://bidd.nus.edu.sg/group/cjttd/ttd.asp) may be the world’s first public 
resource for providing comprehensive information about the reported targets of 
marketed and investigational drugs. There is a significant increase from that of ~500 
targets reported in a 1996 survey [1] to 1,535 targets in latest TTD version, indicating 
that more therapeutic targets and related information recorded in recent publications. 
This part of work is important for laying the foundations to more advanced studies 
about therapeutic targets. By using similar developing strategies, a database of known 
therapeutically relevant multiple pathways (TRMP, http://bidd.nus.edu.sg/group/trmp/ 
trmp.asp), was developed to facilitate a comprehensive understanding of the 
relationship between different targets of the same disease and also to facilitate 
mechanistic study of drug actions. It contains multiple and individual pathways 
information, and also include those relevant targets, disease, drugs information. 
Moreover, a new version of another pharmainformatics database, ADME-AP database 
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(http://bidd.nus.edu.sg/group/admeap/admeap.asp) has been updated in this work. A 
great number of polymorphisms and drug response information have been integrated 
into the old version. By analysis of this kind of information, we assess the usefulness 
of the relevant information for facilitating pharmacogenetic prediction of drug 
responses, and discuss computational methods used for predicting individual 
variations of drug responses from the polymorphisms of ADME-APs.  
With the completion of human genome sequencing and the rapid development of 
numerous computational approaches; continuous effort and increasing interest have 
been directed at the search of new targets, which has led to the identification of a 
growing number of new targets as well as the exploration of known targets. As a 
result, the second aim of this thesis is to carry out a computational study of 
therapeutic targets.  
Firstly, the progress of target exploration is studied and some characteristics of 
currently explored targets, including their sequence, family representation, pathway 
association, tissue distribution, genome location are analyzed. Moreover, from these 
target features, some simple rules can be derived for facilitating the search of 
druggable proteins and for estimating the level of difficulty of their exploration, 
including (1) Protein is from one of the limited number of target families; (2) 
Sequence variation between protein’s drug-binding domain and those of the human 
proteins in the same family allows differential binding of a “rule-of-five” molecule; (3) 
Protein preferably has less than 15 human similarity proteins outside its family (HSP); 
(4) Protein is preferably involved in no more than 3 human pathways (HP); (5) For 
organ or tissue specific diseases, protein is preferably distributed in no more than 5 
human tissues (HT); (6) A higher number of HSP, HP and HT does not preclude the 
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protein as a potential target, it statistically increases the chance of undesirable 
interferences and the level of difficulty for finding viable drugs. The results indicate 
that some simple rules can be derived for facilitating the search of druggable proteins 
and for estimating the level of difficulty of their exploration. 
Secondly, to test the feasibilities of target identification by using Artificial Intelligent 
(AI) methods from protein sequence, an AI system is trained by using sequence 
derived physicochemical properties of the known targets. Furthermore, this prediction 
system is evaluated by using 5-fold cross validation and scanning human, yeast, and 
HIV genomes. The prediction results are consistent with previous studies of these 
genomes, which suggest that AI methods such as Support Vector Machines (SVMs) 
may be potentially useful for facilitating genome search of druggable proteins. With 
more biomedical data added in, the preliminary prediction system of druggable 
proteins will be extended and consolidated for speeding up the process of drug 
discovery.
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1 Introduction 
1.1 Overview of target discovery in pharmaceutical 
research 
Due to the modern life style, an increasing number of people are suffering from 
various health problems. How to deal with those problems has become the research 
focus of many biomedical scientists in both academic and pharmaceutical industry [2]. 
Thus, most scientists pay close attention to drug discovery. It is generally agreed that 
finding effective drugs for specific disease is an essential way to solve the health 
problems [2]. In addition, with the advent of molecular biology, the completion of 
human genome project and the rapid development of numerous computational 
approaches, more innovative biological concepts and technologies have been 
introduced into drug discovery [3-5]. These innovations are essential for constructing 
modern drug discovery programs in which target discovery plays an important role 
[3].  
1.1.1 Process of drug discovery 
Drug development is generally a long, costly and uncertain process. Figure 1-1 
illustrates the process of drug discovery, which can be roughly divided into two 
phases [6]. One is the early pharmaceutical research phase and the other is the late 
phase. The former mainly comprises preliminary investigations, target discovery and 
lead discovery. The latter consists of preclinical and clinical evaluation. According to 
the Tufts Center for the study of drug development (November, 2001), by using 
traditional drug discovery methods, developing a new marketed drug takes 10-15 
years, and spends about $800 million USD.  
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Figure 1-1: Overview of drug discovery process [6] 
 
How to efficiently reduce the cost and the time of drug discovery is a major task of 
current research. As revealed by Figure 1-1, at certain drug design stages, the use of 
computational technologies would be a feasible way to solve this problem. Moreover, 
most drug discovery activities begin with target discovery, which involve the 
identification and early validation of disease modifying targets. Therefore, 
computational study of the target characteristics and developing computer target 
prediction methods are significant for understanding the mechanism of drug action 
and thus speeding up new target discovery [3, 7]. 
1.1.2 Brief introduction to target discovery 
Generally, target discovery includes two parts: target identification and target 
validation [6]. Target identification attempts to find new targets, normally proteins, 
which can be modulated by modulators, such as small molecules and peptides, and 
thus inhibit or reverse disease progression. For target validation, it plays a crucial role 
in demonstrating the function of potential targets in the disease phenotype. The 
various techniques applied to target discovery can be grouped into two broad 























Technology is impacting this process 
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focus is on the study of disease in whole organisms. The information used in this 
approach is derived from the clinical science and in vivo animal studies. Thus the 
system approach has traditionally been the primary target discovery strategy in drug 
discovery. By contrast, molecular approach attempts to identify the novel targets 
through an understanding of the cellular mechanisms. This approach has been driven 
by the development of molecular biology, genomics and proteomics in recent decades. 
As a result, it has become an important strategy in modern target discovery. 
1.1.2.1 Traditional target discovery 
Historically, traditional target discovery, in which classical system approaches are 
usually used, predominated in the 1950s and 1960s [9]. To date, it is still relevant for 
many disease cases in which the related disease phenotypes can only be detected in 
the organism, such as some complex diseases responsible for phenotypic differences 
in genetically identical organisms [10]. In traditional routes, therapeutic target 
identification is just performed in two ways, either from randomly screening possible 
targets known or from clues given by traditional remedies [9]. Obviously, finding a 
good therapeutic target only by chance or experience makes target identification 
uncertain and inefficient. In addition, traditional target validation relies predominantly 
on experimental work in the laboratory by studying animal models in vivo. This is 
also a long-term work and needs continuous investment. Since the whole traditional 
process is expensive and time-consuming, construction of new modern target 
discovery system has become an urgent focus in drug research and development.  
1.1.2.2 Modern target discovery 
Since the late 1990s, as new molecular biology, especially genomic science, novel 
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genetic techniques, bioinformatics tools and in silico analysis have been integrated 
into drug research and development. Target discovery has gradually become a 
cross-disciplinary science, driven not only by biomedical science, pharmacology and 
chemistry but also by computational technology [4]. In modern target discovery, 
scientists mainly focus on specific molecular targets encoded by disease related 
essential genes of known sequence with novel, proven physiological function [5]. 
Instead of following traditional routes, in which an animal model of disease to yield a 
target is applied, current target discovery takes advantage of genomics data and 
bioinformatics techniques. For instance, the genomics information of therapeutic 
targets is analyzed by computational approaches from which useful information is 
generated, which is applied to improve the process of target discovery and ultimately 
to reduce the cost and time needed for drug discovery.  
1.2 Overview of bioinformatics and its role in 
facilitating drug discovery 
In 1988, the Human Genome organization (HUGO), an international organization of 
scientists involved in Human Genome Project, was founded. Just two years later, the 
Human Genome Project (HGP) was started. By referring to the international 13-year 
effort, this project was completed in 2003 successfully. All of the estimated 
20,000-25,000 human genes were discovered and made accessible for further 
biological study. In addition, another goal of HGP, determination of the complete 
sequence of the 3 billion DNA subunits (bases in the human genome), is currently 
under way.  
Undoubtedly, the completed human genome sequence, a grand achievement of HGP, 
provides tremendous opportunities for pharmaceutical research. Despite the 
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opportunities, there are many challenges, such as identifying the genes 
(protein-coding regions, structural RNAs, enzymatic RNAs and regulatory sequences) 
and other functional fragments (DNA-binding sites, promoters, termination sites, etc.) 
from the vast raw genome sequence, understanding physiological function of the 
proteins or peptides coded by those genes, correlating disease states to certain genes 
and figuring out the potential protein-protein interactions and their pathways in 
various situations including pathological conditions. So many promising challenges 
excite everyone in post-genomic era. However, the problem is that a vast amount of 
biological data has been generated by mapping human genome. Now, more than ever, 
scientists need sophisticated computational techniques to store, organize, manage, and 
analyze these genomic data, which belongs to a new discipline named bioinformatics. 
1.2.1 Brief introduction to bioinformatics 
Bioinformatics is an interdisciplinary research area that crosses between biology, 
computer science, physics, mathematics and statistics. As described by National 
Institutes of Health (NIH), bioinformatics is the “research, development, or 
application of computational tools and approaches for expanding the use of biological, 
medical, behavioral or health data, including those to acquire, store, organize, archive, 
analyze, or visualize such data” [11]. In brief, bioinformatics are used to “address 
problems related to the storage, retrieval and analysis of information about biological 
structure, sequence and function” [12]. Even if bioinformatics is a new term, some of 
the major events in bioinformatics occurred long before it was coined. Generally, the 
development of bioinformatics passed through several phases (Table 1-1).  
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Table 1-1: A brief history of bioinformatics 
Phases Important events Year 
Before 
1950s 
Gregory Mendel: “Genetic inheritance” theory 1865 
Alfred Day Hershey & Martha Chase: Proving that DNA alone carries genetic information 1952 
Watson&Crick: Proposing the double helix model for DNA based x-ray data obtained by 
Franklin &  Wilkins 
1953 




Frederick Sanger: analyzing the sequence of the first protein “bovine insulin” 1955 
Sidney Brenner, Franšois Jacob, Matthew Meselson: identifying messenger RNA 1961 
Pauling: theory of molecular evolution  1962 
Margaret Dayhoff: Atlas of Protein Sequences  1965 
1960s 
The ARPANET: created by linking computers at Standford and UCLA 1969 
Needleman-Wunsch algorithm developed: sequence comparison 1970 
Paul Berg’s group: creating the first recombinant DNA molecule  1972 
The Brookhaven Protein DataBank is announced  1973 
Vint Cerf & Robert Khan: developing the concept of connecting networks of computers into 
an "internet" and developing the Transmission Control Protocol (TCP) 
1974 
Bill Gates and Paul Allen: Microsoft Corporation (Popularization of personal computers 
from 1980s) 
1975 
P.H.O'Farrel: Two-dimensional electrophoresis, where separation of proteins on SDS 
polyacrylamide gel is combined with separation according to isoelectric points.  
1975 
1970s 
Staden: DNA sequencing and software to analyze it  1977 
Smith-Waterman algorithm developed  1981 
Doolittle: The concept of a sequence motif  1981 
GenBank  1982 
Phage lambda genome sequenced  1982 
Wilbur-Lipman algorithm developed: Sequence database searching algorithm  1983 
FASTP/FASTN: fast sequence similarity searching  1985 
The Human Genome Organization (HUGO) founded 1988 
National Center for Biotechnology Information (NCBI) created at NIH/NLM  1988 
EMBnet network for database distribution  1988 
Pearson and Lupman: The FASTA algorithm for sequence comparison 1988 
1980s 
The genetics Computer Group (GCG) becomes a private company. 1989 
The Human Genome Project: Mapping and sequencing the Human Genome 1990 
Altschul,et.al.: The BLAST program for fast sequence similarity searching  1990 
ESTs: expressed sequence tag sequencing  1991 
The research institute in Geneva (CERN): announcing the creation of the protocols which 
make -up the World Wide Web. 
1991 
Sanger Centre, Hinxton, UK  1993 
EMBL European Bioinformatics Institute, Hinxton, UK  1994 
Netscape Communications Corporation founded and releases Naviagator, the commercial 
version of NCSA's Mozilla. 
1994 
Attwood and Beck: The PRINTS database of protein motifs 1994 
First bacterial genomes completely sequenced: Haemophilus influenza genome (1.8 Mb) 
and Mycoplasma genitalium genome 
1995 
Yeast genome completely sequenced: Saccharomyces cerevisiae (baker's yeast, 12.1 Mb) 1996 
Bairoch, et.al.: The prosite database  1996 
Affymetrix produces the first commercial DNA chips 1996 
PSI-BLAST  1997 
The genome for E.coli (4.7 Mbp) is published 1997 
deCode genetics publishes a paper that described the location of the FET1 gene, which is 
responsible for familial essential tremor, on chromosome 13 (Nature Genetics).  
1997 
Worm (multicellular) genome completely sequenced  1998 
The genomes for Caenorhabitis elegans and baker's yeast are published 1998 
1990s 
The Swiss Institute of Bioinformatics 1998 
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First Human Chromosome 22 to be sequenced: Human Chromosome 22 completed 1999 
Fly genome completely sequenced  1999 
deCode genetics maps the gene linked to pre-eclampsia as a locus on chromosome 2p13.  1999 
Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL: The large-scale organization of 
metabolic networks 
2000 
Drosophila genome completed: D.melanogaster genome (180 Mb) 2000 
The genome for Pseudomonas aeruginosa (6.3 Mbp) is published 2000 
Draft Sequences of Human Chromosomes 5, 16, 19 Completed 2000 
Human Chromosome 21 Completed 2000 
The completion of a "working draft" DNA sequence of the human genome 2000 
The initial analysis of the working draft of the human genome sequence 2001 
Human Chromosome 20 Completed 2001 
Draft sequence of Fugu rubripes 2002 
Draft sequence of mouse genome 2002 
Human genome project completion (1990-2003) 2003 
Human Chromosome 14, Y, 7, 6 Completed 2003 
Human Chromosome 13, 19, 10, 9, 5 Completed 2004 




The entries in Table 1-1 shows that the most significant progress in bioinformatics has 
been made remarkably in the last thirty years. With the invention of various sequence 
retrieval methods in 1970-80s, increasingly sophisticated sequence alignment 
algorithms were developed. In 1980s, scientists used computational tools to predict 
RNA secondary structure, and then began to predict protein secondary structure or 3D 
structure. In addition, the FASTA for sequence comparison and BLAST algorithm for 
fast sequence similarity searching were published in 1980-90s and they dramatically 
impelled the bioinformatics forward. Since 1990, many of new biotechnologies, 
including automatic sequencing, DNA chips, protein identification, mass 
spectrometers, etc., have been applied more and more widely. Numerous biological 
data have been produced continuously. Furthermore, large quantities of sequence data 
have also been generated by mapping and sequencing genomes of the human and 
other species. Table 1-2 gives some examples about the statistic data of the biological 
information space as of Feb 2005.  
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Table 1-2: The biological information space as of Feb 11th, 2005 
Type of information Number of entries/records 
Nucleotides 44,575,745,176 
Nucleotide records 49,127,925 
Protein sequences 5,785,962 
3D structures in PDB 28,905 
BIND Interactions 134,886 
Human Unigene Cluster 52,888 
Completed Genome project 238 
Different taxonomy Nodes 249,219 
dbSNP records 18,883,945 
RefSeq Genomic records 180,770 
RefSeq RNA Records 352,275 
RefSeq Protein Records 1,310,899 
GenSAT images 98,680 
GEO profiles 11,288,275 
Homologene gene 38,137 
PubChem compounds 897,246 
PubMed records 15,382,675 
PubMed Central records 341,602 
OMIM records 16,521 
 
Obviously, it is impossible to deal with these data manually. These huge data sets 
contain vital information for quantitative study of biology which is expected to 
revolutionize biology and medical research. On the one hand, the biology and 
medicine should not only be treated as specific biochemical technologies, but also as 
an information science. On the other hand, as more biological information becomes 
available and laboratory equipment becomes more automated, it is necessary to 
explore the use of computers and computational methods for facilitating experimental 
design, data analysis, simulation and prediction of biological phenomena and 
processes. Meanwhile, the use of computational methods can also improve the speed 
and efficacy, and reduce the cost of experimental studies.  
At present, there are three primary public domain bioinformatics servers (Figure 1-2): 
National Center for Biotechnology Information (NCBI: http://www.ncbi.nlm.nih. 
gov/), European Bioinformatics Institute (EBI: http://www.ebi.ac.uk/), and Center for 
Information Biology (CBI: http://www.ddbj.nig.ac.jp/). Basically, each server 
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performs two parts of task. One is to develop and provide databases to efficiently 
store and manage data. The other is to invent useful bioinformatics algorithms and 
tools to analyze the data and generate new knowledge for biological and medical use. 
With the exponential growth of sequences, structures, and literature, bioinformatics 
databases are playing an increasingly crucial role in biological data management and 
knowledge discovery [13-16].  
 
Figure 1-2: Primary public domain bioinformatics servers 
 
1.2.2 Brief introduction to bioinformatics databases 
Bioinformatics is the science of using information to understand biology [17]. The 
core of bioinformatics is the organization of information into databases. 
Bioinformatics database is an organized, integrated and shared collection of logically 
related bioinformatics data, which represent any meaningful objects and events in life 
science. These data can be transformed into information through data modeling, and 
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Historically, the first bioinformatics database was established a few years after the 
first protein sequences became available. The first protein sequence (bovine insulin) 
was reported by Frederick Sanger at the end of 1950s [18]. It just consists of 51 
residues. In 1963, the first tRNA molecule to be sequenced was the yeast alanine 
tRNA with 77 bases by Robert Holley and co-workers [19]. After that, Margaret 
Dayhoff gathered all the available sequence data to create the first bioinformatics 
database–Atlas of Protein Sequence and Structure [20-22], which is the origin of 
PIR-International Protein Sequence Database [23]. The Brookhaven National 
Laboratory’s Protein Data Bank (PDB) followed in 1972 with a collection of the 
X-ray crystallographic protein structures [24] and it was considered as the first 
bioinformatics database, which stored and managed 3D protein structure data by using 
computational and mathematical techniques. In 1980s, due to the invention of 
automated DNA sequencing technology, the exponential growth of large quantities of 
DNA sequence data and associated knowledge came into being, and finally became 
the significant driving force for the development of bioinformatics database. The 
biological data and knowledge needs to be stored in a computationally amenable form, 
which can be shared by the bioinformatics community for both humans and 
computers. The Swiss-Prot, an important annotated protein sequence database, was 
established in 1986 and maintained collaboratively, since 1987, by the group of Amos 
Bairoch first at the Department of Medical Biochemistry of the University of Geneva 
and now at the Swiss Institute of Bioinformatics (SIB) and the European Molecular 
Biology Laboratory (EMBL) Data Library [25].  
Subsequently, a huge variety of diverse bioinformatics databases have been growing 
either in the public domain or commercial third parties. Figure 1-3 summarizes the 
development trend of Molecular Biology Database (MBD) collected by Nucleic Acids 
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Research from 1999 to 2005. In comparison with 202 MBDs in 1999, the total 
number of MBD in 2005 was 719. It was about 3.5 times than that of in 1999 and the 
increase rate reached 256%. The data indicates that the development of MBD is likely 
to have a continuous upward tendency in the following years. According to the latest 
database issue of Nucleic Acids Research (NAR) [26], to date, more than 700 
different databases covering diverse areas of biological research, including sequence, 
structure, genetics, genomes, proteomics, intermolecular interactions, pathways, 
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Figure 1-3: Molecular biology database collection in NAR (1999~2005) [26] 
 
On the basis of the scope of databases, a biological database can be grouped into three 
categories [27]: general biological databases, which store the raw data of 
DNA/protein sequence, structure, biological and medical literature; derived databases, 
whose data are derived from the general biological databases, however, contain novel 
information; and subject-specialized databases, which collect individual, specialized 
information for the communities of particular interests. Besides the diverse area 
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covered by different kinds of bioinformatics databases, the application of biological 
databases is broad, both in the academia and industries. In our research, three 
pharmainformatics* databases: Therapeutic Target Database (TTD), Therapeutically 
Relevant Multiple Pathways (TRMP) database, and ADME-associated Proteins 
(ADME-AP) database, which are specific bioinformatics databases applied in 
biomedical science, are developed or updated and their applications in drug discovery 
are also discussed.  
1.3 The need for computational study of therapeutic 
targets and ADME-associated proteins 
Usually, general bioinformatics databases are useful for studying general genetics, 
proteomics, and structural problems, but they are not designed for providing 
information of proteins relevant to drug discovery. However, for many 
pharmaceutical researchers, sometimes they are more interested in specific knowledge 
in their research area. For instance, which kinds of proteins could be considered as 
potential therapeutic targets? Is there any specific databases providing information 
about drug absorption, distribution, metabolism and excretion associated proteins 
(ADME-APs) or disease relevant therapeutic pathways? Obviously, there is a need to 
develop special pharmainformatics databases dedicated to drug studies. 
1.3.1 The need for development of pharmainformatics 
databases 
1.3.1.1 Therapeutic target database 
Researches have shown that the paradigm of modern drug discovery is built on the 
                                                        
*Pharmainformatics is the integration of Bioinformatics & Cheminformatics. 
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search of drug leads against a pre-selected therapeutic target, which is followed by 
testing of the derived drug candidates [9, 28, 29]. So far, continuous efforts in target 
discovery have been made in the exploration of the targets of highly successful drugs, 
and identification of new targets [1, 6, 9, 28, 29]. Furthermore, the search for new 
targets and the study of existing targets are facilitated by rapid advances in protein 
structures [30], proteomics [31], genomics [32, 33], and molecular mechanism of 
diseases [34, 35]. Currently, scientists mainly use these technologies for finding clues 
to new target identification and for probing the molecular mechanisms of drug action, 
adverse drug reactions, and pharmacogenetic implication of variations. Undoubtedly, 
the advances and development of target identification and validation technologies will 
lead to the discovery of a growing number of new and novel targets. Drews and Ryser 
[36] reported that there were ~500 targets underlying current drug therapy undertaken 
in 1996, 120 of which have been reported to be the identifiable targets of currently 
marketed drugs [37]. In the subsequent few years, Drews [9] and other researchers [37] 
made some analysis based on the ~500 targets, including distribution of target 
biochemical class and estimation of possible target number of human species. 
Due to increasing exploration of disease-specific protein subtypes of existing targets 
and new information about previously unknown or un-reported targets of existing 
drugs and investigational agents, the number of successful and research targets should 
significantly increase. However, there is no updated list available on therapeutic target. 
Up to date, almost all review articles about therapeutic targets are based on the targets 
list reported by Drews and Ryser in 1997 [36]. Thus, it is necessary to develop a 
specific pharmainformatics database for providing timely information of the known 
and newly proposed therapeutic protein and nucleic acid targets described in the 
established publications.  
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1.3.1.2 Therapeutically relevant multiple pathways database 
Proteins and nucleic acids that play key roles in disease processes have been explored 
as therapeutic targets for drug development [9, 29]. Knowledge of these 
therapeutically relevant proteins and nucleic acids has facilitated modern drug 
discovery by providing platforms for drug screening against a pre-selected target [9]. 
It has also contributed to the study of the molecular mechanism of drug actions, 
discovery of new therapeutic targets, and development of drug design tools [37, 38]. 
Information about non-target proteins and natural small molecules involved in these 
pathways is also useful in the search of new therapeutic targets and in understanding 
how therapeutic targets interact with other molecules to perform specific tasks. 
A number of web-based resources of therapeutically-targeted proteins and nucleic 
acids are available [39, 40], which provide useful information about the targets of 
drugs and investigational agents. While information about multiple pathways can be 
obtained from the existing individual pathway databases, interfaces that integrate 
multiple pathway maps may provide more convenient platforms for facilitating the 
analysis of the collective effects of different proteins in separate pathways. Moreover, 
the existing databases either include significantly more number of pathways than 
therapeutic ones or they are intended for specific types of pathways that do not cover 
all of the therapeutic ones, which can sometimes make the search of therapeutically 
relevant constituents less convenient. It is thus desirable to have a database 
specifically designed as a convenient source of information about therapeutically 
relevant multiple pathways to complement existing databases. 
In addition, crosstalk between proteins of different pathways is common phenomena 
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and these often have therapeutic implications [41-48]. Cocktail drug combination 
therapies directed at multiple targets have been explored for a number of diseases 
including AIDS [49], cancer [50, 51], Alzheimer disease [52], amyotrophic lateral 
sclerosis [53], and dyslipidemia [54]. These prompted interest for more extensive 
exploration of synergistic targeting of multiple targets in drug discovery [55]. 
Potentially harmful interactions arising from multiple targeting are also closely 
watched and studied [56]. Effective drugs with robust phenotypic effects are known to 
simultaneously affect many proteins in different pathways [55]. For instance, in 
addition to interacting with its main target protein cyclooxygenase, anti-inflammatory 
drug aspirin is known to affect NF-kappa B pathway and other connected cellular 
targets that normally contribute to perpetuate the inflammatory state [57, 58]. 
Therefore, it is necessary for us to develop a therapeutically relevant multiple 
pathway database to facilitate the analysis of the potential implications of multiple 
target-based therapies and for mechanistic study of drug effects. 
1.3.1.3 ADME-associated protein database 
Inter-individual variations in drug response are well recognized and these variations 
are frequently associated with polymorphisms in the proteins involved in  
ADME-APs [59-61] as well as those in therapeutic targets and drug adverse reaction 
(ADR) related proteins [62, 63]. Pharmacogenetic study with respect to these proteins 
and their regulatory sites is important for the understanding of molecular mechanism 
of drug responses and for the development of personalized medicines and optimal 
dosages for individuals [59, 64-67]. Nearly 100,000 putative single-nucleotide 
polymorphisms (SNP) have been identified in the coding regions of human genome 
[68, 69], some of which have been linked to substantial changes in drug response and 
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used for the analysis of individual variations to drug therapies [59-61, 70, 71]. 
Sequence polymorphism is only one of the factors for variations of drug responses. 
Other factors include altered methylation of genes, differential splicing of mRNAs, 
and differences in post-transcriptional processing of proteins such as protein folding, 
glycosylation, turnover and trafficking [63]. Thus, in addition to polymorphisms, 
there is a need to investigate the effects of transcriptional and post-transcriptional 
profiles of ADME-APs as well as therapeutic targets and ADR-related proteins.   
Knowledge of ADME-APs is not only useful for the identification of 
pharmacogenetic polymorphisms, but also enables a focused study of polymorphisms, 
transcriptional and post-transcriptional profiles that alter the function or drug affinity 
of the target [66]. However, for most drugs, not all of the ADME-APs responsible for 
their metabolism and disposition are known. As a result, in many cases, molecular 
study of the pharmacokinetic aspect of pharmacogenetics may need to be based on the 
study of ADME-APs to find out which proteins are responsible for the metabolism 
and disposition of a particular drug, and how the polymorphisms, transcriptional and 
post-transcriptional profiles of these proteins determine the individual variations to 
that drug. 
Up to date, a number of freely-accessible internet databases have appeared which 
provide useful information about drug ADME-APs as well as therapeutic and drug 
toxicity targets [40, 72, 73]. Although they provide comprehensive knowledge about 
ADME-APs, most of these databases are just for specific groups of ADME-APs. 
Moreover, information about reported polymorphisms and pharmacogenetic effects of 
ADME-APs is seldom mentioned. Thus, it is desirable to complete the ADME-AP 
database, which can provide basic biological information about ADME-APs and also 
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reported pharmacogenetic relevant information. Such information contained in 
ADME-AP database can reach a meaningful level for facilitating biomedical research. 
As a result, ADME-AP database may serve as a useful resource for comprehensively 
understanding pharmacogenetics.  
1.3.2 In silico mining of therapeutic targets  
As described in previous section, it is important for the drug discovery communities 
to explore the current targets in the literature, which is a good way to find new 
therapeutics and more effective treatment options. According to computational 
analysis of therapeutic target, at present, the major concern of many researchers is 
about the estimation of the total number of human targets [37, 74, 75]. Hophins and 
Groom [37] statistically analyzed the disease genes and related proteins and suggested 
that the total number of the estimated potential targets in the human genome ranges 
from 600 to 1,500. Moreover, by investigating the yeast genome, they found that 
antifungal targets constitute 2-5% of the whole genome in yeast. Assuming a similar 
percentage of targets in disease-related microbial genomes, the number of potential 
targets in disease-related microbial genomes can be roughly estimated as >1,000. 
Miller and Hazuda [74] pointed out that a typical viral genome contains 1-4 targets, 
which gives a crude estimate of >100 potential targets in disease-related viral 
genomes. According to this, the total number of distinct targets is likely to be within 
range of 1,700~3,000. In another research done by Wen and Lin [75] in 2003, a 
similar estimation was obtained.  
One way to assess the opportunities available for pharmaceutical industry is to begin 
by studying human genome and searching those genes relevant to drugs and diseases. 
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However, in the human genome, there are up to 22,300 or so genes currently [76]. 
Mining useful information from such large data set may be an extremely tough work 
for pharmaceutical scientists. As a result, knowledge discovery from current known 
targets is very important. Some meaningful work, such as generating some common 
rules describing targets and druggable proteins prediction by computational approach, 
would be done for facilitating to cut down the range of genes needed to be studied and 
speeding up the target discovery. 
1.4 Objective and scope of the thesis 
Generally, the research was planned to complete two main aspects of work. The first 
aspect was concerned development of pharmainformatics databases; the second aspect 
of this research involved in silico mining the therapeutic targets and ADME-AP data 
by using bioinformatics tools. Therefore, 
z The first objective was to launch the new version of TTD, which was first 
published in 2002 [39]. Accordingly, we optimized the database structure, 
completed data validation and updating, and provided some more important 
information on the current therapeutic targets. In addition, the web interface was 
improved to be more user-friendly and the query methods were enhanced to 
support complex searching. 
z The second objective was to develop a TRMP database, which was to give 
information about inter-related multiple pathways of a number of diseases and 
physiological processes. 
z The third objective was to update the database of ADME-APs, which was first 
launched in 2002 [73]. Especially, information about reported polymorphisms and 
pharmacogenetic effects were integrated into the ADME-AP database. 
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Furthermore, we also statistically analyzed reported polymorphisms and drugs 
with altered responses linked to protein.  
As we know, target discovery is highly dependent upon a correct understanding of the 
information generated from lots of therapeutic targets and drug ADME-APs. 
Therefore, another significant objective of this research was to carry out 
computational analysis of therapeutic targets and drug ADME-APs data. Regarding 
the pharmacogenetic information of ADME-APs, the purpose of this part of study was 
to discuss how to use the relevant information of ADME-APs for facilitating 
pharmacogenetics research. Particularly, we studied the feasibility of predicting 
pharmacogenetic response to drugs. The other important part of the study aimed to 
provide an overview of the progress in the exploration of therapeutic targets and to 
investigate the characteristics of these targets for finding some useful clues which 
could facilitate the search of new targets. Basically, this objective was planned to be 
achieved in two steps. 
z Firstly, based on the primary information provided by TTD, secondary 
information could be retrieved from other general biological databases, including 
the sequence, structure, family representation, pathway association, tissue 
distribution, genome location features, etc. Subsequently, the main characteristics 
of all successful and research targets could be generated by taking advantage of 
the secondary information.  
z Secondly, we studied the possible rules for guiding the search of druggable 
proteins and discussed the feasibility of using a statistical learning method, 
Support Vector Machines (SVMs), for predicting druggable proteins directly 
from their sequences.  
At present, TTD may be the world’s first public comprehensive database for 
Chapter 1                                                                 Introduction 
 - 29 - 
therapeutic targets. It may serve as an essential data resource for target research and 
development in drug discovery area. Results of this study may suggest several 
common rules for therapeutic targets. The clues based on the knowledge of existing 
targets are useful for new target identification. It is also important for the molecular 
dissection of the mechanism of action of drugs, the prediction of features that guide 
new drug design, and the development of tools for these tasks. Moreover, this 
research may provide an alternative solution rather than BLAST to predict druggable 
proteins. Principally, analysis of these targets may provide useful information about 
general trends, current focuses of research, areas of successes and difficulties in the 
exploration of therapeutic targets for the discovery of drugs against specific diseases. 
About the scope of the thesis, therapeutic target data used here depend mainly on the 
collections in the TTD, and unavoidably we may miss some therapeutic targets, which 
have not been collected by TTD yet. Furthermore, computational analysis of 
therapeutic targets focuses mainly on the ones whose annotations are adequate. In 
addition, this thesis considers the problem of data classification in high dimensional 
space. Generally, there are two different strategies for protein data classification. One 
is structure based approach, including molecular dynamics, molecular mechanics, and 
geometry methods. The other is sequence based approach, including decision tree, 
artificial neural networks, and SVMs. In this thesis, we made use of only SVMs to 
predict druggable proteins. 
1.5 Layout of the thesis 
As introduced above, the problems addressed in this thesis have been focused on 
pharmainformatics database development, computational study of therapeutic targets 
and ADME-APs. In the coming chapters, a brief introduction to the methods used in 
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this study was discussed, and this included the strategy of database development and 
basic theory for SVMs, a computational methods used for data analysis. In chapter 3, 
by using the similar database developing strategy, two pharmainformatics databases 
were constructed and presented. Due to similar developing strategy, the detail about 
how the ADME-AP database was constructed was omitted and integrated its brief 
introduction into the computational analysis section.  
Moreover, applications based on the TTD were also carried out to facilitate target 
discovery. In chapter 4, on the basis of therapeutic target data, the progress of target 
exploration was summarized and the characteristics of the currently explored targets 
were analyzed. Subsequently, chapter 5 described how to use SVMs to in silico 
predict druggable proteins. Chapter 4 and 5 would be considered as the most 
important chapters in this study. In chapter 6, ADME-AP database was updated and a 
discussion on how to use the ADME-APs data to facilitate pharmacogenetics research 
was presented. Finally, conclusion was made in the final chapter.
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2 Methodology 
2.1 Strategy of pharmainformatics database 
development 
Even though pharmainformatics databases have different sorts of applications in 
scientific research, the strategy of database development follows similar basic ideas. 
Thus, this chapter describes general strategy of knowledge-based pharmainformatics 
database development. The similar strategies have been extended to the construction 
of TTD, TRMP database, and ADME-AP database, which are discussed in later. 
Generally, the development of a database is a complicated and time-consuming 
process, including preliminary planning, information collection, database construction, 
and database access and representation. Here a stage by stage development of the 
database is discussed.  
2.1.1 Preliminary plan of the pharmainformatics database 
Making a preliminary plan before the start of the database development may help to 
focus on relevant points and not gather unnecessary information. In this stage, the 
objective and content of the database should be seriously considered and determined.  
As described in previous chapter, target discovery plays a very important role in drug 
research and development. It is essential for biomedical researcher to know more 
about therapeutic targets, therapeutic relevant pathways, and ADME-APs. However, 
up to date, there is no similar pharmainformatics database that provides this specific 
information. Thus, the development of such a kind of knowledge-based 
pharmainformatics databases will be meaningful. To conclude, the database will meet 
the expectations of those corresponding researchers, afford them what they want, and 
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help them find further information they need. After preliminary consideration of the 
whole database, a detail description of the database development will be presented. 
2.1.2 Collection of pharmainformatics database information 
Normally, a knowledge-based pharmainformatics database is supposed to provide 
enough domain knowledge around a specific subject in pharmacology. For instance, 
therapeutic target database will let users know about some biological information for 
specific therapeutic target, relevant disease conditions, and drugs/ligands 
corresponding to this target, and so on. Thus, for every pharmainformatics database 
entry, there are several different knowledge domains. Some of them provide basic 
introduction to entries themselves, and some others give information derived from 
entries or relevant to entries. 
The information mentioned above can be selected from a comprehensive search of 
available literatures including pharmacology textbooks, review articles and a large 
number of other publications. With respect to different type of information, we use 
different collecting methods. The subject of database, such as therapeutic target, 
therapeutic pathways, and ADME-APs, is the primary focus. Thus, in the first step, 
we collect reliable subject information. At present, no ready index or library is 
available and almost all the relevant information is scattered in various biological and 
medical literatures. Therefore, literature information extraction is the only feasible 
way to collect the essential biological and medical information. It is generally agreed 
that literatures are typically unstructured data source. In addition, the names of the 
subject, which may be in some synonymous terms, various abbreviations, or totally 
different expression, are difficult to be recognized by automatic language processing. 
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A fully automated literature information extraction system, thus, cannot be invented 
to gather useful information from literature efficiently.  
In this study, automatic text mining methods with manual reading process was 
combined. Simple automated text retrieval programs developed in PERL were used to 
screen the literature that contained the key word related to searching the subject in 
local Medline abstract packages [77]. Then, the useful subject information was picked 
up manually from these matched Medline abstract. If necessary, the full literature was 
referred to facilitate information searching. Meanwhile, in many cases, the relevant 
information about the same subject could also be found in the same literature. Thus, in 
the first step, not only subject but also relevant information could be obtained and 
recorded. In the second step, detail biological information of subject was 
automatically selected from some relevant general or specific biological databases, 
such as SwissProt, GeneCard, etc., by text mining programs. Likewise, some other 
information derived from the subject was also extracted from the corresponding 
databases in the same way. After information collection, a consideration how to store, 
organize and manage the data by using database techniques was discussed. In the next 
section, the database construction is described. 
2.1.3 Organization and structure of pharmainformatics 
database  
A good database system enables the user create, store, organize, and manipulate data 
efficiently. By integrating databases and web sites, users and clients can open up 
possibilities for data access and dynamic web content. An integrated information 
system of our pharmainformatics database is constructed according to some 
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standardization strategies as follows: 
z Establishment of standardized data format and appropriate data model 
z Database structure construction 
z Development of Database Management System (DBMS)  
Since the original data information collected in previous section is independent, the 
first major activity of a database construction process includes creation of digital files 
from these information fragments and construction of an appropriate data model.  
2.1.3.1 The data model 
The data model is an integrated collection of concepts for describing data, 
relationships between data, and constraints on the data [78]. An organized collection 
of data and relationships among data items is the database. Over the years there have 
been several different basic ways of constructing databases, among which have been 
listed as follow: 
z The flat file model 
z The hierarchical model 
z The network model 
z The relational model 
z The object-oriented model 
The flat-file model is the simplest data model, which is essentially a plain table of 
data. Each item in the flat file, called a record, corresponds to a single, complete data 
entry. A record is made up by data elements, which is the basic building block of all 
data models, not just flat files. The flat-file data model is relatively simple to use; 
however, it is inefficient for large databases.  
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The hierarchical data model organizes data in a tree structure (Figure 2-1). It has been 
used in many well-known database management systems. The basic idea of 
hierarchical systems is to organize data into different groups, which can be divided 
into different subgroups. In a subgroup, there may be some sub-subgroups, among 
which the sub-subgroups may have sub-sub-subgroups, and so on. That is to say, there 
is a hierarchy of parent and child data segments. In a hierarchical database the 
parent-child relationship is one to many. The hierarchical data model will be 
convenient to use and run very efficiently only if the nature of the application remains 
strictly hierarchical. Actually, in real world application, few database management 
problems remain strictly hierarchical. It is the major failing of this kind of data model. 
 
Figure 2-1: The Hierarchical Data Model 
 
In most cases, the relationships of data would be arbitrarily complex (Figure 2-2). The 
circles in triangle (left) represent “children” and the circles in square (right) represent 
“parents”. The broken line links the children to their parents. In this model, some data 
were more naturally modeled with multiple parents per child. So, the network model 
permitted the modeling of many-to-many relationships in data. This model, thus, can 
handle varied and complex information while remaining reasonably efficient. Even so, 
the biggest problem with the network data model is that databases can get excessively 
complicated. 
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Figure 2-2: The Network Data Model 
 
The relational model was formally introduced by E. F. Codd in 1970 and has been 
extensively used in biological database development (Figure 2-3). The model is a 
much more versatile form of database. On the basis of this kind of data model, a novel 
system named relational database management system is established. A relational 
database allows the definition of data structures, storage and retrieval operations and 
integrity constraints. In such a database the data and relations between them are 
organized in tables.  
 
Figure 2-3: The Relational Data Model 
 
Every relational database consists of multiple tables of data, related to one another by 
columns that are common among them. Every table is a collection of records and each 
record in a table contains the same fields. Therefore, if the database is relational, we 
can have different tables for different information. And the common columns, such as 
entry ID, can be used to relate the different tables. Relational database is the 
Data item 1 Data item 2 Data item 3 Data item … 
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predominant form of database in use today, especially in biological research field. It is 
the type which has been used in this research work.  
The object-oriented database (OODB) paradigm is “the combination of 
object-oriented programming language (OOPL) systems and persistent systems” [79]. 
“The power of the OODB comes from the seamless treatment of both persistent data, 
as found in databases, and transient data, as found in executing programs” [79]. The 
database functionality is added to object programming languages in object database 
management systems, which extend the semantics of the C++, Smalltalk and Java 
object programming languages to provide full-featured database programming 
capability. The combination of the application and database development with a data 
model and language environment is a major advantage of the object-oriented model. 
As a result, applications require less code, use more natural data modeling, and code 
bases are easier to maintain. 
2.1.3.2 Relational pharmainformatics database structure construction 
The relational model has been used in our pharmainformatics databases. It represents 
relevant data in the form of two-dimension tables. Each table represents relevant 
information collected. The two-dimensional tables for the relational database include 
entry ID list table (Table 2-1), main information table (Table 2-2), which contains a 
record for the basic information of each entry, data type table (Table 2-3), which 
demonstrates the meaning represented by different number, and reference information 
table (Table 2-4), which gives the general reference information following by 
different PubMed ID in Medline [77].   
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Table 2-1: Entry ID list table 
Entry ID Entry name 
… … 
 
Table 2-2: Main information table 
Entry ID Data type ID Data content Reference ID 
… … … … 
 
Table 2-3: Data type table 
Data type ID Data type 
… … 
 
Table 2-4: Reference information table 
Reference ID Reference 
… … 
 
Figure 2-4 is the general logical view of database we developed. It shows the 
organization of relevant data into relational tables. In these tables, certain fields may 
be designated as keys, by which the separated tables can be linked together for 
facilitating to search specific values of that field. Commonly, in relational table, the 
key can be divided into two types. One is primary key, which uniquely identifies each 
record in the table. Here it is a normal attribute that is guaranteed to be unique, such 
as entry ID in Table 2-1 with no more than one record per entry. The other is foreign 
key, which is a field in a relational table that matches the primary key column of 
another table. The foreign key can be used to cross-reference tables. For example, in 
tables of our databases, there are two foreign keys: Data type ID and Reference ID. 
According to Figure 2-4, a connection between a pair of tables is established by using 
a foreign key. The two foreign keys make three tables relevant. Generally, there are 
three basic types of relationships of related table: one-to-one, one-to-many, and 
many-to-many. In our case, these databases belong to one to many relationships.  
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Figure 2-4: Logical view of the database 
 
2.1.3.3 Development of Database Management System  
By using relational database software (e.g. Oracle, Microsoft SQL Server) or even 
personal database systems (e.g. Access, Fox), the relational database can be organized 
and managed effectively. This kind of data storage and retrieval system is called 
Database Management System (DBMS). An Oracle 9i DBMS is used to define, create, 
maintain and provide controlled access to our pharmainformatics databases and the 
repository. All entry data from the related tables described in previous section are 
brought together for user display and output using SQL queries. 
2.2 Computational methods for the prediction of 
druggable proteins 
Besides pharmainformatics database development, another significant work of this 
study was focused on computational analysis of therapeutic targets and ADME-APs. 
A well known machine learning method, SVMs, has been used. Thus, in this section, 
a general introduction to SVMs is discussed. 
2.2.1 Introduction to machine learning 
Learning is the most typical way in which humans “acquire knowledge, 
Entry ID Data type ID Data information Reference ID 
… … … … 
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comprehension or mastery of (a subject) or skill through experience or study” 
(Oxford English Dictionary, 1989). Human beings, according to evolutionary theory, 
have developed big brains that enable them to observe, interpret, and understand the 
complex world. As a result, in the past few centuries, human learning has been used in 
traditional routes. During the process of human learning, human beings take 
advantage of their intuition to characterize and represent the data. Certainly, there are 
many difficulties, misunderstandings or low efficiencies. Moreover, humans do not 
enough have comprehensive knowledge to enable them to analyze each phenomenon 
in a reasonable way.  
With the invention of computers, it is possible to combine human learning with 
computational technology. Computers have been designed to simulated human’s 
brains to learn about multifarious data coming from various research fields. 
Furthermore, computers are capable of doing “automatic programming”. That is to 
say, a computer program can learn from experience with respect to some class of data, 
knowledge, or experimentation. Such kinds of things are called machine learning, 
whose common tasks include concept learning for prediction, data clustering, and 
association rule mining. In the information age, particularly in biological research 
area, a huge volume of genomic information has been generated increasingly resulting 
from large scale genome sequencing projects. It is obviously beyond the capability of 
human beings to effectively explore the information without the aid of intelligent 
computer technology. One way to match the need for analysis and interpreting huge 
information of biology systems is to utilize the artificial intelligence which aims to 
mimic how the brain works. Statistical machine learning was designed for computers 
to learn from observations, and subsequently the learned knowledge could be used in 
decision making process for the new discovery. It has a long history and has been 
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successfully applied to solve many biological problems in real life. 
Particularly in solving biology information-intensive problems, many statistical 
learning methods such as discretized naïve Bayes [80], C4.5 decision trees [81], and 
instance-based leaning [82], neural networks [83] and SVMs [82, 84-89], have shown 
the potential to predict the unknown characteristic from the observed knowledge. In 
this work, we are going to focus on one of the machine learning methods, support 
vector machines, which is one of the most important machine learning methods and 
are regarded as a main example of “kernel methods”. 
2.2.2 Introduction to support vector machines 
SVMs introduced by Vapnik [90] in 1979, are a set of related supervised learning 
methods used as robust tools for classification and regression in noisy and complex 
domains. Since it was further explained by Vapnik [91] in 1995 and more 
theoretically elaborated by Burges [92] in 1998, increasing effort have been directed 
in both the theory study and application in real life problems, such as text 
categorization [93-95], tone recognition [96], image detection [97-100]; flood stage 
forecasting [101]; cancer diagnosis [102-104], microarray gene expression data 
analysis [105], protein secondary structure prediction [106, 107], identification of 
protein-protein interaction [108] and many other classification problems. Basically the 
tasks of SVMs can be described into two ways: i) extraction of valuable information 
from datasets and ii) construction of fast classification algorithms for massive data, 
which it is based on the structural risk minimization (SRM) principle from statistical 
learning theory [91].  
During the process of classification, SVMs construct a hyperplane which could 
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separate two groups of examples with a maximum margin (Figure 2-5). New data is 
subsequently tested by labeling their comparative position to the separation 
hyperplane, where the two sides of separation hyperplane represent different classes. 
In SVMs theory, this separation hyperplane has been proved to be unique if the 
feature space is fixed. Real life problems are not always straightforward in a linear 
form; the SVMs extrapolated the same idea to the non-linear problem domains by 
introducing kernel mappings which are able to project the input data from input space 
into a high-dimensional feature space in which the training examples can be linearly 
separated. In following section, we will have a closer look on the theory of SVMs. 
 
Figure 2-5: Separating hyperplanes in SVMs (the circular dots and square dots 
represent samples of class -1 and class +1, respectively.) 
 
2.2.3 The theory and algorithms of support vector machines 
The mathematical foundation of SVMs is based on the structural risk minimization 
principle from statistical learning theory [92]. The structural risk expresses an upper 
bound on the generalization error. There are two types of SVMs algorithms, linear 
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pattern reorganization is to construct an optimal separation hyperplane (OSH) 
separating two different classes of feature vectors with a maximum margin [91, 109].  
2.2.3.1 Linear case 
The training data of two separable classes with n samples can be represented by: 
( ) ( ) ( )ll yxyxyx ,,...,,, 2221 , li ,...,2,1=          (2-1)  
The aim of SVMs is to establish a function map from the training examples ( )ii yx ,  
for discriminant patterns: 
 { }1: ±→NRf               (2-2 ) 
where ix  is the N-dimensional feature vectors and 
N
i Rx ∈  is an N dimensional 
space, iy  is the corresponding class label and { }1,1 +−∈iy  is the class index. And  
( )ii yx ,  is under the same probability distribution ),( yxp , 
( ) ( ) ( ) { }1,,...,,, 2221 ±∈ XRyxyxyx Nll . The function f  is considered to be well 
generalized so that the training dataset ( )ii yx , , li ,...,2,1= , satisfy ii yxf =)( . 
As indicated in Figure 2-6, the hyperplane in SVMs is constructed by finding a weight 
vector w  and bias b  that minimizes 2w  which satisfies the following 
conditions:  
1+≥+⋅ bxw i , for 1+=iy  (positive class)       (2-3) 
or  
1−≤+⋅ bxw i  , for 1−=iy  (negative class)       (2-4) 
Here w  is a vector normal to the hyperplane, wb /  is the perpendicular distance 
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from the hyperplane to the origin and 2w  is the Euclidean norm of w . After the 
determination of w  and b , a given vector x  can be classified by using the 
decision function ])[( bxwsign +⋅ , a positive or negative value indicates that the 
vector x  belongs to the positive or negative class respectively. 
 
Figure 2-6: Construction of hyperplane in linear SVMs (the circular dots and square 
dots represent samples of class -1 and class +1, respectively.) 
 
The hyperplane constructed based on the feature space usually works for the problems 
which can be linearly solved, where the above implementation of SVMs is called 
linear SVMs (Figure 2-6). However, many real-world problems are much more 
complicated and usually cannot be solved in a linear form, for instance the protein 
function classification [85, 110], hand-writing identification [93-95] and therapeutic 
regimen diagnosis [102-104]. 
2.2.3.2 Nonlinear case 
The capability of SVMs to solve non-linear separable problems is extended by 
projecting the input data from feature space to higher dimension space through kernel 
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convert the non-liner problem in lower feature dimension to the higher dimension 
where the problem becomes linearly solvable. An example of a kernel function is the 
Gaussian kernel, which has been extensively used in a number of protein 
classification studies [84, 86, 92, 106-108, 111]:  
22 2/),( σij xxji exxK
−−=                          (2-5) 
The same SVMs procedure is then applied to the feature vectors in this feature space 








iii bxxKysignxf α           (2-6) 
Where the coefficients 0iα  and b  are determined by maximizing the following 















1 ααα           (2-7) 







0α . A positive or negative value from Eq. 
(2-6) indicates that the vector x  belongs to the positive or negative group 
respectively. 
2.2.4 Model evaluation of support vector machines 
As in the case of all discriminative methods [112-114], the performance of SVMs 
classification can be measured by the quantity of true positive TP  (correctly 
predicted members), false negative FN  (members incorrectly predicted as 
non-members), true negative TN  (correctly predicted non-members), and false 
positive FP  (non-members incorrectly predicted as members). Because the number 
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of members and non-members is imbalanced, two unique quantities [115], sensitivity 
and specificity, are used to measure the accuracy for the members and non-members 
of a specific class. 
Sensitivity: )/( FNTPTPQp +=           (2-8)  
Specificity: )/( FPTNTNQn +=           (2-9) 
The overall accuracy is: 
)/()( FPTNFNTPTNTPQ ++++=          (2-10) 
Here the positive prediction accuracy pQ  is for proteins that have a specific property; 
the negative prediction accuracy nQ  is for proteins without that property. In some 
cases, Q , pQ , and nQ  are insufficient to provide a complete assessment of the 
performance of a discriminative method [113, 116]. Thus the Matthews correlation 
coefficient: 
))()()((/)( FNTNFPTNFPTPFNTPFNFPTNTPMCC ++++×−×=  (2-11) 
is used to evaluate the randomness of the prediction, where [ ]1,1−∈MCC .  
Chapter 3    Therapeutic target database and therapeutically relevant multiple-pathways database development 
 - 47 - 
3 Therapeutic target database and 
therapeutically relevant multiple-pathways 
database development 
As mentioned in chapter 1, this thesis consists of two parts of work. One is about 
databases development, which is introduced in this chapter; the other is about 
computational analysis of therapeutic targets and ADME-APs, which will be 
discussed in following chapters. With respect to databases development, the TTD was 
reconstructed and updated. A new TRMP database was developed. In addition, 
another pharmainformatics database, ADME-AP database, was updated. Because the 
database structure has no major modification and its development followed similar 
strategy, the detail of ADME-AP database development was omitted and integrated its 
brief introduction into the chapter on computational analysis of ADME-APs.  
3.1 Therapeutic target database development 
3.1.1 Preliminary plan of therapeutic target database 
It is widely known, target discovery is one of the key processes in drug discovery. 
Furthermore, knowledge about known or investigated therapeutic targets is essential 
for target discovery and it may facilitate biomedical researcher to find more potential 
targets. However, up to date, there is no similar publicly accessible web-based 
database providing specific information about therapeutic target. Thus, it is 
meaningful to develop such kind of target information database, which can provide 
timely information of the known and newly proposed therapeutic protein and nucleic 
acid targets described in the established publications. As a repository of specific 
pharmainformatics database, it is helpful in catering for the need and interest of the 
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biological and medical research communities. Therefore, the relevant information of 
targets, such as drug/ligands information, corresponding disease conditions, is 
essential. For facilitating to understand these targets in further, extra information, such 
as cross links to other databases, is also included to make TTD comprehensive and 
applicable.  
3.1.2 Collection of therapeutic target information 
As indicated in previous section, three important information communities should be 
included in TTD: therapeutic target information, information about targets binding 
ligands and therapeutic effects. Detail information items are given here:  
z Therapeutic target information: Target name, Synonyms of target, Type of 
target (if successful target, the example of relevant market drug is given.), 
Biological function of target 
z Disease information: Disease name, Relevant PubMed references 
z Drugs/ligands information: Drugs/ligands name, Drugs/ligands function 
(agonist, antagonist, inhibitor, blocker, etc.), Drugs/ligands detail information 
(name, synonyms, CAS number, etc.) 
z Others: Relevant US patent information (register number, patent title, author, 
issued year, corresponding diseases, etc.), some useful cross links (3D 
structure, on-line medical dictionary, etc.) 
The information mentioned above is obtained by two steps. Firstly, therapeutic target 
was selected from a large number of relevant literatures by combining automatic text 
mining techniques and manual reading process. Some automated text retrieval PERL 
programs were developed to retrieval the literature containing the key work “target” 
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in local Medline abstract packages [77]. Next, useful therapeutic target and relevant 
disease and drugs/ligands information were collected manually from the matched 
Medline abstracts. In most cases, the full literature was referred to find more detail 
and exact information. After the first step, not only target information but also 
relevant information about disease conditions and possible corresponding 
drug/ligands were recorded. In the second step, detail information of targets was 
automatically selected from some relevant general or specific biological databases, by 
using text mining PERL programs. Likewise, related US patent information was 
extracted from US Patent and Trademark Office USPTO Web Patent Databases by 
accessing the following website http://www.uspto.gov/patft/. Moreover, according to 
mechanism of drug action published by US Food and Drug Administration (FDA, 
published at http://www.centerwatch.com/patient/drugs/druglsal.html), targets were 
roughly divided into two broad groups: successful target, which target by at least one 
marketed drug, and research target, which is targeted by investigational agents. 
Regarding the successful target, some examples of corresponding marketed drugs 
were given. When information collection was completed, TTD construction followed. 
3.1.3 Construction of therapeutic target database 
TTD adopts the relational data model, which represents therapeutic target data in the 
form of two-dimension tables. The two-dimensional tables here include therapeutic 
target ID table (Table 3-1), main information table (Table 3-2), data type table (Table 
3-3), and reference information table (Table 3-4). In these tables, TTD ID serves as 
the primary key; Data type ID and Reference ID are considered as foreign keys. 
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Table 3-1: Therapeutic target ID list table 
 
 
Table 3-2: Target main information table 
TTD ID Data type ID Data content Reference ID 
TTT0000001 101 Placenta growth factor  
TTT0000001 102 Research target  
TTT0000001 103 PlGF-131  
TTT0000001 104 Cancers 12678905 
… … … … 
 
Table 3-3: Data type table 
 
 
Table 3-4: Reference information table 
Reference ID Reference 
12678905 Vascular endothelial cell growth factor (VEGF), an emerging target for cancer 
chemotherapy. Curr Med Chem Anti-Canc Agents. 2003 Mar;3(2):95-117. Review. 
… … 
 
3.1.4 Therapeutic target database structure and access 
Basically, TTD web interface comprises four layers. The top layer is the main 
graphical user interface with a querying tool for finding specific entries of therapeutic 
target (Figure 3-1). The searching results followed by some specific matching rules 
will be listed in the second layer (Figure 3-2). By clicking into each entry, the browser 
can access the detail information for specific target, which is displayed in the third 
layer (Figure 3-3). More information is given in the fourth layer (Figure 3-4). The 
detail information about each layer will be discussed in the following parts. 
TTD ID Target name 
TTT0000001 Placenta growth factor 
TTT0000002 P2Y purinoceptor 1 
… … 
Data type ID Data type 
101 Target name 
102 Target category 
103 Synonyms 
… … 
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Figure 3-1: The web interface of TTD. Five types of search mode are supported 
 
TTD can be accessed at http://bidd.nus.edu.sg/group/cjttd/ttd.asp. Its web interface is 
shown in Figure 3-1. The new version of TTD is searchable by five types of search 
mode: target name, drugs/ligands name, disease name, drugs/ligands function, and 
drug classification. Queries can be submitted by entering or selecting the required 
information in any one or combination of the five fields in the form. Users can specify 
full name or any part of the name in a text field, or choose one item from a selection 
field. Wild character of '*' and '?' is supported in text field. The relevant disease 
conditions are classified according to international statistical classification of diseases 
of World Health Organization (WHO) [117] listed in Table 3-5. In addition, the lists 
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Table 3-5: Disease class and associated diseases  
Disease class Associated diseases Disease class Associated diseases 
Coagulation disorders Arthritis 
Platelet disorders Connective tissue disorders 
Blood and 
blood-forming 
organs diseases Red blood cell disorders Movement disorders 







Cardiovascular disorders Bladder cancers 
Circulation disorders Brain cancers 
Heart disorders Breast cancers 
Circulatory 
system diseases 
Water-retaining diseases Cancer metastasis 
Adrenal glands disorders Endocrine cancers Congenital 
anomalies Cerebral disorders Gastrointestinal cancers 
Gallbladder disorders Hepatic cancers 
Gastric disorders Leukaemia 
Gastrointestinal disorders Lung cancers 
Gastrointestinal motility disorders Lymphoma 
Hepatic disorders Mesothelioma 
Intestinal disorders Muscular cancers 
Digestive 
system diseases 
Pancreatic disorders Myeloma 
Aldosterone disorders Neuronal cancers 
Antidiuretic hormone disorders Pancreatic cancer 
Glucocorticoid hormone disorders Renal cancers 
Growth hormone disorders Reproductive organ cancers 
Insulin disorders Skeletal cancers 
Neurotransmitter disorders Skin cancers 
Parathyroid hormone disorders Thyroid cancers 





Thyroid hormone disorders Alzheimer’s disease 
Female reproductive organ disorders Eye disorders 
Lower urinary tract disorders Headache 
Male reproductive organ disorders Huntington's disease 
Renal disorders Neuronal disorders 
Genitourinary 
system diseases 
Reproductive organ disorders Parkinson's disease 












Bacterial infections Electrolyte disorders 






Infections Bronchus disorders 
Parasitic infections Lung disorders 








Inflammation Inflammation/pain Hair disorders 
Injuries Lupus erythematosus Injury and 






Drug dependence Cellular disorders 
Eating disorders Ill-defined disorders 
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Table 3-6: Drug classification listed in TTD 
Drug Class Name 
Alzheimer's Antidiarrheal Antitussive Immunostimulant 
Analgesic Antidote Antiviral Immunosuppressant 
Anthelminthic Anti-emetic Anxiolytic Lipid-lowering 
Anti-acne Antifungal Bronchodilator Muscular agents  
Anti-allergy Anti-gastric secretion Cardiotonic Nasal decongestion 
Anti-androgen Antihypertensive Cardiovascular agents Neurologic agents 
Anti-angiogenic Anti-infectives Central nervous system agents Ocular agent 
Anti-arrhythmia agents Anti-inflammatory Dermatologic agents Parkinson's 
Anti-asthmatic Antimalarial Diuretics Procoagulant 
Antibacterial Anti-migraine Drug dependence (narcotics) Urinary agents 
Anticancer Anti-obesity Electrolyte Vasoconstrictor 
Anti-cholesterol Antiparasitic Endocrinologic agents Vasodilator 
Anti-coagulant Antiplatelet Gastrointestinal agent Vitamin 
Anticonvulsant /Antiepileptic Antipruritic Glaucoma treatment Misc 
Antidepressant Antipsychotic Gout medicines  
Antidiabetic Antipyretic Hormone  
 
The result of a typical search (e.g. Leukemia) is illustrated in Figure 3-2. All of 
therapeutic targets that satisfy the search criteria are listed along with the disease 
conditions to be treated, drugs or ligands directed at the target, and the drug class.  
 
 
Figure 3-2: Interface of a search result on TTD 
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More detailed information of a target can be obtained by clicking the corresponding 
target name (e.g. 5-HT 2B receptor). The result is displayed in an interface shown in 
Figure 3-3. From this interface, information related to type of target (successful target 
or research target), target synonyms (for facilitating search), target function, relevant 
diseases, drugs/ligands and their functions (such as agonist, activator, antagonist, 
inhibitor, blocker, etc.), related US patent and some of the cross-database shortcuts are 
provided. If the type of target is marked as successful target, the corresponding drug(s) 
is listed in this sheet. For an enzymatic target, its EC number is also given here.  
 
 
Figure 3-3: Interface of the detailed information of target in TTD 
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According to those targets with US patent number, information relevant to US patent 
can be found by clicking the corresponding register number of corresponding US 
patent (Figure 3-4). Meanwhile, the details about those ligands used as drugs are also 
given in further information layers (Figure 3-5). 
 
 




Figure 3-5: Interface of the ligand detailed information in TTD 
 
3.1.5 Statistics of therapeutic targets database data  
TTD is now a publicly accessible web-based database that provides comprehensive 
information about the therapeutic targets, which includes both therapeutic protein and 
nucleic acid targets together with the targeted disease conditions, the corresponding 
drugs/ligands, and related US patent information. Cross-links to other databases are 
introduced to facilitate the access of information regarding the function, 3D structure, 
and relevant literatures of each target. 
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The first version of TTD was launched in 2002 [39], which contained only 433 entries 
of protein and nucleic acid targets, 809 different drugs/ligands, and around 800 
disease and literature entries. On the basis of the old version, we collected more target 
data by key words searching comprehensively relevant abstracts on Medline [77]. At 
present, the number of targets described in the new version of TTD has reached to a 
total of 1,535 distinct proteins (including subtypes). 268 successful targets, which are 
confirmed to be targeted by a marketed drug, and 1,267 research targets, which are 
specifically described as a therapeutic target in a referred journal publication, have 
been categorized in this database. Both the human and non-human targets are 
collected. Protein subtypes targeted by subtype-specific agents are counted as separate 
targets. So far, the TTD is considered as the first comprehensive database for 
therapeutic targets. It may serve as an essential data resource for target research and 



















Old version of TTD










Figure 3-6: Comparison between old and new version of TTD data 
 
Figure 3-6 is a comparison between the old and the new version of TTD data records. 
As revealed by this figure, there is a sharp increase in target data. Currently, the total 
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number of therapeutic target entries amounts to 1,535. In addition, the number of 
disease and reference records is about 3.5 times than that of old ones respectively. 
Obviously, the abundant data make further knowledge discovery from therapeutic 
target possible. The comprehensive analysis of therapeutic target is one of the most 
important parts in this thesis and it will be discussed in the next section. 
3.2 Therapeutically relevant multiple-pathways 
database development 
In this section, the Therapeutically Relevant Multiple Pathway (TRMP) database, 
which gives information about inter-related multiple pathways of a number of 
diseases and physiological processes, is introduced. As mentioned in previous chapter, 
the database development strategy used in TTD has been extended to construct the 
TRMP database. Therefore, the procedure of TRMP database development will be 
described in the same way. 
3.2.1 Preliminary plan of therapeutically relevant multiple- 
pathways database 
Most of the existing pathway databases are focused on describing the whole 
biological relationships or some protein in a specific pathway. According to 
therapeutically relevant multiple pathways, the primary concern is centered around 
important proteins, which are mostly considered as drug targets in relevant diseases 
and physiological processes. TRMP database, thus, will collect not only therapeutic 
pathways but also information for those key proteins, which play important roles in 
relevant disease and physiological conditions. The comprehensive information 
provided in TRMP database will serve as useful resources for facilitating the analysis 
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of the potential implications of multiple target-based therapies and the study of 
mechanism of drug actions.  
3.2.2 Collection of therapeutically relevant pathway 
information 
Two groups of information need to be gathered in TRMP database. One is pathways 
information, which gives the user useful inter-related multiple pathways information; 
the other is key protein information, which explains some key protein of pathways. 
Information about pathways is listed as follows: 
z Information of multiple pathways 
z Information of individual pathways 
z Related therapeutic targets (colored in chart) 
z Relevant disease conditions or physiological processes 
In addition to specific protein, its corresponding information is displayed in similar 
pattern to TTD. The information including: 
z Protein name, synonyms 
z SwissProt access number 
z Species 
z Gene information: gene name, gene location 
z Sequence information: protein sequence (AASEQ), gene sequence (NTSEQ) 
z Potential therapeutic implications while applicable 
z Cross-links to other databases (GeneCard, GDB, Locuslink, NCBI, KEGG, 
OMIM, SwissProt) 
Pathway relevant information can be obtained or extracted from various internet 
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pathway databases and protein databases. These include Expasy Biochemical 
pathways (http://www.expasy.ch/cgi-bin/search-biochem-index) [118], Kyoto 
Encyclopedia of Genes and Genomes (http://www.genome.ad.jp/kegg) [119], 
Metabolic Pathways of Biochemistry (http://www.gwu.edu/~mpb/) [120], Signaling 
Pathway database (http://www.grt.kyushu-u.ac.jp/eny-doc/spad.html) [121], Cell 
Signaling Networks database (http://geo.nihs.go.jp/csndb) [122], Enzymes and 
Metabolic Pathways (http://emp.mcs.anl.gov) [123], PathDB system for pathways 
(http://www.ncgr.org/pathdb/) [124], Encyclopedia of E. Coli Genes and metabolism 
(http://www.biocyc.org) [125], Biocarta (http://www.biocarta.com) [126], the 
University of Minnesota Biocatalysis/Biodegradation database (http://umbbd.ahc.umn. 
edu) [127], Soybean metabolic pathways (http://cgsc.biology.yale.edu/metab.html) 
[128], Nicholson minimaps (http://www.tcd.ie/Biochemistry/IUBMB-Nicholson) 
[129], Database of Interacting Proteins (http://dip.doe-mbi.ucla.edu/) [130], 
Biomolecular interaction network database (http://www.blueprint.org/bind/bind.php) 
[131], TRANSPATH (http://www.biobase.de/pages/products/databases.html) [132], 
and Signal transduction knowledge environment (http://stke.sciencemag.org/index.dtl) 
[133]. Moreover, detail information for pathway entries are obtained by 
comprehensive searching of related publications in Medline [77]. Combination of 
three keywords (disease name, target name, and “pathway”) is used in searching the 
relevant publications. The relevant information is derived primarily from review 
articles and pharmacology textbooks. Primary articles are also used for clarification 
purpose. The extracted information is double checked against the referenced articles 
independently by different persons. All of the references used for generating the 
pathways are provided in the database. Human data are used for human pathways and 
proteins. Likewise, the corresponding species data are used for bacterial or viral 
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pathways and proteins.  
The data collecting methods were similar to those mentioned in TTD development. 
Generally, by using PERL programs, the literature within “pathway” information was 
retrieved automatically. Next, more details were obtained by manually reading the 
downloaded literature. The preliminary data collection included the gathering of 
pathways information, relevant therapeutic targets and disease information, and 
corresponding drugs/ligands directed at each of these targets. Furthermore, 
information of specific protein was automatically generated by text mining programs, 
which picked up relevant information from other general or specific biological 
databases. 
3.2.3 Construction of therapeutically relevant multiple- 
pathways database 
Differing from TTD, TRMP database has not only literal data, but also graphic data. 
Thus, two data models are applied in TRMP database. The pathway graphic data were 
recorded by simple flat-file model. Each multiple pathway map was considered as one 
flat file. All of the flat files were displayed by means of HTML web pages. The 
interactive maps of each pathway entry of TRMP database were constructed by using 
Macromedia FLASH. The corresponding database architect associated with the 
pathway interactive maps is developed by using Active Server Page with Oracle 9i 
support, which was the same as the one used in TTD Database management system. 
In additional, the protein information data of TRMP database used a relational data 
model. The relational data tables are designed as same as those of TTD (Table 3-7, 
Table 3-8, Table 3-9). Here, TRMP database ID is designed as primary key and data 
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type ID is foreign key. 
Table 3-7: Pathway related protein ID table 





Table 3-8: Pathway related protein main information table 
TRMP ID Data type ID Data content 
TRMP01001 100 AccA 
TRMP01001 102 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha 
… … … 
 
Table 3-9: Data type table 
Data type ID Data type 
100 Entry 
101 Potential therapeutic implications 




3.2.4 Therapeutically relevant multiple-pathways database 
structure and access 
During the development of TRMP database, three layers were used. The top layer was 
the main graphical user interface with a querying tool for finding specific entries of 
the multiple pathways (Figure 3-7). The second layer was the graphical interface for 
the interactive maps of multiple pathways with a browser tool for retrieving additional 
information (Figure 3-8). The browser tool was used both for accessing information 
about the constituent individual pathways from other databases and for retrieving 
information about individual targets or non-target proteins directs a retrieving request 
from TRMP database. The third layer is the graphic interface for entries of individual 
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targets or non-target proteins with a browser tool for accessing additional information 





Figure 3-7: Web interface of TRMP database 
 
TRMP database can be accessed at http://bidd.nus.edu.sg/group/trmp/trmp.asp. Its 
web interface is shown in Figure 3-7. Three types of search mode are supported. 
Firstly, this database is searchable by selecting the name of a particular entry of 
multiple-pathways. Also, it can be accessed by selection of a disease or an individual 
pathway name from the list provided in the corresponding selection field.  
Moreover, searches involving any combination of these three selection fields are also 
supported. The pathways are indexed according to multiple pathway or individual 
pathway, which are listed in Table 3-10. Meanwhile, the list of pathway related 
diseases or conditions is given in Table 3-11. 
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Table 3-10: Multiple pathways and corresponding individual pathways 
Multiple Pathway Individual Pathway 
Bacterial biosynthesis and 
attachment-sensing 
Cpx system pathway; Lipid synthesis pathway; Peptidoglycan synthetic 
pathway 
Bacterial infection induced cytokine 
production, cytokine response and toxin 
response 
Chemokine signaling pathway; MAPK pathway; NF-kB activation pathway; 
Pathway of growth factor induced microfilament bundling; Pathway of 
pseudomonas exotoxin induced cell death; Pathway of toxins induced block of 
actin polymerization; TLR signaling pathway 
Blood coagulation, platelet adhesion, 
fibrinolysis 
Fibrin formation pathway; Platelet activation pathway 
Cancer growth Adrenaline pathway; Apoptosis pathway; COX pathway; EGF pathway; 
Estrogen pathway; GnRH pathway; Hypersensitive pathway; IGF pathway; 
MAPK pathway; Myc pathway; NF-kB pathway; p53 Pathway; PI3K-AKT 
pathway; RAS-signaling pathway; Rb Pathway; RHO regulated cell-cycle 
pathway; TGF pathway; TRADD pathway; TRAIL induced apoptosis pathway; 
Wnt signaling pathway 
Cancer invasion and migration and cancer 
induced pain 
Integrin-dependent intracellular signaling pathway; MET down regulation 
pathway; MET-dependent invasive growth signaling pathway; Nociceptor 
signaling pathway; Plexin-B-mediated pathway; RAC pathway; RAS pathway 
Cardiovascular system related disease Acetylcholine pathway; ATII pathway; Bradykinin pathway; Bradykinin 
synthesis pathway; CNP/NPR-B/cGMP pathway; Endothelin pathway; 
Noradrenalin pathway; PLC-IP3 pathway; Rho-Rho-kinase pathway; Serotonin 
pathway; Serotonin synthesis pathway 
Chemical mediator metabolism and 
transmission 
Acetylcholine pathway; Acetylcholine synthesis pathway; Adrenaline pathway; 
MAO pathway; Noradrenalin synthesis pathway; Serotonin pathway; Serotonin 
synthesis pathway 
Cytokine induced inflammatory response 
and T-cell response 
CD14 pathway; Interleukin-1 pathway; Interleukin-18 pathway; TLR signaling 
pathway; TNF signaling pathway 
Inflammation Bradykinin pathway; Bradykinin synthesis pathway; COX pathway; 
Glucocorticoid pathway; Glucocorticoid synthesis pathway; Histamine pathway; 
Leukotriene synthesis pathway; Noradrenalin Pathway; Noradrenalin synthesis 
pathway; NOS pathway; Pathway of arachidonate release; TNF signaling 
pathway 
Lipid, carbohydrate 
metabolism in adipose 
tissue cells 
Beta-oxidation pathway; cAMP/PKA/CREB pathway; cAMP-PKA pathway; 
CRH pathway; Glucose transport pathway; Glycolysis pathway; Hexose 
monophosphate pathway; Insulin pathway; Interleukin-6 pathway; Leptin 
pathway; Lipid fatty acid synthesis pathway; Lipid synthesis pathway; LPL 
pathway; Melanocortin pathway; NPY pathway; TCA pathway; TNF signaling 
pathway 
Lipid, carbohydrate 
metabolism in liver cells 
Bile acid recovery pathway; Cholesterol synthesis pathway; Fatty acid 
synthesis pathway; Glycogen synthesis; Glycolysis pathway; Hexose 
monophosphate pathway; Lipid synthesis pathway 
Lipid, carbohydrate 
metabolism in muscle 
tissue cells 
Beta-oxidation pathway; cAMP-PKA pathway; Glucose transport pathway; 
Glycolysis pathway; Insulin pathway ; Interleukin-6 pathway; Leptin pathway; 
LPL pathway; TNF signaling pathway 






Protein, carbohydrate, lipid 
digestion and absorption 
Carbohydrate absorption pathway; Carbohydrate digestion pathway; Lipid 
absorption pathway; Lipid digestion pathway; Protein absorption pathway; 
Protein digestion pathway 
Viral infection induced 
cytokine production, RNA 
translation inhibition, viral 
protein and genome 
synthesis 
DNA synthesis pathway; IRF-3 activation pathway; MAPK pathway; NF-kB 
activation pathway; Protein synthesis pathway; RNA replication pathway; RNA 
synthesis pathway 
Viral infection induced 
cytokine production 2 
Death receptor pathway; MAPK pathway; MyD88-dependent pathway; 
MyD88-independent pathway; NF-kB activation pathway; TLR signaling 
pathway; TNF signaling pathway 
Cytokine induced RNA 
degradation and 
translation inhibition 
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Table 3-11: Therapeutically relevant multiple pathways related disease or conditions 
Therapeutically Relevant Multiple Pathways related Disease Name 
Acute Heart attack/Myocardial infarction Fever(Syndromes) Nasal decongestion (conditions) 
Alzheimer’s disease Gastrointestinal disorder Neuromuscular disorders 
Angina Glaucoma Obesity 
Anxiety tremor Heart failure Pancreatic cancer 
Asthma Hemorrhage  Parkinson 
Bacterial infection AIDS Phaeochromocytoma 
Begin prostatic hypertrophy Hypercholesterolemia Postmenopausal breast cancer 
Bradycardia Hyperlipidemia Progressive renal insufficiency 
Breast cancer Hypertension Prostate cancer 
Cancer Hypertension in pregnancy Prostatic hyperplasia 
Cancer pain Hypotension Psychosis 
Cardiac arrhythmias Hypoxia (Syndromes) Purpura (conditions) 
Cardiac dysrhythmias Inflammation Refractory angina 
Cardiac failure Insulin resistance Rheumatoid arthritis 
Cardiogenic shock Ketoacidosis Schizophrenia 
Colon cancer Lactic acidosis Sepsis 
Coronary artery spasm Lung cancer Septic shock 
Cushing (Syndromes) Melanoma Thrombosis and embolism 
Depression Metastasis Type 2 diabetes 
Diabetes mellitus Migraine Viral infection 
Diabetic nephropathy Migraine prophylaxis (conditions) Vomiting/Nausea (Syndromes) 
Disseminated intravascular coagulation Mood disorders Von willebrand 
Endotoxin shock Multiple myeloma  
Erectile dysfunction Myasthenia gravis  
 
Figure 3-8 illustrates the interface for an entry of therapeutically relevant multiple 
pathways. A therapeutically targeted protein is represented by a red rectangle box and 
a non-target protein by a yellow or blue rectangle box respectively, with the name of 
the target or protein included in each respective box. Genes and RNAs are represented 
by orange boxes so that they can be easily distinguished from proteins. More detailed 
information about each target can be obtained by clicking the respective red rectangle 
box which is linked to the corresponding target information page provided in our 
database. Proteins in the yellow boxes are those with detailed information available. 
The relevant information can be accessed by clicking a yellow box which is linked to 
the corresponding protein information page provided in our database. Proteins in the 
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blue boxes are those with only a general name specified in the literature which is not 
specific enough to determine their identity. As a result, no detailed information about 
these proteins is available in the current version of our database. 
 
 
Figure 3-8: Interface of a multiple pathways entry of TRMP database 
A small molecule ligand is represented by its name and its action of a protein is 
indicated by a white circular box with one of the following symbols inside. These 
symbols are +, -, ↑, ↓, P, R, B, D and A which represents activation of the protein, 
inhibition of the protein, increase of the protein level, decrease of the protein level, 
protein phosphorylation, release of the protein to extra-cellular environment, binding 
to the protein with unknown effect, binding to the protein leading to its dimerization, 
and binding to the protein as an antibody respectively. A pink circular box indicates 
the site and action of a drug or investigative agent and the type of drug action is 
represented by the same set of symbols as that for small molecule ligands. More 
detailed information about the corresponding drugs is represented through a 
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mouse-over-effect upon clicking a relevant pink drug action circular box. The names 
of the constituent individual pathways contained in each entry are given. Cross links 
to other pathway databases are provided for those individual pathways that are 
described in other pathway databases. The effects of the pathways are given by the 
green boxes with unregulated dot line which include the description about each effect. 
There are cases that the actual protein involved in a particular process in a pathway is 
unidentified. Thus, instead of the actual protein, the related process is described in the 
same way. In addition, the complex of several proteins is demonstrated by the 
light-blue boxes with dot line. 
 
 
Figure 3-9: Interface of a target entry of TRMP database 
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Figure 3-9 gives the interface of a target entry of TRMP database, which is similar to 
that of a non-target protein entry with the exception that the former contain a section 
for potential therapeutic implications. Information provided include protein name, 
synonyms, SwissProt AC number, species, gene name and location, protein sequence 
(AASEQ) and gene sequence (NTSEQ) as well as potential therapeutic implications 
while applicable. Cross-links to other databases are provided which include GeneCard, 
GDB, Locuslink, NCBI, KEGG, OMIM and SwissProt to facilitate the access of more 
detailed information about various aspects of particular target or non-target protein. 
 
3.2.5 Statistics of therapeutically relevant multiple-pathways 
database data 
TRMP database is also a publicly accessible web-based database, which is designed to 
provide information about known therapeutic targets within each network of multiple 
pathways, the corresponding drugs/ligands directed at each of these targets, the 
constituent individual pathways, and information about the proteins involved in these 
pathways. Cross-links to other databases are introduced to facilitate the access of 
information about the constituent individual pathways: the function, sequence, 
nomenclature, and related literatures of each protein in the pathways. 
The TRMP database currently contains 11 entries of multiple pathways that include 
97 distinct individual pathways and 120 therapeutic targets covering 72 different 
disease conditions. A total of 32 of the 97 distinct individual pathways are included in 
other pathway databases. Apart from multiple pathways and distinct individual 
pathways, the related diseases, the number and examples of associated known 
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therapeutic targets, and examples of corresponding drugs directed at these targets are 
also included. With rapid advances in proteomics [31], pathways [55] and systems 
[134], new information about therapeutically relevant multiple pathways can be 
incorporated or the corresponding databases can be cross-linked to TRMP database to 
provide more comprehensive information about the therapeutically relevant pathways, 
related targets and their relationship to other biomolecules and cellular processes. 
Furthermore, the approach of linking human proteins to the human pathway 
constituents (with the exception of the viral and bacterial specific ones) was critically 
based on the assumption that all of the shown pathways were found in human 
although this might not have been experimentally verified. The pathway models in the 
review articles and textbooks were often based on the results of a patchwork of 
experimental systems involving genes and proteins of different species origin. Thus 
caution was needed to interpret the molecular interactions and pathway constituents in 
TRMP database. Effort would be made to promptly update newly reported results in 
the database. So far, the part of pharmainformatics databases development has been 
described. In next chapter, the focus on computational study of therapeutic targets, 
which was one of the most important parts in this thesis.
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4 Computational analysis of therapeutic targets 
Therapeutic targets can be divided into successful targets, which are targeted by at 
least one marketed drug [9, 135], and research targets, which are targeted only by 
investigational agents [136-140]. The search for new targets has been facilitated by 
advances in genomics [32, 33] and proteomics [31], a deeper understanding of 
molecular mechanism of diseases [34, 35], and the development and improvement of 
technologies for target identification and validation [4, 5, 8, 9, 141, 142]. Since 1996, 
a growing number of new and novel research targets have emerged [136-138, 140]. 
Drug design effort has increasingly been focused on disease-specific protein subtypes 
[143, 144]. Progress has been made in probing some of the previously unknown 
targets of marketed and investigational drugs [9, 28, 29, 145, 146]. While a relatively 
small number of research targets are known to have become successful targets since 
1996, the number of successful targets collected in the TTD appears to have 
substantially increased since previous reports [9, 37, 135]. This could be due in part to 
a variety of factors such as the inclusion of nonhuman targets and protein subtype 
targets in the new report, the approval of a growing number of subtype-specific drugs 
since the publication of previous reports and the gain of new knowledge about 
previously unknown targets of marketed drugs.  
This chapter provides a comprehensive analysis of these targets so as to provide 
useful hints about the current trends of exploration of therapeutic targets and the focus 
of interest for drug discovery for various diseases. 
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4.1 Distribution of therapeutic targets with respective 
disease classes 
4.1.1 Distribution pattern of successful target 
Distribution of successful targets with respect to different disease classes is given in 
Table 4-1. The total number of distinct successful targets is 268, 120 of which are for 
more than one disease classes. Because of this redundancy of targets, the sum of the 
number of targets in these classes is greater than 268. The number of targets shared 
between different disease classes is also given in the Table 4-1. Disease classes are 
based on the international statistical classification of diseases of WHO [117].  
Targets for neoplasms, infectious and parasitic diseases, nervous system and sense 
organs disorders, circulatory system diseases, and mental disorders, which contain 78, 
78, 56, and 46 targets respectively, constitute the groups with the largest number of 
targets. Other groups consisting of substantial numbers of targets are those of 
respiratory system diseases, genitourinary system diseases, musculoskeletal system 
and connective tissue diseases, and endocrine disorders. The number of targets for 
each of these classes is 35, 24, 23, and 21, respectively.  
Examples of successful targets in the class of neoplasms are estrogen receptor and 
aromatase (breast cancer), thymidylate synthase and DNA topoisomerase I (colorectal 
cancer), leutinizing-hormone-releasing hormone (prostate cancer) and BCR-ABL 
tyrosine kinase (chronic myeloid leukemia). Examples in the class of infectious and 
parasitic diseases are HIV-1 protease (AIDS), influenza A virus M2 protein (influenza 
A), HBV polymerase (Hepatitis B), penicillin-binding proteins and 
DD-carboxypeptidase (bacterial infections), histamine N-methyltransferase and 
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dihydropteroate synthetase (malaria), 1,3-beta-glucan synthase and lanosterol 
14-alpha-demethylase (fungal diseases). Those in the class of nervous system and 
sense organs disorders are acetylcholinesterase and NMDA receptor (Alzheimer's 
disease), catechol-O-methyl-transferase and D2 dopamine receptor (Parkinson's 
disease), alpha-2 and beta-1 adrenoceptor (glaucoma and ocular hypertension), 
5-HT1D receptor (migraine), and mu/kappa opioid receptor (drug dependence). 
Additional examples of successful targets are platelet glycoprotein IIb/IIIa receptor 
(acute coronary syndrome), angiotensin-converting enzyme, angiotensin receptor AT1, 
beta-1 and alpha adrenoceptor (hypertension, cardiac failure, arrhythmias), endothelin 
receptor (primary pulmonary hypertension) for circulatory system diseases; 
monoamine oxidase A and serotonin transporter (depression), D2 dopamine receptor 
(schizophrenia), GABA receptor and beta adrenergic receptor (insomnia, anxiety) for 
mental disorders; beta-2 adrenergic receptor, 5-lipoxygenase and leukotriene receptor 
(asthma) and sigma-type opioid receptor (cough) for respiratory system diseases; 
phosphodiesterase type 5 (erectile dysfunction) and muscarinic receptor M3 
(overactive bladder) for genitourinary system diseases; cyclooxygenase 2, tumor 
necrosis factor-alpha, interleukin 1 receptor (rheumatoid arthritis, osteoarthritis) and 
farnesyl pyrophosphate synthetase (osteoporosis) for musculoskeletal system and 
connective tissue diseases; gastrointestinal lipases, fatty acid synthase (obesity) and 
farnesyl pyrophosphate synthetase (hypercalcemia) for nutritional and metabolic 
diseases; and insulin receptor and peroxisome proliferator activated receptor-gamma 
(diabetes) for endocrine disorders. 
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Table 4-1: Number of successful targets in different disease classes 





(a) (b) (c) (d) (e) (f) (g) (h) (i) (j) (k) (l) (m) (n) (o) (p) (q) (r) 
(a) Blood and Blood-Forming Organs 
Diseases 
13 2 - 8 1 1 1 2 2 0 0 1 0 2 0 4 2 3 1 1 
(b) Circulatory System Diseases 54 9 8 - 11 10 10 24 15 6 7 6 2 6 12 19 6 8 8 2 
(c) Digestive System Diseases 19 4 1 11 - 5 3 8 9 4 3 5 1 2 5 5 3 6 1 1 
(d) Genitourinary System Diseases 24 0 1 10 5 - 6 11 7 3 6 1 1 2 6 12 1 2 2 3 
(e) Musculoskeletal System and 
Connective Tissue Diseases 
23 4 1 10 3 6 - 10 6 2 2 5 4 6 6 12 1 5 2 3 
(f) Nervous System and Sense Organs 
Diseases 
56 7 2 24 8 11 10 - 17 4 6 3 2 7 27 13 3 14 7 2 
(g) Respiratory System Diseases 35 5 2 15 9 7 6 17 - 5 3 8 2 5 12 10 2 8 4 1 
(h) Skin and Subcutaneous Tissue 
Diseases 
13 2 0 6 4 3 2 4 5 - 3 3 1 1 2 7 2 2 2 1 
(i) Endocrine Disorders 21 6 0 7 3 6 2 6 3 3 - 3 0 3 3 8 4 1 1 1 
(j) Immunity Disorders 18 2 1 6 5 1 5 3 8 3 3 - 3 6 2 9 2 3 2 1 
(k) Infectious and Parasitic Diseases 78 57 0 2 1 1 4 2 2 1 0 3 - 4 1 17 4 1 1 2 
(l) Inflammation 15 1 2 6 2 2 6 7 5 1 3 6 4 - 2 8 1 4 1 1 
(m) Mental Disorders 46 10 0 12 5 6 6 27 12 2 3 2 1 2 - 5 3 10 2 0 
(n) Neoplasms 78 29 4 19 5 12 12 13 10 7 8 9 17 8 5 - 5 5 6 4 
(o) Nutritional and Metabolic Diseases 21 5 2 6 3 1 1 3 2 2 4 2 4 1 3 5 - 1 0 0 
(p) Symptoms, Signs, and Ill-Defined 
Conditions 
22 2 3 8 6 2 5 14 8 2 1 3 1 4 10 5 1 - 1 2 
(q) Injury and Poisoning 15 3 1 8 1 2 2 7 4 2 1 2 1 1 2 6 0 1 - 0 
(r) Congenital Anomalies 4 0 1 2 1 3 3 2 1 1 1 1 2 1 0 4 0 2 0 - 




148 Redundancy of therapeutic targets =120 ; Non-redundancy of therapeutic targets =148 
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There are a number of innovative targets emerged since 1996 that are based on new 
mechanisms or new targets for treating diseases, which usually finds large market and 
become highly successful [38]. These targets, together with the year of first FDA 
approval and the name of the approved drug, are vascular endothelial growth factor 
(2004, Bevacizumab) for the treatment of colorectal cancer, NMDA receptor (2003, 
Memantine) for Alzheimer's disease, HIV gp41 envelope glycoprotein (2003, 
Enfuvirtide) for HIV infection, HBV DNA polymerase (2002, Adefovir dipivoxil) for 
hepatitis B, mineralocorticoid receptor (2002, Eplerenone) for hypertension, 
endothelin receptor (2001, Bosentan) for primary pulmonary hypertension, BCR-ABL 
tyrosine kinase (2001, Imatinib) for chronic myeloid leukemia, retinoid receptors 
(1999, Bexarotene) for cutaneous T cell lymphoma, gastrointestinal lipase (1999, 
Orlistat) for obesity, FK-binding protein 12 (1999, Sirolimus) for the prevention of 
organ rejection following renal transplantation, Receptor protein-tyrosine kinase 
erbB-2 (HER2/neu) (1998, Trastuzumab) for HER2 positive metastatic breast cancer, 
phosphodiesterase 5 (1998, Sildenafil) for erectile dysfunction, platelet glycoprotein 
IIb/IIIa receptor (1998, Tirofiban, Eptifibatide) for severe chest pain and small heart 
attacks, cyclooxygenase 2 (1998, Celecoxib) for arthritis, peroxisome proliferator 
activated receptor (1997, Troglitazone) for type 2 diabetes mellitus, and platelet 
P2Y12 receptor (1997, Clopidogrel) for stroke and heart attack. 
4.1.2 Targets for the treatment of diseases in multiple classes 
Some targets have been explored for the treatment of diseases from more than one 
class. Disease classes with higher concentration of shared targets are those for 
circulatory system diseases, neoplasms, and nervous system and sense organs 
disorders. For instance, there are 24, 19, and 15 targets of circulatory system diseases 
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that are shared with those of nervous system and sense organ disorders, neoplasms, 
and respiratory diseases respectively. High concentration of shared targets in this class 
may be partly attributed to the involvement of circulatory system in various disease 
conditions. For example, there are strong interactions between nervous systems and 
cardiovascular systems, and it is not surprising that targets involved in the crosstalk 
between these systems are used for both diseases [147]. Moreover, tumor growth 
relies on the formation of new blood vessels, and proteins involved in angiogenesis 
have been targeted for anticancer drug development as well as circulatory system 
diseases [138]. In addition, sensory receptors in the respiratory system are known to 
respond to irritants and subsequently induce cardiovascular responses, and targets 
involved in these responses are used for symptom relief of respiratory diseases as well 
as for the treatment of cardiovascular diseases [148]. 
An example of a shared target is beta-adrenoceptor for circulatory system diseases, 
nervous system disorders, and respiratory system diseases. Heart failure is known to 
harmfully activate sympathetic nervous system as well as the rennin-angiotensin 
system, and these circulatory system disease-associated disorders can be treated by 
beta-adrenoceptor antagonists [149]. Meanwhile, beta-adrenoceptor blocking drugs 
have been used in the central nervous system related disorders, such as psychiatry and 
neurology [150, 151]. In addition, beta-adrenoceptor agonists have also been used for 
the treatment of asthma, a typical respiratory system disease, by dilating the bronchial 
smooth muscle [152].  
Another example of a shared target is dual-specificity protein phosphatases (DSPases), 
which represent a subclass of the protein tyrosine phosphatases with highly conserved 
phosphatase active site motifs. DSPases dephosphorylate serine, threonine, and 
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tyrosine residues in the same protein substrate, and they play important roles in 
multiple signaling pathways and appear to be deregulated in cancer and Alzheimer’s 
disease [153]. Because of their roles and properties, there has been increasing effort 
for identifying DSPase inhibitors that are more potent and selective than the general 
tyrosine phosphatase inhibitor sodium orthovanadate, for the treatment of both 
diseases, which has led to the discovery of several promising leads [154]. 
4.1.3 Distribution pattern of research targets 
Table 4-2 lists the distinct research target distribution in different disease classes. The 
majority of the research targets are distributed in the class of neoplasms and infectious 
and parasitic diseases, which accounts for 37% and 23% respectively. Moreover, four 
other disease class, namely nervous system and sense organs disorders, circulatory 
system diseases, nutritional and metabolic disorders and inflammation, are also 
important in research target discovery.  
According to Table 4-2, 13%, 13%, 9%, and 9% of the research targets are distributed 
in these classes respectively. Overall, the number of non-redundant research targets in 
these six disease classes is 708 which accounts for 56% of the total number of 
research targets. This reflects the intensive efforts directed at the search for effective 
therapeutics for cancer treatment and prevention [155-157], cardiovascular diseases 
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Table 4-2: Distinct research target distribution in different disease classes 
Disease Classes Number of therapeutic targets Distinct research 
target in different 
disease classes % 
Blood and Blood-Forming Organs Diseases 41 3% 
Circulatory System Diseases 168 13% 
Digestive System Diseases 45 4% 
Genitourinary System Diseases 50 4% 
Musculoskeletal System and Connective 
Tissue Diseases 
92 7% 
Nervous System and Sense Organs 
Diseases 
171 13% 
Respiratory System Diseases 63 5% 
Skin And Subcutaneous Tissue Diseases 32 3% 
Endocrine Disorders 91 7% 
Immunity Disorders 70 6% 
Infectious and Parasitic Diseases 287 23% 
Inflammation 111 9% 
Mental Disorders 61 5% 
Neoplasms 468 37% 
Nutritional and Metabolic Diseases 120 9% 
Symptoms, Signs, and Ill-Defined 
Conditions 
62 5% 
Injury and Poisoning 51 4% 
Congenital Anomalies 2 0% 
total distinct research targets=1267 100% Total research therapeutic targets based on 
disease classes total duplicate research targets=1989   
 
4.1.4 General distribution pattern of therapeutic targets 
The number of research targets of each disease class is given in Figure 4-1 along with 
that of successful targets. With the exception of the class of congenital anomalies, 
there appears to be a significant increase in the level of exploration of targets for 
every disease class, as evidenced by the significantly larger number of research targets 
than that of successful targets, which reflects intensive efforts for finding effective 
treatment options against all diseases. Little success seems to have been made in the 
identification of useful targets for congenital anomalies. The low target distribution of 
this disease class may be due partly to the use of surgical therapies as primary 
treatment options [167, 168] and partly to the lack of knowledge of the mechanism of 
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the relevant diseases [169]. 
The disease classes with the largest increase of targets are those of neoplasms with 
468 research targets versus 78 successful targets, infectious and parasitic diseases 
with 287 research targets versus 78 successful targets, nervous system and sense 
organs disorders with 171 research targets versus 56 successful targets, circulatory 
system diseases with 168 research targets versus 54 successful targets, nutritional and 
metabolic disorders with 120 research targets versus 21 successful targets, 
inflammation with 111 research targets versus 15 successful targets, musculoskeletal 
system and connective tissue diseases with 92 research targets versus 23 successful 
targets, and endocrine disorders with 91 research targets versus 21 successful targets. 
Examples of specific diseases in these key classes that have a substantial number of 
research targets are various cancers with 468 targets [155-157], cardiovascular 
diseases with 120 targets [158, 159], diabetes with 65 targets[170], arthritis with 64 
targets[171], obesity with 57 targets [35, 161-164], Alzheimer's disease with 44 
targets [172, 173], and high cholesterol with 12 targets [165, 166]. These diseases 
affect a significant number of patients and thus have received substantial interest in 
the development of new therapeutics for their treatment. Another class with high ratio 
of research versus successful targets is that of infectious and parasitic diseases, which 
has a ratio of 78/287. The significant increase in the number of research targets for 
this disease class primarily stems from the pursuit for new generation of antibiotics 
[174], antifungal agents [175], and anti-HIV drugs [176] as well as for the 
development of effective drugs for malaria [177] and a variety of viral infections such 
as hepatitis, herpes simplex virus, and respiratory syncytial virus [176]. 
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Figure 4-1: Distribution of therapeutic targets against disease classes
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4.2 Current trends of exploration of therapeutic 
targets 
4.2.1 Targets of investigational agents in the US patents 
approved in 2000-2004 
Clues about the current trend of target exploration can be obtained from the targets 
described in the recently approved patents of investigational agents. Most of these 
patents describe molecular mechanism and many of them provide the identifiable 
target for each group of patented agents. Table 4-3 and Table 4-4 give some of the 
successful targets and research targets described in the US patents approved between 
January 2000 and September 2004. A total of 2,080 US patents of investigational 
agents have been approved during this period, 1,606 or 77.2% of which have an 
identifiable target. 
There are 395 identifiable targets described in these 1,606 patents. Of these targets, 
264 have been found in more than one patent and 50 appear in more than 10 patents. 
The number of patents associated with a target can be considered to partly correlate 
with the level of effort and intensity of interest currently being directed at it. 
Approximately 1/3 of the patents with an identifiable target were approved in the past 
year. This suggests that the effort for the exploration of these targets is on going and 
there has been steady progress in the discovery of new investigational agents directed 
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Table 4-3: Some of the successful targets explored for the new investigational agents 













4 Congestive Heart Failure, Hypertension,  Benign 
Prostatic Hyperplasia, Eye Disorders 
Alpha-1D 
adrenoceptor 
5 Benign Prostatic Hyperplasia, Peripheral Vascular 
Disease, Congestive Heart Failure, Hypertension 
Alpha-1B 
adrenoceptor 
3 CNS Disorders, Anxiety, Sleep Disorders, Schizophrenia, 
Hypertension, Sexual Dysfunction 
Alpha-2 
adrenoceptor 




1 Mental Illnesses 
Beta adrenoceptor 6 Airway Inflammatory Disorders, Asthma, Obstructive 
Lung Disease, Ocular Hypertension, Glaucoma 
Beta-2 
adrenoceptor 
5 Pulmonary Disorders, Asthma, Emphysema, 





30 Metabolic Disorders, Atherosclerosis, Gastrointestinal 
Disorders, Type II Diabetes 
HIV protease (58)    Retroviral Infection, Viral Infections (HIV), Viral Infections 
(EHV) 
5-HT receptor 1 Headaches 
5-HT 1 receptor 7 Depression, Anxiety, Eating Disorders, Obesity, Drug 
Abuse, Cluster Headache, Migraine, Pain 
5-HT 1A receptor 4 Mood Disorders, Pain, Neuronal Disorders 
5-HT 1B receptor 4 Migraine, Depression, Psychological Disorders 
5-HT 1D receptor 6 Depression, Psychological Disorders 
5-HT 1F receptor 2 Headaches 
5-HT 2 receptor 3 Cardiovascular Disorders, Central Nervous System 
Disorders, Gastrointestinal Disorders, Glaucoma 
5-HT 2A receptor 5 Psychotic Disorders, Schizophrenia, Sleep-Disordered 
Breathing, Sleep Apnea Syndrome 
5-HT 2B receptor 2 Irritable Bowel Syndrome 
5-HT 2C receptor 6 Obesity, Obsessive Compulsive Disorder, Depression 
5-HT 3 receptor 8 Gastrointestinal Motility Disorders, Headache, Anxiety, 
Depression, Psychosis, Rheumatoid Disease 




5-HT 7 receptor 4 CNS Disorders, Aforementioned Disorders, Disorders Of 
The Bladder, Urinary Retention 
Factor Xa (47)    Thrombotic Disorders, Coronary Artery, Cerebro-Vascular 
Disease, Inflammatory Diseases, Cancers 
Substance-P 
receptor (39) 
   Asthma, Cough, Bronchospasm, Depression, Emesis, 
Imflammatory Diseases, Gastrointestinal Disorders 
Tyrosine-protein 
kinase 




5 Immune Diseases,  Cancers,  Atheroscelerosis, Graft 
Rejection, Rheumatoid Arthritis 
Tyrosine-protein 
kinase JAK3 
3 Allergic Disorders 
Tyrosine-protein 
kinase SYK 
1 Inflammatory Diseases, Obstructive Airways Disease 
Tyrosine kinases 
(39) 
Tyrosine-protein 2 Cancers, Immune Diseases 
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   Alzheimer's Disease, Osteoporosis, Glaucoma, 
Inflammation, Asthma, Cancers, Heart Diseases 
Thrombin (36)    Blood Coagulation, Cardiovascular Disorders, 
Thrombosis, Ischemia, Stroke, Restenosis, Inflammation 
NMDA receptor 14 Central Nervous System Disorders, Inflammatory 
Diseases, Allergic Diseases, Depression, Drug Abuse 
NMDA receptor (27) 
NMDA receptor 
NR2B 
13 Pain, Migraine, Depression, Anxiety, Schizophrenia, 
Parkinson's Disease, Stroke 
opioid receptor 4 Eating Disorders, Narcotic Dependence, Alcoholism, 
Pain, Drug Dependence 
Mu-type opioid 
receptor 
2 Constipation, Vomiting And/Or Nausea, Pain, Anxiety 
Delta-type opioid 
receptor 
3 Central Nervous System Disorders, Peripheral Nervous 





16 Depression, Headaches, Inflammation, Arthritis, Stroke,  
Abdominal Pain, Pruritus 
Inducible NOS (24)    CNS Disorders, Inflammation, Shock, Immune Disorders, 
Disorders Of Gastrointestinal Motility 
Muscarinic 
receptor 
10 Cognitive Disorders, Alheimer's Disease, Neurologic, 
Psychiatric Disorders, Pain 
M1 receptor 3 Cognitive Disorders, Alheimer's Disease, Glaucoma 
M2 receptor 8 Cognitive Disorders, Alheimer's Disease, Smooth Muscle 
Disorders 
M3 receptor 5 Smooth Muscle Disorders 
Muscarinic 
receptors (22) 
M4 receptor 4 Mental Disorders,  Parkinson's Disease, Glaucoma 
Adenosine 
receptor 
1 Cardiac And Circulatory Disorders, CNS Disorders, 
Respiratory Disorders 
A1 receptor 6 Allergic Disorders,  CNS Disorders, Asthma 
A2a receptor 10 Central Nervous System Disorders, Parkinson's Disease 




A3 receptor 6 Bronchus Disorders, Inflammation, Allergosis 
HIV RT (20)    Viral Infections (HIV) 
PDE5 (19)    Cardiovascular And Cerebrovascular Disorders, 
Urogenital System Disorders, Erectile Dysfunction 
H1 receptor 8 Allergy, Rhinitis, Congestion, Inflammation, CNS 
Diseases, Respiratory Disorders, Viral Infections 
H2 receptor 6 Dry Eye, Duodenal Ulcer, Gastro-Esophogeal Reflux 
Disease, Gastrointestinal Disorders 
Histamine receptors 
(16) 
H3 receptor 5 Allergy, Congestion, Inflammation, CNS-Related 
Diseases 
TNF (16)    Inflammatory Diseases, Allergic Diseases, 
Cytokine-Induced Toxicity, Muscular Disorders 
Serotonin re-uptake 
(16) 
   CNS-Related Diseases, Anxiety  
GnRH receptor (16)    Sex-Hormone Related Disorders, Steroid-Dependent 
Tumors, Prostate Cancer 
Endothelin 
receptor 
11 Angina, Pulmonary Hypertension, Raynaud's Disease, 
Migraine, Blood Vessel Disorders, Renal Diseases 
Endothelin A 
receptor 
4 Hypertension, Acute Myocardial Infarct, Raynaud's 





2 Hypertension, Acute Myocardial Infarct, Stroke, Benign 
Prostate Hypertrophy, Atherosclerosis, Asthma  
HMG-CoA 
reductase (13) 
   Atherosclerosis, Lipid Disorders, Hypercholesterolemia, 
Hypertriglyceridemia, Combined Hyperlipidemia 
Gastric H+/K+ 
ATPase (12) 
   Bacterial Infections, Gastric Acid Related Diseases, 
Nasal Disorders,  Bronchus Disorders, Osteoporosi 
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U-plasminogen 
activator (12) 
   Angiogenic Disorders, Arthritis, Inflammation, 
Osteoporotic, Cancers, Lymphomas, Chronic Dermal 
Ulcers 
LHRH receptor (12)    Hormone-Dependent Tumours and Disorders, Benign 
Prostate Hyperplasia, Endometriosis 
LH-RH (12)    Hormone-Dependent Tumours and Disorders, Benign 
Prostate Hyperplasia, Endometriosis 
Retinoic acid 
receptor 
5 Acne, Psoriasis, Rheumatoid Arthritis, Viral Infections 
RAR-alpha 1 Systemic Erythematosus, Glomerulonephritis, Lupus 
Nephritis,  Autoimmune Anemia 
RARs (11) 
RAR- gamma 5 Emphysema And Associated Pulmonary Diseases, 
Dermatological Disorders, Epithelial Lesions, Tumors 
PPAR-alpha 4 Abnormality Of Lipidmetabolism, Type II Diabetes 
PPAR-gamma 5 Diabetes, Obesity, Metabolic Syndrome, Cardiovascular 
Diseases, Dysplidemia, Cancers 
PPARs (10) 
PPAR-delta 2 Dyslipidemia, Syndrome X, Cardiovascular Diseases, 
Diabetes, Obesity, Anorexia Bulimia 
Glycogen synthase 
kinase-3 (9) 
   Cancers, Diabetes, Alzheimer's Disease 
Prostanoid FP 
receptor (9) 
   Bone Disorders, Glaucoma, Ocular Hypertension 
calcium channel (9)    Cardiovascular Disorders, Angina, Hypertension, 
Ischemia 
5-lipoxygenase (8)    Asthma, Atherosclerosis, Cancers 
GP IIb/IIIa receptor 
(8) 
   Cancers, Osteoporosis, Arteriosclerosis, Restenosis, 
Opthalmia 
DNA Topo I 3 Cancers DNA 
topoisomerases (7) DNA Topo II 6 Bacterial Infections, Cancers 
ACE (7)    Diabetic Complications, Diabetic Retinopathy, Diabetic 
Neuropathy, Diabetic Nephropathy 
Glucocorticoid 
receptor (7) 
   Cocaine Addiction , Depression, Alzheimer's Disease, 
Aforementioned Diseases, Dibetes 
serine protease (7)    Cardiovascular Disorders, Thrombosis, Asthma 




AT2 6 Acute Myocardial Infarction, Cancers, Hypertension, Qt 
Dispersion, Wounds Healing 
Estrogen receptor 2 Breast Cancer, Inflammatory Diseases, Sepsis, Viral 





4 Uterine Cancer, Adjuvant Breast Cancer, Prostate 
Cancer, Benign Prostatic Hyperplasia, Ovarian Cancers 
Tryptase (6)    Cardiovascular Disorders, Inflammatory Diseases, 
Cancers 
Dopamine receptor 2 Cancers, Parkinson's Disease 
D(2) receptor 2 Fibromyalgia, Musculoskeletal Pain Symptoms 
Associated With Fibromyalgia 
D(3) receptor 2 Fibromyalgia, Musculoskeletal Pain Symptoms 
Associated With Fibromyalgia 
Dopamine receptors 
(5) 
D(4) receptor 1 Central Nervous System Disorders, Psychotic Disorders, 
Schizophrenia 
IL-1R 4 Hypotension, Tachycardia, Lung Edema, Renal Failure Interleukin 1 
receptor (5) IL-1R-beta 1 Allergic Rhinitis, Allergic Asthma, Allergic Inflammatory 
Diseases 




   Cancers, Hematological Disorders,  Metabolic 
Disorders, Cystic Fibrosis, Adrenoleukodystrophy 
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Table 4-4: Research targets explored for the new investigational agents described in 









62 Arthritis, Cancers, Tissue Ulceration, Periodontal 
Disease, Bone Disease, Diabetes 
MMP-1 1 Pulmonary Emphysema 
MMP-2 12 Cancers 
MMP-3 9 Multiple Sclerosis, Heart Failure, Cancers, Inflammation, 
Arthritis, Autoimmune Disorders 
MMP-4 1 Arthritis, Cancers 
MMP-7 1 Inflammatory Diseases, Rheumatoid Arthritis, Tumours 
MMP-8 1 Inflammatory Diseases, Cancers 
MMP-9 5 Cancers, Arthritis 
MMP-11 1 Cancers 
MMP-12 1 Ulcerative Colitis, Crohn's Disease,  Atherosclerosis, 
Gastro-Intestinal Ulcers, Emphysema 
MMPs (79) 
MMP-13 9 Osteoarthritis, Rheumatoid Arthritis, Cancers, 
Inflammation, Heart Failure 
Phosphodiesterase 3 Erectile Dysfunction, Sexual Dysfunction 
PDE1A 2 Cardiovascular And Cerebrovascular Disorders,  
Erectile Dysfunction 
PDE2A 2 Cardiovascular And Cerebrovascular Disorders, 
Disorders of Urogenital System 
PDE3 5 Airway Obstructions, Inflammatory Diseases, Premature 
Ejaculation, Sexual Dysfunction 
PDE4 49 Airway Obstructions, Inflammatory Diseases, Allergic 
Disorders 
PDE4A 1 Respiratory Disorders, Asthma 
PDEs (78) 
PDE7 4 Asthma, Rheumatoid Arthritis, Psoriasis, Atopic 
Dermatitis, Chronic Bronchitis 
Alpha v beta 3 
integrin receptor 
39 Cancers, Arteriosclerosis, Restenosis, Osteolytic 
Disorders, Osteoporosis, Ophthalmic Diseases 
Alpha v integrin 
receptors (40) 
alpha v beta 5 
integrin receptor 




   Cancers, Restenosis, Atherosclerosis 
ADAM 17 (25)    Arthritis, Tumor Metastasis, Tissue Ulceration,  Bone 
Disease, Diabetes, HIV Infection 
Cathepsin K (23)    Autoimmune Diseases, Cartilage Degradation, 
Osteoporosis, Pulmonary Disorders 
Substance-K 
receptor (22) 
   Asthma, Cough, Bronchospasm, Depression,  
Imflammation, Gastrointestinal Disorders 
Tachykinin NK(3) 
receptor (19) 
   CNS Disorders, Inflammation, Pain, Migraine, Asthma, 
Emesis, Gastrointestinal Disorders 
Neuropeptide Y 
receptor 
10 Eating Disorders, Feeding Disorders, Cardiovascular 
Disorders, Physiological Disorders 
Neuropeptide Y 
receptor (18) 




12 Cancers, Inflammation, Arthritis, Alzheimer's Disease, 
Cardiovascular Disorders 
Cell division protein 
kinase 2 
4 Alopecia, Cancers 
CDKs (17) 
Cell division protein 
kinase 4 
1 Cancers 
Stress kinase p38    Chronic Inflammatory, Autoimmune Diseases, 
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(17) Hypercholesterolemia 
Hexokinase D (17)    Type II Diabetes 






4 Inflammation, Asthma, Arthritis, Inflammatory Bowel 
Disease, Neurodegenerative Diseases 
Cytochrome 
P450RAI (15) 
   Skin Diseases, Cancers,  Cardiovascular Diseases, 
Inflammation, Neurodegenerative Diseases 
Cathepsin S (14)    Osteoporosis, Autoimmune Disorders 
Vasopressin 
receptor 
4 Cerebrovascular Disease, Cerebral Edema, Cerebral 
Infarction, Depressant, Anxiety 
Vasopressin V1a 
receptor 






7 Diabetes Insipidus, Nocturnal Enuresis, Nocturia, Urinary 
Incontinence, Coagulation Disorders 
Trypsin-like serine 
protease (13) 
   Thrombosis, Ischemia, Stroke, Restenosis, Inflammation 
Interleukin-8 
receptor (13) 
   Inflammation 
Corticoliberin (12)    Circadian Rhythm Disorders, Congestive Heart Failure, 
Hypertension, Metabolic Disorders, Stroke 
cathepsin B (12)    Autoimmune Diseases, Pancreatitis, Inflammatory 
Airway Disease, Bone And Joint Disorders 
cathepsin L (12)    Autoimmune Diseases, Myocardial Infarct, Inflammation, 
Muscular Dystrophies, Alzheimer's Disease 
Caspase 4 Cancers 
Caspase-8 8 Inflammation,  Cancers, Autoimmune Disorders, 
Neuronal Disorders 
Caspases (12) 
caspase-9 1 Inflammation, Cancers, Autoimmune Diseases, Ischemic 
Diseases, Neurodegenerative Disorders 
CCR1 2 Inflammation, Immune Diseases 
CCR2 2 Atherosclerosis, Inflammatory Diseases, Immune 
Disorders, Transplant Rejection, Aids 
CCR3 3 Respiratory Disorders, Bronchus Disorders, 
Inflammatory Diseases, Allergy 
CCRs (12) 
CCR5 5 Inflammatory Diseases, Viral Infections (HIV) 
Prenyl-protein 
transferase (12) 
   Cancers 
Prostaglandin E 
receptor 
3 Dry Eye, Keratoconjunctivitis, Sjogren's Syndrome, 
Ocular Surface Diseases, Glaucoma 
Prostanoid EP2 
receptor 






4 Renal Failure, Dry Eye 
PTP-1B (10)    Diabetes, Obesity, Autoimmune Diseases, Acute And 
Chronic Inflammation, Osteoporosis, Cancers 
Serine/threonine 
protein kinase 
2 Tumor Growth, Restenosis, Atherosclerosis, Cancers Serine/threonine 
protein kinase (10) 
Serine/threonine 
protein kinase 12 
8 Cancers, Diabetes, Alzheimer's Disease 
Endothelin 7 Angina, Pulmonary Hypertension, Raynaud's Disease, 
Migraine, Heart Failure,  Respiratory Disorders 
Endothelin (9) 
Endothelin-1 2 Pulmonary Hypertension, Cerebral Infarction, Cerebral 
Ischemia, Congestive Heart Failure 
Beta-lactamase (9)    Bacterial Antibiotic Resistance, Bacterial Infections 
mGLUR 7 Neurological Disorders, Psychosis, Schizophrenia, 
Alzheimer's Disease, Cognitive and Memory Disorders 
Metabotropic 
glutamate receptor 
(9) mGLUR1 1 Neurological Diseases, Neurodegenerative Diseases, 
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Psychotic Diseases 
mGLUR5 1 Neurological Disorders, Psychiatric Disorders 
Interleukin-1 beta 
convertase (8) 
   Inflammatory and Autoimmune Diseases, Bone 
Disorders, Proliferative Disorders, Infectious Diseases 
Glutamate receptor, 
ionotropic kainate 1 
3 Headaches, Neuronal Disorders GluRs (8) 
Glutamate receptor 
AMPA 
5 Epilepsy, Diseases Resulting In Muscle Spasm, Various 
Neurodegenerative Diseases, Stroke 
Aldose reductase 
(8) 
   Diabetic Neuropathy, Diabetic Nephropathy, Diabetic 
Retinopathy, Diabetic Cardiomyopathy 
Protease activated 
receptor 1 (8) 
   Aggregation Of Blood Platelets, Thrombosis, 
Thromboembolism, Myocardial Infarction 
 
Many of the highly explored targets (those described in a large number of patents) are 
successful targets, which seem to indicate continuous effort and prolonged interest in 
the exploration of the targets of highly successful drugs for deriving new therapeutic 
agents. Successful targets described in a higher number of patents are adrenoceptor 
subtypes (63 distinct patents, 41 beta- and 22 alpha- subtypes, for cardiovascular 
diseases, depression, hypertension, asthma, diabetes, and obesity etc.), HIV protease 
(58 patents, for HIV infections), 5-HT receptor subtypes (43 distinct patents, 23 
5-HT1, 16 5-HT2, 8 5-HT3 , 2 5-HT6 and 4 5-HT7 subtypes, for depression, anxiety, 
eating disorders, obesity, irritable bowel syndrome, attention deficit hyperactivity 
disorder, bladder disorder etc.), coagulation factor Xa (47 patents, for 
thromboembolic disorders), Substance-P receptor (39 targets, for asthma, bronchitis, 
migraine etc.), tyrosine kinases (39 patents, for angiogenic disorders, cancer, 
inflammatory diseases, allergic diseases etc.), cyclooxygenase 2 (38 patents, for 
inflammation, senile dementia, cancer, asthma, and congestive heart failure), 
thrombin (36 patents, for thrombosis, myocardial ischemia, myocardial infarction 
etc.), NMDA receptors (27 patents, for central nervous system disorders), opioid 
receptors (25 patents, for depression, pain, inflammation, arthritis, pruritus, alcohol 
and drug dependence etc.), inducible nitric oxide synthase (24 patents, for 
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inflammation, pain, arthritis, asthma, bronchitis etc.), muscarinic receptors (22 patents, 
for Alzheimer's disease, pain, glaucoma etc), and adenosine receptors (22 patents, for 
asthma, inflammation, diabetes, coronary artery disease, hepatic fibrosis, renal 
dysfunction etc.). 
Research targets that are described in a higher number of patents are matrix 
metalloproteinase (79 patents, for cancers, tissue ulceration, abnormal wound healing, 
periodontal disease, bone disease, diabetes, arthritis, atherosclerosis, inflammation 
etc.), phosphodiesterase 4 (49 patents, for inflammation, asthma, prostate diseases, 
osteoporosis etc.), alpha v beta 3 integrin receptor (39 patents, for angiogenic 
disorders, inflammation, bone degradation, cancer, diabetic retinopathy, thrombosis 
etc.), farnesyl-protein transferase (26 patents, for arthropathies, arthritis, gout, cancers, 
restenosis etc.), ADAM 17 (25 patents, for arthritis, cancers, tissue ulceration, 
abnormal wound healing, periodontal disease, bone disease etc.), cathepsin K (23 
patents, autoimmune diseases, cartilage degradation, osteoporosis, pulmonary 
disorders), and substance-K receptor (22 patents, for asthma, cough, bronchospasm, 
inflammatory diseases, arthritis, central nervous system disorders etc.). 
4.2.2 Known targets of the FDA approved drugs in 2000-2004 
Analysis of the known targets of recently approved drugs provides a useful hint about 
how therapeutic targets have been successfully explored. Drug discovery typically 
takes 10~15 years for a successful drug to move from the initial designing stage to the 
market [9, 28, 29]. Thus these targets also offer some picture about where some of 
efforts and resources have been directed by the pharmaceutical industry and research 
communities since the early 1990s.  
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1 Abilify (aripiprazole) Oral drug for the treatment of schizophrenia Bristol-Myers 
Squibb and Otsuka 
America 
Pharmaceutical 
Axert (almotriptan malate) tablets For the treatment of migraine attacks  Pharmacia 
Zomig-ZMT (zolmitriptan) Orally disintegrating tablet for the treatment of 
acute migraine in adults 
AstraZeneca 




Relpax (eletriptan hydrobromide) For the acute treatment of migraine headaches Pfizer 
Axert (almotriptan malate) tablets For the treatment of migraine attacks  Pharmacia 
Zomig-ZMT (zolmitriptan) Orally disintegrating tablet for the treatment of 
acute migraine in adults 
AstraZeneca 




Relpax (eletriptan hydrobromide) For the acute treatment of migraine headaches Pfizer 
Geodon (ziprasidone mesylate) To control agitated behavior and psychotic 




Ziprasidone (ziprasidone HCl) Oral capsule for the treatment of schizophrenia Pfizer 
Aloxi (palonosetron) For the prevention of nausea and vomiting 
associated with emetogenic cancer chemotherapy 
MGI Pharma / 
Helsinn Healthcare 
Kytril (granisetron) Solution For the prevention of nausea and vomiting 






Lotronex (alosetron HCl) Tablets Indicated for Irritable Bowel Syndrome (IBS) in 












agonist 1 Zelnorm (tegaserod maleate)  For the short-term treatment of irritable bowel 
syndrome in women whose primary bowel 
symptom is constipation 
Novartis 
Pharmaceuticals 
Adrenergic receptor (8) Alpha-1 antagonist 1 UroXatral (alfuzosin HCl For the treatment of the signs and symptoms of Sanofi-Synthelabo 
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receptor extended-release tablets) benign prostatic hyperplasia 
Alpha-2 
receptor 
antagonist 1 Remeron SolTab (mirtazapine) Orally disintegrating tablet for the treatment of 
depression 
Organon 
Betapace AF Tablet (Sotalol) For treatment of the irregular heartbeats in 






Betaxon (levobetaxolol) For lowering IOP in patients with chronic 
open-angle glaucoma or ocular hypertension 
Alcon 
Laboratories, Inc. 
DuoNeb (albuterol sulfate and 
ipratropium bromide) 
For the treatment of bronchospasm associated 
with COPD 
Dey Laboratories 
Foradil Aerolizer (formoterol 
fumarate inhalation powder) 
Bronchodilator for COPD, asthma and 
bronchospasm 
Novartis 
Ventolin HFA (albuterol sulfate 
inhalation aerosol) 







Xopenex (levalbuterol HCl) For treatment of the reversible obstructive airway 
disease 
Sepracor 
Cymbalta (duloxetine) Depression Eli Lilly 
Lexapro (escitalopram oxalate) An orally administered selective serotonin 




Paxil CR Oral tablet for the treatment of depression and 
panic disorder 
GlaxoSmithKline 
Prozac Weekly (fluoxetine HCl) For the treatment of depression Eli Lilly and 
Company 
Ultracet (acetaminophen and 
tramadol HCl) 
For the short-term management of acute pain Ortho-McNeil 
Pharmaceutical 
Serotonin re-uptake   inhibitor 6 
Zoloft (sertraline HCl) Oral tablets for the treatment of premenstrual 
dysphoric mood disorder (PMDD) 
Pfizer 
Angiomax (bivalirudin) As an anticoagulant in conjunction with aspirin in 
patients with unstable angina undergoing 
percutaneous transluminal coronary angioplasty 
Medicines 
Company 




Thrombin inhibitor 3 
Argatroban Injection Anticoagulant for prophylaxis or treatment of 
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Beecham 
Innohep (tinzaparin sodium) 
injectable 





Factor Va inhibitor 1 Xigris (drotrecogin alfa 
[activated]) 
For the treatment of severe sepsis Eli Lilly 
Factor VIIIa inhibitor 1 Xigris (drotrecogin alfa 
[activated]) 
For the treatment of severe sepsis Eli Lilly 




Factor Xa inhibitor 2 
Innohep (tinzaparin sodium) 
injectable 





Detrol LA (tolterodine tartrate) For the treatment of overactive bladder with 











agonist 1 Evoxac (cevimeline HCl) For the treatment of symptoms of dry mouth in 
patients with Sjogren's Syndrome 
SnowBrand 
Pharmaceuticals 
antagonist 1 Vesicare (solifenacin succinate) For the treatment of overactive bladder with 
symptoms of urge urinary incontinence 
Yamanouchi, 
GlaxoSmithKline 
agonist 1 Evoxac (cevimeline HCl) For the treatment of symptoms of dry mouth in 










inhibitor 1 Spiriva HandiHaler (tiotropium 
bromide) 








Oral tablets for the adjuctive treatment of 
hypercholesterolemia 
Andrx 




  inhibitor 5 
Crestor (rosuvastatin calcium) For the treatment of primary hypercholesterolemia 
(heterozygous familial and nonfamilial) and mixed 
dyslipidemia 
AstraZeneca 
  - 90 - 
Lescol XL (fluvastatin sodium) 
tablet, extended release 
For the use as an adjunct to diet to reduce 




Bayer Extra Strength Aspirin Mild to moderate migraine pain Bayer Corporation  
Children's Motrin Cold Common cold McNeil Consumer 
Healthcare 
COX inhibitor 3 




Bextra Oral tablet for the treatment of osteoarthritis, 





COX-2 inhibitor 2 
Vioxx (rofecoxib) For the treatment of rheumatoid arthritis Merck 
D(1B) 
receptor 




1 Abilify (aripiprazole) Oral drug for the treatment of schizophrenia Bristol-Myers 
Squibb and Otsuka 
America 
Pharmaceutical 
agonist 1 Apokyn (apomorphine HCl) Parkinson's Disease Mylan Bertek 
Pharmaceuticals 
Geodon (ziprasidone mesylate) To control agitated behavior and psychotic 





Ziprasidone (ziprasidone HCl) Oral capsule for the treatment of schizophrenia Pfizer 
D(3) 
receptor 
agonist 1 Apokyn (apomorphine HCl) Parkinson's Disease Mylan Bertek 
Pharmaceuticals 






agonist 1 Apokyn (apomorphine HCl) Parkinson's Disease Mylan Bertek 
Pharmaceuticals 
Cymbalta (duloxetine) Depression Eli Lilly 
Ritalin LA (methylphenidate HCl) Oral capsules for the treatment 





  inhibitor 4 
Strattera (atomoxetine HCl) For the treatment of Attention-Deficit/Hyperactivity 
Disorder (ADHD) in children, adolescents and 
adults. 
Eli Lilly 
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Ultracet (acetaminophen and 
tramadol HCl) 
 For the short-term management of acute pain Ortho-McNeil 
Pharmaceutical 
Avelox I.V. (moxifloxacin HCl) Injectable antibacterial agent for adults with 
susceptible strains of bacterial infections 
Bayer 
Novantrone (mitoxantrone HCl) For reducing neurologic disability and/or the 




DNA TopII inhibitor 3 
Quixin (levofloxacin) For treatment of bacterial conjunctivitis Santen 
Avelox I.V. (moxifloxacin HCl) Injectable antibacterial agent for adults with 
susceptible strains of bacterial infections 
Bayer 
DNA topoisomerase (3) 
  
DNA TopIV inhibitor 2 
Quixin (levofloxacin) For treatment of bacterial conjunctivitis Santen 
Eligard (leuprolide acetate) For the palliative treatment of advanced prostate 
cancer 
Atrix Laboratories agonist 2 
Viadur (leuprolide acetate 
implant) 




releasing hormone (3) 
GnRH 
antagonist 1 Plenaxis (abarelix for injectable 
suspension) 
For treatment of advanced prostate cancer Praecis 
Pharmaceuticals 
Kaletra Capsules and Oral 
Solution 
For the treatment of HIV-1 infection Abbott 
Laboratories 
Lexiva (fosamprenavir calcium) For the treatment of HIV infection in adults in 
combination with other antiretroviral agents. 
GlaxoSmithKline 
HIV-1 protease   inhibitor 3 
Reyataz (atazanavir sulfate) For the treatment of HIV-1 infection in combination 
with other antiretroviral agents 
Bristol-Myers 
Squibb 




Trizivir (abacavir sulfate; 
lamivudine; zidovudine AZT) 
Tablet 
For the treatment of HIV-1 infection Glaxo Wellcome 
HIV-1 reverse 
transcriptase 
  inhibitor 3 
Viread Once-daily oral tablet for the treatment of human 
immunodeficiency virus (HIV) infection 
Gilead Sciences 
Aciphex (rabeprazole sodium) For the treatment of symptomatic 
gastroesophageal reflux disease 
Eisai Proton pump   inhibitor 3 
Nexium (esomeprazole 
magnesium) 
For the eradication of Helicobacter pylori, the 
healing of erosive esophagitis, and the treatment 
AstraZeneca 
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of symptomatic GERD 
Protonix (pantoprazole sodium) 
Intravenous Formulation; Delayed 
Release Tablets 
For the short-term treatment of gastroesophageal 
reflux disease; Oral tablets for the treatment of 






Erbitux (cetuximab) Colorectal Cancer Imclone, 
Bristol-Myers 
Squibb 
  inhibitor 2 
Iressa (gefitinib) For the second-line treatment of non-small-cell 
lung cancer 
AstraZeneca 




inhibitor 1 Tarceva (erlotinib) For the treatment of advanced refractory 
metastatic non-small cell lung cancer 
Genentech, OSI 
Pharmaceuticals 
Benicar Oral tablet for the treatment of hypertension Forest 
Laboratories 
Diovan Oral capsules and tablets for the treatment of 
hypertension 
Novartis 





Teveten HCT (eprosartan 
mesylate/hydrochlorothiazide) 





antagonist 1 Subutex/Suboxone 
(buprenorphine/naloxone) 
Oral tablets for the treatment of opiate 
dependence 









Oral tablets for the treatment of opiate 
dependence 
Reckitt Benckiser 
H1 receptor antagonist 1 Clarinex Once-daily oral tablet for the treatment of allergic 
rhinitis and chronic ideopathic urticaria 
Schering-Plough Histamine receptor (2) 
  
H2 receptor antagonist 1 Pepcid Complete For use in the relief of heartburn associated with 
acid indigestion and sour stomach 
Merck Research 
Laboratories 
Cialis (tadalafil) Oral agent for the treatment for erectile 
dysfunction 
Eli Lilly CGMP-specific 
3',5'-cyclic 
phosphodiesterase 
PDE5 inhibitor 2 
Levitra (vardenafil) For the treatment of erectile dysfunction related to 




growth factor (2) 
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  binder 1 Avastin (bevacizumab) Colorectal Cancer Genentech 
Alimta (pemetrexed for injection) Mesothelioma Eli Lilly Dihydrofolate reductase   inhibitor 2 
Malarone (atovaquone; proguanil 
HCl) 







inhibitor 1 dutasteride For the treatment of symptomatic benign prostatic 
hyperplasia 












  inhibitor 1 Orfadin (nitisinone) Capsules for the treatment of hereditary 





  inhibitor 1 Cancidas Intravenous infusion for the treatment of invasive 
aspergillosis 
Merck & Co. 
23S rRNA   binder 1 Ketek (telithromycin) Respiratory Infections Aventis 
Pharmaceuticals 
Acetylcholinesterase   inhibitor 1 Reminyl (galantamine 
hydrobromide) 
For the treatment of mild to moderate dementia of 
the Alzheimer's type 
Janssen Research 
Alpha-1-antitrypsin   inhibitor 1 Zemaira (alpha1-proteinase 
inhibitor) 
For the treatment of alpha1-proteinase inhibitor 




  antigen 1 Bexxar For the treatment of patients with CD20 positive, 
follicular, non-Hodgkin's lymphoma following 
chemotherapy relapse 
Corixa 
Calcineurin   inhibitor 1 Elidel Topical cream for the treatment of atopic 
dermatitis 
Novartis 
Cholinesterase   inhibitor 1 Exelon (rivastigmine tartrate) Indicated for the treatment of mild to moderate 




Cytochrome P450 19   inhibitor 1 Femara (letrozole)  First-line treatment of postmenopausal women 
with locally advanced or metastatic breast cancer 
Novartis 
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DNA polymerase   inhibitor 1 Hepsera (adefovir dipivoxil) For the treatment of chronic hepatitis B in adults 
with evidence of active viral replication 
Gilead Sciences 
Endothelin receptor   antagonist 1 Tracleer (bosentan) For the treatment of pulmonary arterial 
hypertension 
Actelion 
Estrogen receptor   antagonist 1 Faslodex (fulvestrant) For the treatment of hormone receptor positive 





  inhibitor 1 Alimta (pemetrexed for injection) Mesothelioma Eli Lilly 
Interleukin-1   blocker 1 Kineret Injectable therapy for the treatment of rheumatoid 
arthritis 
Amgen 
NMDA receptor   antagonist 1 Namenda (memantine HCl) For the treatment of moderate to severe dementia 






  agonist 1 Avandamet (rosiglitazone maleate 
and metformin HCl) 





  agonist 1 Travatan (travoprost ophthalmic 
solution) 
For the reduction of elevated intraocular pressure 
in patients with open-angle glaucoma or ocular 
hypertension 
Alcon 
Dopamine reuptake   blocker 1 Ritalin LA (methylphenidate HCl) Oral capsules for the treatment 
Attention-Deficit/Hyperactivity Disorder (ADHD) 
Novartis 
Pharmaceuticals 
Substance-P receptor   antagonist 1 Emend (aprepitant) For the treatment of nausea and vomiting 
associated with chemotherapy 
Merck 
Thymidylate synthase   inhibitor 1 Alimta (pemetrexed for injection) Mesothelioma Eli Lilly 
Tumor necrosis factor   inhibitor 1 Remicade (infliximab) For inhibiting the progression of structural damage 
in patients with rheumatoid arthritis; Intravenous 
infusion for the treatment of rheumatoid arthritis 
Centocor 
Tyrosine-protein kinase   inhibitor 1 Gleevec (imatinib mesylate) Oral therapy for the treatment of chronic myeloid 
leukemia;For the treatment of gastrointestinal 




 inhibitor 1 Clolar (clofarabine) For the treatment of acute lymphoblastic leukemia 
in pediatric patients 
Genzyme 
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Table 4-5 gives the known targets of the approved drugs by the United States FDA in 
2000-2004 together with the corresponding drug name, drug action, targeted diseases 
and the drug inventing/marketing company. There are a total of 66 identifiable targets 
that are targeted by 100 distinct drugs approved during the period. Most of these 
targets are for antagonist/inhibitor drugs, only 17 are for agonist/partial agonist drugs. 
The significantly smaller number of agonist drugs is likely due in part to the higher 
level of difficulty in finding agonist drugs. Agonist drugs generally require more 
specific binding configuration than that of antagonist/inhibitor drugs. Some targets, 
such as 5-HT receptors and adrenoceptors, are targeted by both agonist and antagonist 
drugs for the treatment of different diseases.  
There are 90 drugs, which constitutes 43% of the total number of approved drugs, 
without identifiable target described in the FDA documents. Some of these drugs are 
protein-based, peptide-based, or gene-therapy-based agents whose target is not 
specifically mentioned. Some drugs, such as trileptal (oxcarbazepine) and zonegran 
(zonisamide), were discovered without the knowledge of their precise molecular 
mechanism at the time of their filing. Trileptal is known to have blocking effects on 
voltage sensitive sodium and calcium channels [178]. Zonegran activates dopamine 
synthesis and moderately inhibits monoamine oxidase [179]. It also inhibits carbonic 
anhydrase, modulates GABA A receptor, and exerts blocking effects on voltage 
sensitive sodium and calcium channels [178]. It remains unclear how these drugs 
affect these proteins and which of these actions directly contribute to their therapeutic 
effects. 
The reported mechanism of a number of drugs, such as Plavix (clopidogrel bisulfate) 
and Rapamune (sirolimus), was not specific enough to point to a particular target at 
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the time of their filing. It is noted that the mechanism of some of these drugs has since 
been determined. For instance, it has been reported that plavix inhibits ADP-induced 
platelet aggregation because one of its metabolite antagonizes platelet ADP receptor 
P2Y [180]. It has been found that rapamune binds to and forms a complex with 
cytosolic FKBP-12, which inhibits the protein kinase mTOR and thereby produces its 
antifungal, antiproliferative, and immunosuppressive activities [181].  
Most of the 66 identifiable targets of the FDA approved drugs during the period are 
also targeted by drugs marketed before 2000. Given that there were ~120 known 
targets of marketed drugs in the previous reports [9, 37, 135], it appears that the 
majority of the known successful targets have been continuously explored for 
deriving new therapeutic agents. The targets with larger number of drugs approved 
during the period are 5HT receptors with 11 drugs, adrenoceptors with 8 drugs, and 
serotonin reuptake with 6 drugs. Moreover, coagulation factor, muscarinic 
acetylcholine receptor, HMG-CoA reductase, and cyclooxygenase are targeted by 5 
drugs each. Dopamine receptor and noradrenergic reuptake are targeted by 4 drugs 
each. The other 7 targets, such as DNA topoisomerase, gonadotropin-releasing 
hormone, HIV-1 protease, HIV-1 reverse transcriptase, proton pump, epidermal 
growth factor receptor, and angiotensin II receptor are targeted by 3 drugs each. In 
addition, another 5 targets namely opioid receptor, histamine receptor, 
phosphodiesterase, vascular endothelial growth factor and dihydrofolate reductase are 
targeted by 2 drugs each. These targets represent highly successful targets that have 
been extensively explored for deriving new therapeutic agents. 
There are 12 targets that are targeted by subtype-specific drugs, representing 18.2% of 
the total number of identifiable targets of the FDA approved drugs during the period, 
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which suggests that substantial efforts have been directed at the discovery of subtype 
specific drugs since the early 1990s and these efforts have led to the success. These 
targets include phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction 
[144], cyclooxygenase 2 inhibitors for arthritis and menstrual pain [182], tumor 
necrosis factor alpha blockers for rheumatoid arthritis, dopamine receptor D2 agonists 
for schizophrenia, 5-HT2 receptor antagonists for schizophrenia, adrenoceptor alpha1 
antagonist for hyperplasia, and histamine receptor H2 antagonist for heartburn [183].  
According to the literature, a total of 16 innovative targets emerged since1996 [38]. 
Examples of these targets are receptor protein-tyrosine kinase erbB-2 (HER2/neu) 
with the first drug Trastuzumab approved in 1998 for HER2 positive metastatic breast 
cancer, BCR-ABL tyrosine kinase with the first drug Celecoxib approved in 2001 for 
chronic myeloid leukemia, vascular endothelial growth factor with the first drug 
Bevacizumab approved in 2004 for colorectal cancer, HBV DNA polymerase with the 
first drug Adefovir dipivoxil approved in 2002 for hepatitis B, HIV gp41 with the first 
drug Enfuvirtide approved in 2003 for HIV infection, NMDA receptor with the first 
drug Memantine approved in 2003 for Alzheimer's disease, platelet P2Y12 receptor 
with the first drug Clopidogrel approved in 1997 for stroke and heart attack, platelet 
glycoprotein IIb/IIIa receptor with the first two drugs Tirofiban and Eptifibatide 
approved in 1998 for severe chest pain and small heart attacks, endothelin receptor 
with the first drug Bosentan approved in 2001 for primary pulmonary hypertension, 
mineralocorticoid receptor with the first drug Eplerenone approved in 2002 for 
hypertension, phosphodiesterase 5 with the first drug Sildenafil approved in 1998 for 
erectile dysfunction, cyclooxygenase 2 with the first drug Celecoxib approved in1998 
for arthritis, gastrointestinal lipase with the first drug Orlistat approved in 1999 for 
obesity, and peroxisome proliferator activated receptor with the first drug 
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Troglitazone approved in 1997 for type 2 diabetes mellitus. 
4.2.3 Progress and difficulties of target exploration 
Some of these highly explored research targets have been used for drug development 
well before 2000. Great progresses have been made towards the discovery and testing 
of agents directed at these targets. However, for some of these targets, many 
difficulties remain to be resolved before viable drugs can be derived. The appearance 
of a high number of patents associated with these targets partly reflects the intensity 
of efforts to find effective drug candidates against these targets.  
Farnesyl-protein transferase inhibitors have been designed and tested as novel agents 
for the treatment of myeloid malignancies since the early 1990s [184]. Initially 
developed to inhibit the prenylation necessary for Ras activation, their mechanism of 
action seems to be more complex, involving other proteins unrelated to Ras. 
Preliminary results from clinical trials demonstrated inhibition of enzyme target, a 
favorable toxicity profile and promising efficacy [185]. This led to the initiation of 
phase II trials in a variety of hematologic malignancies and disease settings [186]. 
Phosphodiesterase-4 (PDE4) has been explored as the target of novel 
anti-inflammatory agents since the mid 1990s [187]. The rationale for selecting this 
target is, in part, from the clinical efficacy of theophylline, an orally active 
nonselective PDE inhibitor. It has been found that intracellular cyclic adenosine 
monophosphate levels regulate the function of many of the cells thought to contribute 
to the pathogenesis of respiratory diseases such as asthma and COPD, and these cells 
also selectively express PDE4 [188]. Recent clinical studies of selective PDE4 
inhibitors such as cilomilast and roflumilast used for the treatment of inflammatory 
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lung disease showed positive results that offered some optimism, and efforts were 
being made to reduce the side effect of these drug candidates [188].  
Matrix metalloproteinases (MMPs) have been targeted for cancer and other diseases 
since the early 1990s [189]. MMPs degrade the extracellular matrix, promote tumor 
invasion and metastasis, and regulate host defense mechanisms and normal cell 
function. Blocking all MMPs may not lead to a positive therapeutic outcome. So far, 
most clinical trials of MMP inhibitors have not yielded good results, due primarily to 
the lack of subtype selectivity, bioavailability and efficacy, and in some cases 
inappropriate study design [190]. Intensive efforts are being directed at the discovery 
of potent, selective, orally bioavailable MMP inhibitors for the treatment of cancer. 
There have been encouraging news about some inhibitors, such as ABT-518, that have 
entered in Phase I clinical trials in cancer patients [191]. 
Intensive research efforts have been directed at developing beta 3-adrenergic receptor 
(beta3-AR) selective agonists for the treatment of type 2 diabetes and obesity in 
humans since early 1990s [192]. These agonists have been observed to simultaneously 
increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the 
belief that this receptor might serve as an attractive target for the treatment of diabetes 
and obesity. However, drug design efforts have been hindered by the obstacles in the 
pharmacological differences between the rodent and human beta3-AR, the lack of 
selectivity of leads, and unsatisfactory oral bioavailability and pharmacokinetic 
properties of tested agents [193]. A recent test of beta3-AR agonists directed at the 
human receptor showed promising results in their ability to increase energy 
expenditure in humans following a single dose. However, they do not appear to be 
able to sustain their effects when administered chronically. Further clinical testing will 
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be necessary, using compounds with improved oral bioavailability and potency, to 
help assess the physiology of the beta3-AR in humans and its attractiveness as a 
potential therapeutic for the treatment of type 2 diabetes and obesity [193]. 
Inspection of the targets reported in these patents also provides useful indication about 
the progress for the search of new targets. Examples of newly explored targets are 88 
kDa glycoprotein growth factor for the treatment of cancer (US patent 6,670,183), 
anandamide amidase for pain (US patent 6,579,900), FK506-binding protein 4 for 
neurological disorders (US patent 6,495,549), galanin receptor type 2 for CNS 
disorder (US patent 6,407,136), gamma secretase for Alzheimer's disease (US patent 
6,448,229), glycogen synthase kinase-3 beta for diseases characterized by an excess 
of Th2 cytokine (US patent 6,479,490), orexin receptor 1 for obesity (US patent 
6,677,354), and tripeptidyl-peptidase II for eating disorder and obesity (US patent 
6,335,360). Most of these new research targets are explored for the treatment of high 
impact diseases needing effective or more treatment options. 
4.2.4 Targets of subtype specific drugs 
There are 62 targets explored for the design of subtype-specific drugs, which 
represents 15.7% of the 395 identifiable targets in the US patent approved in 
2000-2004. Compared with the 12 targets of FDA approved subtype-specific drugs 
during the same period, a significantly larger number of targets are being explored for 
the design of subtype-specific drugs. However, the percentage of these targets with 
respect to the total number of targets in the US patent is smaller than that of the FDA 
approved drugs during the same period, which seems to indicate the level of difficulty 
of finding subtype-specific agents directed at a variety of targets. For instance, 
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although there are 79 patents for matrix metalloproteinase (MMP), only 3 patents 
describe subtype-specific investigational drugs. These are MMP-9 inhibitors (US 
patent 6,667,388), MMP-4 inhibitors (US patent 6,544,761), and MMP-13 inhibitors 
(US patent 6,656,932).  
The targets with a higher number of patents of subtype-specific investigational drugs  
are phosphodiesterase 4 with 49 patents (for the treatment of asthma, inflammation 
and osteoporosis), cyclooxygenase 2 with 38 patents (inflammation, cancer and 
others), adrenoceptor beta with 41 patents (hyperglycemia, obesity, gastrointestinal 
disorders and others), adrenoceptor alpha with 22 patents (hypertension, pain, gastric 
ulcers, vascular diseases and others), phosphodiesterase 5 with 19 patents (sexual 
dysfunction), cytochrome P450RAI with 15 patents (diseases responsive to retinoid 
treatment), 5-HT1 receptor with 17 patents (depression, eating disorders, obesity, 
headache and others), 5-HT2 receptor with 12 patents (irritable bowel syndrome), 
5-HT3 receptor with 8 patents (blood glucose control), and 5-HT7 receptor with 4 
patents (bladder disorder and urinary retention).  
4.3 Characteristics of therapeutic targets 
4.3.1 What constitutes a therapeutic target? 
The majority of clinical drugs achieve their effect by binding to a cavity, and 
modifying the activity, of its protein target. Specific structural and physicochemical 
properties, such as the “rule-of-five†” [194], are required for these drugs to have a 
sufficient level of efficacy, bioavailability and safety, which define target sites to 
                                                        
† “Rule-of-five” was firstly introduced by Lipinski in 1997. It has become an awareness tool for 
discovery chemists. Compounds with two or more of the following characteristics are flagged as likely 
to have poor oral absorption: 1) More than 5 H-bond donors; 2) Molecular weight >500; 3) c log P>5; 
4) Sum of N's and O's (a rough measure of H-bond acceptors) > 10. 
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which drug-like molecules can bind. In most cases, these sites exist out of functional 
necessity, and their structural architectures accommodate target-specific drugs that 
minimally interact with other functionally important but structurally similar sites. 
These constraints limit the types of proteins that can be bound by drug-like molecules, 
leading to the introduction of the concept of druggable proteins [37, 195]. Druggable 
proteins do not necessarily become therapeutic targets [37], only those that play key 
roles in diseases can be explored as potential targets. Nonetheless, analysis of the 
characteristics of these druggable proteins is useful for facilitating molecular 
dissection of the mechanism of drug targeting and for guiding new targets searching.  
Certain characteristics are expected for therapeutic targets [37]. These targets play 
critical and preferably un-substitutable roles in disease processes. They have certain 
functional and structural novelty to allow for drug specificity. They are not 
significantly involved in other important processes in humans to limit potential 
side-effects. Expression of these targets is either at a constrained level or tissue 
selective to allow for sufficient drug efficacy. Drug-binding sites are expected to have 
certain structural and physicochemical properties to accommodate high-affinity 
site-specific binding and subsequent modification of protein activity by drug-like 
molecules. These characteristics likely define the sequence features, structural 
architectures, genomic signatures, and proteomic profiles of therapeutic targets and 
their roles at the pathway, cellular and physiological levels. Useful hints about some 
of the characteristics of therapeutic targets may be probed by analyzing their sequence 
properties, protein families, structural folds, biochemical classes, similarity proteins, 
gene locations in human genome, associated pathways. These hints may be potentially 
used for deriving rules and developing predictive tools for searching druggable 
proteins from genomic data. As part of the effort for supporting such a goal, relevant 
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features of 268 successful targets and 1267 research targets are described. 
4.3.2 Protein families represented by therapeutic targets 
The sequence and functional similarities within a protein family usually indicates 
general conservation of binding site architecture between family members. If a drug 
can specifically target one member of a family, then it is possible to design molecules 
with similar physicochemical properties for specific binding to some of the other 
members of the family, and multiple members of a family have been explored for 
developing drugs of different therapeutic applications [196, 197]. A recent analysis of 
the identifiable drug-binding domains of 399 targets (including 120 successful targets) 
suggested that these targets are represented by 130 protein families, nearly half of 
which are represented by 6 families [196], which indicate the level of extensive 
exploration of multiple members of specific families as therapeutic targets.  
With the availability of the information of a significantly higher number of targets 
than that used in the recent analysis, it is of interest to re-investigate family 
representations of therapeutic targets. There are 173 successful targets and 906 
research targets with identifiable drug-binding domain. Analysis of the Pfam [198] 
protein family of these domains finds that these targets are represented by 92 and 412 
families respectively.  
About 42% of the 173 successful targets fall into 10 families. These, in terms of Pfam 
family names, are 7 transmembrane receptor rhodopsin family (32 targets), nuclear 
hormone receptor (11 targets), protein kinase (5 targets), short chain dehydrogenase (4 
targets), amino acid permease (4 targets), cytochrome P450 (4 targets), 
neurotransmitter-gated ion-channel l (4 targets), sodium: neurotransmitter symporter 
Chapter 4                                       Computational analysis of therapeutic targets 
 
 - 104 - 
(3 targets), reverse transcriptase (3 targets), and ion transport protein (3 targets).  
About 40% of the 906 research targets fall into 26 families, which include 7 
transmembrane receptor rhodopsin family (94 targets), protein kinase (87 targets), 
immunoglobulin (29 targets), trypsin (21 targets), nuclear hormone receptor (16 
targets), receptor family ligand binding region (12 targets), papain family cysteine 
protease (11 targets), matrixin (10 targets), small cytokines (9 targets), 3'5'-cyclic 
nucleotide phosphodiesterase (8 targets), neurotransmitter-gated ion-channel (7 
targets), subtilase family (7 targets), ABC transporter (7 targets),  prolyl 
oligopeptidase family (6 targets), eukaryotic-type carbonic anhydrase (6 targets), short 
chain dehydrogenase (6 targets), eukaryotic aspartyl protease (6 targets), ZIP 
transcription factor (6 targets), TNFR/NGFR (5 targets), ion transport protein (5 
targets), peptidase family (5 targets), Reprolysin (M12B) family zinc metalloprotease 
(5 targets), sugar transporter (5 targets), and hormone receptor (5 targets).  
Overall, 40% or 436 of the 1,079 successful and research targets are distributed in 26 
protein families, which include all of the 6 top target-representing families found in 
the recent study [196]. The remaining 60% or 643 targets are distributed in 434 
families. There are 6 families both in the top 10 families of successful targets and top 
26 families of the research targets. These are 7 transmembrane receptor rhodopsin 
families, ligand-binding domain of nuclear hormone receptor, protein kinase domain, 
short chain dehydrogenase, neurotransmitter-gated ion-channel ligand binding, and 
ion transport protein.  
Two parallel lines of target exploration are indicated. One is the extensive use of 
successful targets and additional members of a relatively small group of protein 
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families. On average, 17 targets from each of the 26 heavily-used families have been 
explored. The other is the exploration of a diverse range of proteins in a variety of 
families. On average, only 1 or 2 targets from each of the other 434 protein families 
have been explored or are being evaluated. It is expected that more members from 
some of these families may be used as viable targets.  
It is of interest to estimate the total number of families that represent all of the 3,000 
targets that are postulated to exist. Assuming that all of the 1,535 currently explored 
targets are viable ones, which is doubtful but not significantly affect our estimate, 
there are ~1,500 un-discovered targets. If these un-discovered targets roughly follow 
the same pattern of protein family representation of the currently explored targets, it is 
expected that 40% of them are from a relatively small group of families, probably no 
more than a few dozen. Moreover, the bulk, say 60%, of the remaining 60% of these 
targets is likely from the 434 families that represent 60% of the currently explored 
targets. Therefore, there are no more than 24% of the un-discovered targets that are 
from protein families not represented by the known targets, and these targets are 
represented by no more than 480 families. This gives a crude estimate of no more than 
940 of target-representing protein families, likely to be substantially less, for all of the 
therapeutic targets. The total number of protein families in Pfam database is 7677 
[198]. Thus target-representing families account for less than 12% of all protein 
families, and 40% of the targets are expected to be represented by just a few dozen 
families. 
4.3.3 Structural folds 
A common feature of targets in a particular family is the general conservation of 
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binding site architecture. Binding sites of drugs are usually located within specific 
cavity of their target proteins, and drug binding is primarily facilitated by 
hydrophobic, aromatic stacking, hydrogen bonding, and van der Waals interactions 
[199]. Certain constrains on the architectures of drug-binding domains are expected 
for accommodating the binding of target-specific “rule of five” small molecules that 
minimally interact with other functionally important but structurally similar sites. 
There have been reports about specific drug-domain architecture [200-202]. 
Because of the distribution of therapeutic targets in a relatively small number of 
protein families, it is expected that these targets are represented by a relatively small 
number of structural folds. Examination of the structural folds of the drug-binding 
domains can therefore shed light on the structural characteristics of therapeutic targets. 
Structural folds of proteins can be obtained from the SCOP database [203], which 
contains 701 structural folds generated from the analysis of 1,7406 protein entries 
from the PDB database [204]. There are 52 successful targets that have both available 
3D structure and identifiable drug binding domain. Analysis of the SCOP structural 
folds of these targets shows that they are represented by 29 folds, which is given in 
Table 4-6. All data is based on 113 successful targets that have available 3D structure. 
About 60% of these targets are represented by just 8 folds. These 8 folds, given by 
SCOP fold names, are nuclear receptor ligand-binding domain (8 targets), TIM 
beta/alpha-barrel (6 targets), protein kinase-like (4 targets), 4-helical cytokines (3 
targets), NAD(P)-binding Rossmann-fold domains (3 targets), trypsin-like serine 
proteases (3 targets), alpha/beta-hydrolases (2 targets), and galactose-binding 
domain-like (2 targets). 
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Table 4-6: Structural folds represented by successful targets. Structural folds are from 
the SCOP database.  
SCOP Fold 
ID 
Fold Description Number of 
Targets 
a.123 Nuclear receptor ligand-binding domain 8 
c.1 TIM beta/alpha-barrel 6 
d.144.1 Protein kinase-like (PK-like) 4 
a.26.1 4-helical cytokines 3 
b.47.1 Trypsin-like serine proteases 3 
c.2 NAD(P)-binding Rossmann-fold domains 3 
b.18.1 Galactose-binding domain-like 2 
c.69 alpha/beta-Hydrolases 2 
c.65.1.1 Formyltransferase 1 
c.19.1 FabD/lysophospholipase-like 1 
g.39.1 Glucocorticoid receptor-like (DNA-binding domain) 1 
c.71.1 Dihydrofolate reductases 1 
a.104.1.1 Cytochrome P450 1 
b.74.1 Carbonic anhydrase 1 
c.82.1 ALDH-like 1 
b.68 6-bladed beta-propeller 1 
d.163.1 DNA breaking-rejoining enzymes 1 
d.32 Glyoxalase/Bleomycin resistance protein/Dihydroxybiphenyl dioxygenase 1 
d.68 IF3-like 1 
d.174.1.1 Nitric oxide (NO) synthase oxygenase domain 1 
d.6.1.1 Prion-like 1 
d.110 Profilin-like 1 
c.66.1 S-adenosyl-L-methionine-dependent methyltransferases 1 
a.126 Serum albumin-like 1 
d.179.1.1 Substrate-binding domain of HMG-CoA reductase 1 
d.168.1 Succinate dehydrogenase/fumarate reductase flavoprotein, catalytic domain 1 
d.117.1 Thymidylate synthase/dCMP hydroxymethylase 1 
b.22 TNF-like 1 
j.61.1.1 Human glutathione reductase (HGR) inhibitor 1 
 
There are 283 research targets that have both available 3D structure and identifiable 
drug binding domain, which are represented by 107 folds. 60% of these targets are 
represented by 21 folds. These include Protein kinase-like (21 targets), 4-helical 
cytokines (14 targets), trypsin-like serine proteases (14 targets), P-loop containing 
nucleoside triphosphate hydrolases (12 targets), zincin-like (12 targets), TIM 
beta/alpha-barrel (11 targets), IL8-like (9 targets), cysteine proteinases (8 targets), 
cystine-knot cytokines (8 targets), nuclear receptor ligand-binding domain (8 targets), 
C-type lectin-like (7 targets), NAD(P)-binding Rossmann-fold domains (7 targets), 
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immunoglobulin-like beta-sandwich (6 targets), caspase-like (5 targets), 
flavodoxin-like (5 targets), acid proteases (4 targets), alpha/beta-hydrolases (4 targets), 
concanavalin A-like lectins/glucanases (4 targets), knottins (4 targets), 
phosphorylase/hydrolase-like (4 targets), and PLP-dependent transferases (4 targets). 
4.3.4 Biochemical classes 
Distribution of successful and research targets with respect to biochemical classes is 
given in Figure 4-2 and Figure 4-3 respectively. Biochemical classes include enzymes, 
receptors, nuclear receptors, channels and transporters, factors and regulators (factors, 
hormones, regulators, modulators, and receptor-binding proteins involved in a disease 
process), antigens and the remaining binding proteins not covered in other classes, 
structural proteins (non-receptor membrane proteins, adhesion molecules, envelop 
proteins, capsid proteins, motor proteins, and other structural proteins), and nucleic 
acids [9]. The targets unable to be assigned into any of these biochemical classes are 
tentatively grouped into a separate “unknown” class.  


























Figure 4-2: Distribution of successful targets with respect to different biochemical 
classes 
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Figure 4-3: Distribution of research targets with respect to different biochemical 
classes 
 
The overall distribution pattern of successful targets and research targets are roughly 
similar to the pattern of the 120 successful targets [37] and that of the targets with 
drug-like leads[9, 135]. The class with the largest number of targets is that of enzymes, 
which includes 134 successful and 551 research targets representing 50% and 44% of 
the total number of successful and research targets respectively. The second largest 
group of successful targets is that of receptors with 61 targets representing 23% of 
successful target population. The second largest group of research targets is that of 
factors and regulators with 242 targets representing 18% of the research target 
population, which is compared to the corresponding group of 8 successful targets that 
represents only 3% of the total successful target population. Thus there appears to be a 
dramatic increase in the number of factors and regulators being explored for the 
treatment of various diseases including cancers [205], autoimmune diseases [206], 
inflammation, diabetes and neurodegenerative diseases [207]. 
In addition, target distribution profiles of the groups with a substantial number of 
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successful targets are channels and transporters with 32 targets representing 12 % of 
the successful target population, nuclear receptors with 15 targets representing 6 % of 
the successful target population, and factors and regulators with 8 targets representing 
3% of the successful target population. The data shows, at present, ion channels are 
also important targets for the treatment of pain, neurological and psychiatric disorders 
[208], ligand-gated channels have been used as the targets for diseases such as 
neuropsychiatric disorders [209], transporters are the targets of drugs like 
antidepressants [210], and nuclear receptors have been used as targets of cancer [211], 
inflammatory and immune diseases [212]. With respect to research target groups, the 
distribution patterns of them are receptors with 230 targets representing 18% of the 
research target population, channels and transporters with 75 targets representing 6% 
of the research target population, structural protein with 56 targets representing 4.4% 
of the research target population, antigens and other substrate-binding proteins with 
50 targets representing 4% of the research target population, nucleic acids with 36 
targets representing 3% of the research target population, and nuclear receptors with 
19 targets representing 1% of the research target population.  
4.3.4.1 The distribution of enzyme targets with respect to enzyme 
families 
The biochemical class containing the largest number of successful targets is the 
enzyme class, which includes 134 enzymes representing 50% of the 268 successful 
targets collected in the TTD. This percentage is very similar to the reported figure of 
47% enzyme targets among the marketed small molecule drug targets reported in 
2002 [37]. There are 122 successful and 494 research enzyme targets with available 
enzyme classification EC number.  
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Substantial portion of these enzyme targets appears to be concentrated in a few 
enzyme families. Figure 4-4 shows the distribution of enzyme targets with respect to 
enzyme families. An enzyme family is represented by an enzyme classification (EC) 
number. Examples of therapeutically important enzyme families are EC3.4 (proteases 
and reverse transcriptases), EC2.7 (kinases and polymerases), EC3.1 (esterases, 
phosphatases, phosphodiesterases, phospholipases, and ribonucleases), EC1.1 
(dehydrogenases and oxidases), EC2.3 (acyltransferases), EC2.4 (glycosyl- 
transferases), EC1.14 (monooxygenases and dioxygenases), and EC4.1 (carboxylases 
and aldolases). 
The majority research enzyme targets are distributed in the family of EC2.7, EC3.4, 
and EC3.1, which accounts for 24%, 20%, and 11% respectively. By comparison, 
14%, 11%, and 7% of successful enzyme targets are distributed in the EC2.7, EC3.4, 
and EC3.1 family respectively. EC2.7 contains various kinases and polymerases, 
EC3.4 is composed of proteases and reverse transcriptases, and EC3.1 includes 
esterases such as phosphodiesterases, phosphatases, phospholipases, and 
ribonucleases. Kinases [213], proteases [214], polymerases [215], and esterases [144, 
216, 217] have been frequently explored as therapeutic targets for antiviral, 
antibacterial, anticancer, and cardiovascular effects because of their key roles in the 
regulatory, synthesis and metabolism processes essential for the progression of the 
relevant disease. Thus it is not surprising that these enzymes constitute the largest 
group of enzymatic targets. 
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EC distribution (based on Successful and Research targets)
17



































0 2 1 0 1 0 0 0 1 0 0
6


































































































































































































































































































Figure 4-4: Distribution of enzyme targets with respect enzyme families 
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Moreover, according to the research enzyme targets, 2.8%-3.5% of them are 
distributed in each of the EC1.1, EC2.3, EC2.5, EC4.2, and EC2.4 family respectively. 
EC1.1 is composed of dehydrogenases and oxidases, EC2.3 contains acyltransferases, 
EC2.5 belongs to one kind of transferases, EC 4.2 is constituted by Carbon-oxygen 
lyases and EC2.4 includes glycosyltransferases. dehydrogenases [218], 
acyltransferases [219], transferases [220], lyases [221] and glycosyltransferases [222] 
are increasingly explored for the treatment of high impact diseases such as cancer, 
obesity, depression, diabetes, tumor and inflammation. This seems to indicate a trend 
for targeting metabolizing enzymes as a novel strategy for the treatment of these 
diseases. 
4.3.4.2 The distribution of receptors with respect to receptor families 
The biochemical class containing the second largest number of successful targets is 
the GPCR superfamily. This class consists of 42 GPCRs representing 16% of the 
successful targets collected in the TTD. In contrast, 115 GPCRs represents 9% of the 
research targets. The percentages are comparable to that of 30% GPCRs among the 
marketed small molecule drug targets reported in 2002 [37]. According to successful 
targets, the targets belonging to GPCRs are further divided into 37 in the rhodopsin 
family and 4 in the metabotropic glutamate family respectively. These receptors are 
the target of >50% of the current therapeutic agents in the market, including more 
than a quarter of the 100 top-selling drugs with benefits in the range of several billion 
US dollars [37, 223, 224]. They have been considered as the best drug targets because 
of their key roles in various signaling processes essential for such diseases as 
neurodegenerative diseases, epilepsy, idiopathic pain, drug addition, cardiovascular 
diseases, allergic inflammatory and autoimmune diseases [183]. 
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There are 115 G-protein coupled receptors (GPCR), 22 cytokine receptors and 22 
transmembrane receptor enzymes known to be explored as research therapeutic 
targets. These GPCR targets are further divided into 95 in the rhodopsin family, 10 in 
the metabotropic glutamate family, and 8 in the secretin family. Targets in the 
rhodopsin family account for 7.5% and those of the GPCR superfamily represent 
9.1% of the total number of research targets respectively. The rhodopsin family 
contains a large number of targets because they have been good therapeutic targets for 
various diseases including neurodegenerative diseases, epilepsy, idiopathic pain, drug 
addition, cardiovascular diseases, allergic inflammatory and autoimmune diseases 
[183]. Examples of the targets in the rhodopsin family includes 5-hydroxytryptamine 
receptors, adenosine receptors, adrenergic receptors, bradykinin receptors, 
cannabinoid receptors, chemokine receptors, dopamine receptors, histamine receptors, 
muscarinic acetylcholine receptors, P2Y purinoceptors, and so on. 
4.3.5 Human proteins similar to therapeutic targets 
In the present day drug development processes, drug candidates have frequently been 
intentionally designed to bind to their target specifically and to avoid strong 
interactions with other human protein members of the same protein family to which 
the target belongs [6, 9, 29, 36, 135]. The successfully designed agents are thus less 
likely to significantly interfere with the function of human proteins of the same family, 
reducing the risk of some of the potential unwanted effects. However, their possible 
interactions with human proteins outside the family cannot intentionally avoided at 
the design stage, and the potential unwanted effects associated with some of these 
interactions can only be detected at the later testing stages. Therefore, it tends to be 
easier to find successful drugs for those targets that have fewer human similarity 
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proteins outside of their family. One can then speculate that targets with fewer human 
similarity proteins outside their family tend to be more likely to be explored for drug 
development.  
Some crude estimate about the number of human similarity proteins outside the 
family of each individual target can be provided by conducting a sequence similarity 
search against the 59,618 proteins in the human genome that are currently available in 
protein databases. Table 4-7 summarizes the results of a BLAST search of the 
drug-binding domain of each of the 173 targets with identifiable drug-binding domain 
against available human proteins. About 57% of the targets have less than 5 human 
similarity proteins outside their respective family, and a further 18% of the targets 
have 6-10 similarity proteins. This seems to support the postulation that targets with 
fewer human similarity proteins outside their family tend to be more likely to be 
explored for drug development.  
Table 4-7: Statistics of the number of human similarity proteins of successful targets 














Examples of Targets 
0 -- 5 100 57% 5-hydroxytryptamine 3 receptor, Acetylcholinesterase, 
Adenosine A2b receptor, ATP-sensitive K+ channel 
6 -- 10 32 18% Alpha-1D adrenergic receptor, Dopamine D1 receptor, 
Histamine H1 receptor, HIV-1 reverse transcriptase, 
Muscarinic acetylcholine receptor M1 
11 -- 20 16 9% Coagulation Factor VIIIa, Epidermal growth factor 
receptor, HIV-1 protease, Insulin receptor, Kappa-type 
opioid receptor 
21 -- 40 14 8% Androgen receptor, Estrogen receptor, 
Gamma-aminobutyric acid B receptor, Peroxisome 
proliferator activated receptor alpha 
41 -- 80 6 5% Lutropin-choriogonadotropic hormone receptor, 
Sulfonylurea receptor 2B , Thrombin, Urokinase-type 
plasminogen activator 
> 80 5 3% Human keratin, Receptor-type protein-tyrosine 
phosphatase S, Thyroid peroxidase, Toll-like receptor 7 
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However, fewer number of human similarity proteins outside the family of a target is 
not a necessary condition for finding successful drugs. It merely makes the tasks for 
finding successful drugs against these targets easier as the probability of un-wanted 
interactions with human proteins outside the family is reduced. For targets with a 
higher number of similarity proteins, it is still possible to find agents that can 
specifically bind to a particular target and has no significant interactions with human 
proteins both inside and outside of the family to which the target belongs. This is 
supported by the existence of several successful targets with more than 80 human 
proteins outside the family of the respective target. 
4.3.6 Associated pathways 
Targets associated with a fewer number of pathways tend to reduce the chance of 
un-wanted interference with other processes, and are more likely to be successfully 
discovered and explored for generating a higher number of clinical drugs. This can be 
tested by studying the 132 successful targets that have available pathway information 
in the KEGG database[16]. Table 4-8 gives the statistics of the number of pathways 
these targets are involved. There are 64 (49%), 36 (27%) and 15(11%) targets found 
to be associated with 1, 2, and 3 pathways respectively. Each of the remaining targets 
is involved in 4 to 15 pathways. Some indications about the success rate of the 
exploration of the targets in each group can be probed by looking at the highest 
number of clinical drugs directed at any single target in each group. From Table 4-8, it 
is found that the groups of targets associated with no more than 3 pathways have a 
substantially higher number of clinical drugs than those with more than 3 pathways, 
which seems to support the hypothesis that targets associated with a fewer number of 
pathways tend to be more successfully explored. 
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Table 4-8: Statistics of the number of pathways of successful targets 
Number of 
pathways 
Number of targets in this 
number of pathways 
Percentage of targets in this 
number of pathways 
Highest number of 
drugs for a target 
1 64 49% 8 
2 36 27% 8 
3 15 11% 5 
4 3 2% 1 
5 4 3% 2 
6 3 2% 3 
8 4 3%  
9 1 1% 2 
>10 2 2% 1 
 
4.3.7 Tissue distribution 
Some therapeutic targets have been chosen primarily because of their high and 
selective expression in specific tissues, despite the existence of unfavorable 
conditions such as high expression abundance [32]. Efforts have been made to employ 
more broadly tissue selective strategies [225]. This raises an interest for studying 
tissue distribution patterns of the successful targets to find out to what extent tissue 
specificity has already been used in existing therapeutics. There are 158 successful 
targets with available information about tissue distribution in human. Their tissue 
distribution patterns are given in Table 4-9. 79% of these targets are distributed in less 
than 6 tissues, which seem to indicate that tissue selectivity may be an important 
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Number of Targets 
Predominantly 
Distributed in This 
Number of Tissues 
Percentage of Targets 
Predominantly 
Distributed in This 
Number of Tissues 
Examples of Targets 
1 45 28% D(3) dopamine receptor, Potassium-transporting 
ATPase alpha chain 1, Solute carrier family 12 
member 3 
2 39 25% Lutropin-choriogonadotropic hormone receptor, 
Potassium voltage-gated channel subfamily H 
member 2, Ryanodine receptor 1 
3 23 15% Acetyl-CoA carboxylase 2, Fatty acid synthase, 
Pregnane X receptor 
4 12 8% Inducible Nitric oxide synthase, Peroxisome 
proliferator activated receptor alpha 
5 5 3% Catechol-O-methyl-transferase,  Amine oxidase 
[flavin-containing] A 
6 2 1% Fibroblast growth factor receptor 2, Fatty-acid 
amide hydrolase 
7 3 2% Aldehyde oxidase, Toll-like receptor 7 
8 6 4% Peroxisome proliferator activated receptor 
gamma, P2Y purinoceptor 12, Insulin receptor 
9 1 1% Voltage-gated sodium channel 
10 1 1% Inhibitor of nuclear factor kappa B kinase 
Many 
Tissue 
21 12% Adenosine deaminase, Na-K-2Cl cotransporter, 
Receptor-type protein-tyrosine phosphatase S 
 
4.3.8 Chromosome locations 
Members of a protein family are known to be distributed in specific clusters in 
genomes [226, 227]. Functionally similar but non-homologous proteins have also 
been found to be located at specific regions of genomes, which allow these proteins to 
be similarly regulated [228]. A large percentage of therapeutic targets are from 
multiple members of specific protein families or non-homologous proteins of similar 
function of other targets. It is thus of interest to study the distribution pattern of 
existing human targets in human genome to determine whether there are any level of 
clustering of these targets in specific regions of the chromosomes. 
Distribution patterns of the human successful and research targets in each of the 23 
chromosomes are given in Figure 4-5. These patterns are arranged from the left to 
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right for chromosome 1, 2, …, 22, and X respectively. For each chromosome, the 
pattern of successful targets is given on the left and that of research targets is given on 
the right. The location of each target in a chromosome is marked by a line, with a red 
line for a successful target and a black line for a research target. It appears that a 
substantial percentage of research targets are more densely distributed in or near the 
regions of higher concentration of successful targets. Thus, there seems to be some 
level of clustering of targets at specific regions where successful targets are located.  
The chromosomes with larger number of targets are chromosome 1, 3, 11 and 17. 
Chromosomes 2, 7, 12 and 19 also contain relatively higher concentrations of targets. 
Distribution of targets in certain chromosomes appears to be less even than those in 
other chromosomes. In particular, there are specific sections of larger number of 
targets in chromosome 1, 3, 5, 9, 12, 17 and 19. Targets in the rest of chromosomes 
are relatively evenly distributed. 
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Figure 4-5: Distribution patterns of human therapeutic targets in 23 human chromosomes (For each chromosome, the pattern of 
successful targets is given on the left and that of research targets is given on the right.) 
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5 Computer prediction of druggable proteins as 
a step for facilitating therapeutic targets 
discovery 
In modern drug discovery, pharmaceutical agents have been designed to exert their 
therapeutic effect by interacting with a pre-selected therapeutic target [9, 28, 29]. 
Increasing effort and considerable interest have been directed at the identification of 
effective targets [7, 9, 28, 29, 217]. A 1996 survey showed that, at that time, drug 
therapies and investigational agents were based on ~500 molecular targets [9, 28]. The 
reported number of identifiable targets of the marketed drugs was ~120 [9, 37, 135]. 
Statistical analysis of disease genes and related proteins suggested that the total 
number of potential targets in the human genome is 600~1,500 [37]. Investigation of 
the yeast genome found that antifungal targets constitute 2-5% of the genome [37]. 
Assuming a similar percentage of targets in disease-related microbial genomes, the 
number of potential targets in microbial genomes is estimated to be greater than1,000. 
A typical viral genome such as that of HIV-1 [74], HBV [229], and SARS coronavirus 
[230] contains 1-4 targets, which gives an estimated number of more than 100 
potential targets in disease-related viral genomes. Therefore, the estimated total 
number of distinct targets is in the range of 1,700~3,000.  
In this chapter, potential drug interferences with target proteins are discussed in the 
context of pathway and tissue distribution to provide useful hints about general trends 
of target exploration, current focus in drug discovery for the treatment of high impact 
diseases needing effective or more treatment options, and possible reasons why 
certain targets are easier to explore than others. Meanwhile, a computational system, 
Support Vector Machines (SVMs), is trained for druggable proteins prediction. How 
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to develop and evaluate this prediction system are also discussed. As an important 
item used in this section, druggable protein is elucidated firstly. 
5.1 Druggable proteins and therapeutic targets 
Druggable proteins represent those proteins with specific structural features that favor 
interactions with potent, small drug-like chemical compounds [37]. That is to say, the 
druggable proteins can be readily amenable to be modulated by pharmaceutical small 
molecules. Such kind of capability is called “druggability” [231]. Likewise, 
therapeutic targets here are those proteins that can be targeted and modified by drug 
molecules, where the modulation can change the proteins’ biological functions and 
subsequently provide some therapeutic benefits. The definition for druggable proteins 
and therapeutic targets appears to be quite similar. However, they belong to different 
concept categories. Although they have some overlaps in the definition, druggable 
does not equal drug targets. Figure 5-1 illustrates how to define a potential drug 
target.  
 
Figure 5-1: Definition of potential drug targets 
 
In this figure, there are four different proteins and two biological pathways. These 
four proteins may control access to their corresponding pathways. Proteins 1 and 2 are 
Protein 3 Protein 4 
Druggable 
Domain 
Non-disease related pathways 
Protein 1 Protein 2 
Druggable 
Domain Disease related pathways 
Potential drug target 
Pathway 1 
Pathway 2 
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located in pathway 1, while proteins 3 and 4 are located in pathway 2, respectively. 
Among them, it is supposed that only proteins 1 and 4 have suitable druggable 
domains (or binding domains). According to pathways, one of them is related to 
disease condition. It is known that, only if the protein has appropriate druggable 
domain (e.g. Protein 1 and Protein 4), drug molecules can bind to the protein, modify 
its biological functions, and further impact cellular effects of the pathway. Thus, both 
proteins 1 and 4 can be considered as druggable proteins. However, only protein 1 is 
qualified as drug target, due to its disease relevance. Therefore, it is concluded that a 
protein with druggability is necessary to be considered as a potential drug target, but it 
is not sufficient.  
In 2002, Hopkins drew a figure to explain the relationship between druggable genome 
and drug targets (Figure 5-2)[37]. They pointed out that “the effective number of 
exploitable drug targets can be determined by the intersection of the number of genes 
linked to disease and the ‘druggable’ subset of the human genome”. In their study, 
they also gave some estimated number in detail.     
 
Figure 5-2: Estimated number of drug targets 
 
As shown in Figure 5-2, the group of drug targets (~600-1,500 genes) is the 
intersection of the druggable genome (~3,000 genes) and disease modifying genes 
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rapid progress for Human Genome Project, an estimate of about 30,000 human genes 
[232, 233] has dropped to the current 22,287 genes [76]. Even now, the human gene 
data set is still too large to be handled. As a result, it makes the process of target 
development extremely complex. However, it is also noted that the number of genes 
in human genome is far greater than that of druggable genes. Due to this remarkable 
difference, we may provide a feasible and efficient way to facilitate drug target 
discovery (Figure 5-3).  
 
Figure 5-3: Flow chart about how to facilitate drug target discovery 
 
Firstly, lots of druggable proteins are found by computational scanning of the whole 
human genome. Secondly, biological pathways relevant to the druggable proteins are 
studied. Then, those druggable proteins related to diseases may be picked up for 
further investigation. Finally, scientists will choose some of them as potential drug 
targets and study their various physical-chemical as well as pharmacological 
properties. Here, the focus will be on the first two steps and an attempt to use 
biological statistics and computational methods to facilitate druggable proteins 
searching will be discussed.    
5.2 Prediction of druggable proteins from their 
sequence 
Advances in high-throughput gene sequencing have led to rapid identification 









Going into further drug discovery procedure 
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industry, the sequencing of the human genome and the genomes of disease species 
proved to be both a blessing and a curse. Where potential targets were once hard to 
come by, the industry is now awashed with them. This has left drug discovery 
communities with the difficult task of sifting through the gene data to find novel 
targets [32, 234]. Genomics approaches such as large-scale gene expression analysis, 
functional screens in model organisms, genome scans for disease susceptibility genes, 
and the search of new members of effective drug target classes have enabled the 
finding of countless candidates for many diseases [3, 235, 236]. The determination of 
druggable candidates still relies on experimental studies. Methods that facilitate the 
identification of druggable proteins from these candidates or directly from genomes 
are thus particularly useful for target identification.  
The investigation of the features of known therapeutic targets from earlier studies [37, 
195] and in the previous chapters suggests that targets have certain common 
characteristics, which may be used as the basis for deriving rules for the identification 
of druggable proteins from their sequence in a similar manner to the rule-based 
methods (such as “rule-of-five”) for predicting “drug-like” compounds from their 
structures [194, 237]. Statistical learning methods have also been successfully applied 
for developing tools for predicting “drug-like” molecules from their structures on the 
basis that they have common structural and physicochemical features [238, 239]. It is 
expected that these statistical learning methods are equally applicable for predicting 
druggable proteins from their sequences on the basis that druggable proteins share 
common characteristics. 
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5.2.1 “Rules” for guiding the search of druggable proteins 
Therapeutic targets are grouped into target families, which are defined as protein 
domain families that contain at least one therapeutic target. These target families 
constitute a small percentage, 6.6%, of the 7,677 protein families in the Pfam database 
[198]. A study of 120 targets of clinical drugs (successful targets) and 279 targets of 
investigational agents (research targets) found that they are represented by 130 
families [196]. In the study of 173 successful and 906 research targets in TTD [39], it 
was found that they are distributed in 92 and 412 families, respectively.  
In addition to the distribution in a limited number of target families, certain 
characteristics are expected for therapeutic targets [37]. They play critical roles in 
disease processes, have certain level of structural novelty and physicochemical 
properties, and are involved minimally in other important human processes. Target 
expression is either at a constrained level or tissue selective to allow for drug efficacy. 
These characteristics are likely encoded in the sequence of targets and useful clues 
may be derived from comparative study of these targets against the human genome. 
Drug discovery has been focused on agents that bind to their targets specifically 
without interactions with other human proteins in the respective target family [6, 28, 
29]. However, their possible interactions with human proteins outside the family are 
not intentionally avoided at design stages, and the corresponding unwanted-effects 
can only be detected at later testing stages. It tends to be easier to find viable drugs for 
targets having fewer number of human similarity proteins outside their family. 
Therefore, target comparative studies need to be conducted on the basis of separate 
considerations of proteins outside and inside a target family. 
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Targets associated with a fewer number of pathways tend to reduce the chance of 
undesirable interference with other processes, and are more likely to be successfully 
explored. Some targets have been chosen primarily because of their high and selective 
expression in specific tissues, despite the existence of unfavorable conditions such as 
high expression abundance [32]. Therefore, human pathway and tissue distribution 
profiles are important indicators for characterizing targets and for determining the 
level of difficulty of their exploration.  
The profile of comparative study of therapeutic targets against the human genome is 
generated from the results of BLAST [240] alignment of the drug-binding domain of 
173 successful targets against 59,618 proteins encoded in the human genome. 
Pathway distribution profile is obtained from the available human pathway 
information of 132 successful targets in KEGG database [16]. Tissue distribution 
profile is obtained from the available human tissue distribution information of 158 
successful targets from the SwissProt database [25]. All these profiles are given in 
Table 5-1.  
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Table 5-1: Statistics of the characteristics of successful targets 
Category Human similarity 
proteins outside target 
family 
Human similarity proteins 
in target family 
Target participating 
pathways 
Tissue distribution Sub-cellular location 
Number of Targets 
in Statistics 







































0-5 57% 0-5 26% 1 49% 1 28% Membrane 60% 
6-10 18% 6-30 25% 2 27% 2 25% Cytoplasm 16% 
11-15 3% 31-100 22% 3 11% 3 15% Nucleus 10% 
16-20 6% >100 29% 4 2% 4 8% Extra-cellular 
and Secreted 
8% 
21-40 8%   5 3% 5 3% Mitochondrion 3% 
41-80 5%   6 2% 6 1% Endoplasmic 
reticulum 
2% 
>80 3%   7  7 2% Peroxisome 1% 
    8 3% 8 4%   
    9 1% 9 1%   
Statistical data 
    >10 2% >=10 13%   
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A total of 57% of the investigated targets have less than 6, and a further 21% have 
6-15 human similarity proteins outside their respective target family. In contrast, 
human similarity proteins inside the respective target family are evenly distributed 
between 1 to 40 proteins. There are 49%, 27%, and 11% of the studied targets 
primarily associated with 1, 2 and 3 human pathways respectively. Each remaining 
target is involved in 4 to 15 pathways. Targets associated with no more than 3 
pathways are found to have a substantially higher number of clinical drugs than those 
with more than 3 pathways. A total of 79% of the investigated targets are distributed 
in no more than 5 human tissues. Based on the characteristics of therapeutic targets 
described in earlier studies [37, 195] and in the previous profiles, it seems that the 
following “rules” can be proposed for guiding the search of druggable proteins: 
z The protein is derived from one of the target-representing protein families. The 
number of these families is currently estimated to be no more than 940. So far, 92 
confirmed families (each containing at least one successful target) and 412 likely 
families (each containing at least one research target) have been found. 
z Sequence variation between the drug-binding domain of a protein and those of 
the other human members of its protein family needs to allow sufficient degree of 
differential binding of a “rule-of-five” molecule to the common binding site. 
z Protein preferably has less than 15 human similarity proteins outside its family 
(HSP). While existence of a higher number of human similarity proteins does not 
rule it out as a druggable protein, it generally increases the chance of undesirable 
interferences and thus the level of difficulty for finding viable drugs. (78% of the 
successful targets with identifiable drug-binding domain have less than 15 human 
similarity proteins). 
z Protein is preferably involved in no more than 3 pathways in human (HP). While 
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association with a higher number of human pathways does not rule it out as a 
druggable protein, it generally increases the chance of undesirable interferences 
with other human processes and thus the level of difficulty for finding a viable 
target. (87% of the successful targets with pathway information are associated 
with no more than 3 pathways). 
z For organ or tissue specific diseases, protein is preferably distributed in no more 
than 5 tissues in human (HT). While distribution in a higher number of tissues 
does not rule it out as a druggable protein, it generally increases the chance of 
undesirable interferences with other tissues and thus the level of difficulty for 
finding a viable target. (79% of the successful targets with tissue distribution 
information are distributed in no more than 5 tissues). 
z A higher number of HSP, HP and HT doesn’t preclude the protein as a potential 
target, it statistically increase the chance of undesirable interferences and the level 
of difficulty for finding viable drugs. 
There are 57%, 76% and 53% of the investigated targets with the number of HSP, HP, 
and HT lower than those specified in rule (3), (4), and (5) respectively. Based on this 
result, therapeutic targets can be divided into the “easy” and “difficult” class by using 
a simple rule: targets with HSP≤5, HP≤2 and HT≤2 are “easy” targets, and those with 
a higher number are “difficult” targets. The smaller percentage of targets having a 
higher number of HSP, HP and HT is consistent with the notion that these targets are 
more difficult to explore than those with a smaller number. The suitability of using 
these numbers as indicators of the level of difficulty of target exploration were studied 
by examining the target exploration time (TET) of some of the innovative targets of 
the FDA approved drugs since 1994, which have no marketed drug prior to their 
approval [38]. TET is the number of years between the first reported compound 
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investigation and the first FDA approval. Table 5-2 shows that targets with a fewer 
number of HSP, HP and HT generally have a statistically shorter TET. There are two 
target difficulty levels, E represents “easy” target with a shorter expected target 
exploration time, and D represents “difficult” target with a longer expected target 
exploration time. From Table 5-2, the TET of the “easy” targets is generally shorter 
than 10 years and that of the “difficult” targets is generally longer than 14 years, 
suggesting that the level of difficulty of target exploration may be roughly estimated 
by using this simple rule. 
Table 5-2: Profiles of some innovative targets of the FDA approved drugs since 1994 
Target 
Year of First Reported Com
pound 
Investigation 













in Target Protein Fam
ily 
Num




ber of Pathways Target is 
Distributed 
Predicted Target Difficulty Level 
First FDA Approved Drug 
Maltase-glucoamylase, 
intestinal 
1967 1995 28 1 12 3 2 D Acarbose 
Mineralocorticoid receptor 1975 2002 27 31 101 Many ? D Eplerenone 
Prostaglandin G/H synthase 2 1975 1998 23 33 13 4 1 D Celecoxib 
Acetyl-CoA carboxylase 2 1975 1994 19 30 0 3 5 D metformin 
Inosine-5'-monophosphate 
dehydrogenase 2 
1979 1995 16 4 10 2 1 E mycophenolate 
mofetil 
Phosphodiesterase 5 1984 1998 14 3 74 5 1 D Sildenafil 
Myeloid cell surface antigen 
CD33 
1987 2000 13 2 21 2 1 E Gemtuzumab 
Ozogamicin 
Type-1 angiotensin II receptor 1984 1995 11 8 388 4 2 D Losartan 
Potassium 
Cysteinyl leukotriene receptor 1 1986 1996 10 5 386 2 2 E Zafirlukast 
Receptor protein-tyrosine 
kinase erbB-2 
1988 1998 10 18 482 1 4 D Trastuzumab 
FK-binding protein 12 1989 1999 10 0 30 2 ? E Sirolimus 
P2Y purinoceptor 12 1989 1997 8 3 280 2 ? E Clopidogrel 
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5.2.2 Prediction of druggable proteins by a statistical 
learning method 
New targets may not bear sequence similarity to known targets or known proteins. 
Consequently, a straightforward sequence similarity search against effective drug 
target classes [3] and known disease genes [235] may not always be useful for 
identification of novel targets. While targets appear to have common characteristics 
that are reflected in their sequences, they are from a diverse range of different families 
and structural folds. Thus, methods that do not rely on sequence and structure 
similarity are needed for facilitating the prediction of druggable proteins directly from 
their sequences. 
5.2.2.1 Development of SVM prediction system 
Statistical learning methods, such as SVMs and neural networks, have emerged in the 
last few years as attractive methods for the prediction of protein functional classes 
[82-85, 87-89] and structural classes [241, 242] without the use of sequence similarity. 
These classes contain proteins of diverse functions and structures. Examples of some 
of these classes are RNA-binding proteins, EC2.7 transferases of 
phosphorus-containing groups, EC3.4 peptidases, and TC1.A alpha-type channels. It 
appears that the prediction accuracy of these methods has reached a level sufficient 
for facilitating the prediction of the functional and structural classes of proteins. For 
instance, the overall accuracy of SVMs prediction of the functional family of 13,891 
enzymes and 447 RNA-binding proteins is 86% and 98% respectively. Thus, it is of 
interest to investigate the feasibility of using statistical learning methods for 
predicting druggable proteins from their sequences. 
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Currently, SVM appears to be the most accurate statistical learning method for protein 
predictions [84, 85, 87-89, 241]. Therefore, only this method is investigated here. 
SVM is based on the structural risk minimization principle from statistical learning 
theory [92]. Known proteins are divided into druggable and non-druggable classes, 
each of these proteins is represented by their sequence-derived physicochemical 
features [85]. These features are then used by SVMs to construct a hyperplane in a 
higher-dimensional hyperspace that maximally separate druggable proteins and 
non-druggable ones. By projecting the sequence of a new protein onto this hyperspace, 
it can be determined if this protein is druggable from its location with respect to the 
hyperplane. It is a druggable protein if it is located on the side of druggable class. The 
accuracy of SVMs depends on the diversity of the protein samples used for finding 
the hyperspace and its hyperplane, the quality of the representation of protein features, 
and the efficiency of the SVMs algorithm. To a certain extent, no sequence and 
structural similarity is required per se. Thus SVM is an attractive approach for 
facilitating the prediction of classes of proteins with diverse sequences and structures, 
and thus the prediction of druggable proteins. 
A total of 1,368 sequence entries of 1,535 successful and research targets were used to 
construct the druggable class, and 12,956 representative proteins from 6,856 Pfam 
[198] protein families (with all of the known target-representing families excluded 
from these families) were used to construct the non-druggable class. Multiple 
sequence entries of some viral protein targets were included in the druggable class 
because of significant sequence variations across strains. Proteins in each class were 
randomly divided into five subsets of approximately equal size. Four subsets were 
selected as the training set and the fifth as the testing set. This process was repeated 
five times such that every subset was selected as a testing set once.  
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5.2.2.2 Evaluation of prediction model  
The average prediction accuracy from this 5-fold cross validation study was 69.8% 
for druggable proteins and 99.3% for non-druggable proteins. The accuracy for 
non-druggable proteins was comparable but that of druggable proteins was somehow 
lower than those of protein functional and structural families [84, 85, 87-89, 241], 
which was expected because of the significantly higher level of sequence and 
structural diversity of therapeutic targets. Nonetheless, these accuracies were 
meaningful for facilitating the prediction of druggable proteins.  
To test its potential for practical applications, the constructed SVM prediction system 
was used to scan the human genome for identifying potential druggable proteins that 
are not in the training and testing sets. A total of 1,102 human proteins were predicted 
to be druggable, which included 153 G-protein coupled receptors (GPCR), 65 other 
receptors, 333 enzymes, and 56 channels. These numbers were within the estimated 
numbers of druggable proteins and therapeutic targets in the human genome. For 
instance, the total number of druggable proteins and actual targets in the human 
genome has been estimated to be ~3,000 and ~1,500 respectively [37], and the total 
number of 400 GPCRs has been suggested to be potential targets [243]. Some 
examples of predition results are listed in appendix A. Moreover, the yeast genome 
was also searched by using this SVM system to test whether the prediction results 
would be consistent with previous studies of this genome. The search of the yeast 
genome identified 353 druggable proteins, which constituted 4% of the 8,904 encoded 
proteins. This number was consistent with the report that antifungal targets constitute 
2-5% of the yeast genome [37].  
This SVM prediction system was further tested by a comparison of its predicted 
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druggable proteins in an HIV genome with known HIV targets. This genome was 
selected because it was one of the most extensively explored genomes for finding 
therapeutic targets, and it was highly likely that all of the potential targets in this 
genome have been identified [244]. The NCBI [13] HIV-1 genome entry NC_001802, 
with none of its encoded protein sequences used in the SVM training and testing sets, 
was used for this test, and the results are given in Table 5-3.  
There are 4 successful and 7 research targets in HIV-1 genome. SVM was able to 
predict 2 successful and 6 research targets as druggable. Overall, 72% of the known 
successful and research targets and 100% of the non-targets were correctly predicted. 
This prediction accuracy was consistently similar to that of the five-fold cross 
validation study. These three tests seem to indicate that SVM has some potential for 
facilitating the identification of druggable proteins from genomic data. The prediction 
accuracy for druggable proteins needs to be improved. One reason for the lower 
accuracy of druggable proteins is the large imbalance between the number of 
druggable and non-druggable proteins. Such a large imbalance is known to affect the 
accuracy of a SVM prediction system and methods for solving these problems are 
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Table 5-3: Comparison of the known HIV-1 protein targets and the SVM predicted 
druggable proteins in the NCBI HIV-1 genome entry NC_001802  
Protein in HIV-1 genome NCBI protein 
accession number 
Target status SVM prediction 
status 
Gag-Pol NP_057849.4   
Gag-Pol Transframe peptide NP_787043.1   
Pol NP_789740.1   
protease NP_705926.1 Successful target Druggable 
reverse transcriptase NP_705927.1 Successful target Druggable 
reverse transcriptase p51 subunit NP_789739.1   
integrase NP_705928.1 Research target Druggable 
Gag NP_057850.1 Research target Druggable 
matrix NP_579876.2   
capsid NP_579880.1   
p2 NP_579882.1   
nucleocapsid NP_579881.1 Research target Druggable 
p1 NP_787042.1   
p6 NP_579883.1   
Vif NP_057851.1 Research target Druggable 
Vpr NP_057852.2   
Tat NP_057853.1 Successful target  
Rev NP_057854.1   
Vpu NP_057855.1   
Envelope surface glycoprotein gp160 NP_057856.1 Research target Druggable 
envelope signal peptide  NP_579893.2   
Envelope surface glycoprotein gp120 NP_579894.2 Research target  
Envelope transmembrane glycoprotein gp41 NP_579895.1 Successful target  
Nef NP_057857.2 Research target Druggable 
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6 Computational analysis of drug ADME- 
associated proteins 
Pharmacogenetic prediction and mechanistic elucidation of individual variations of 
drug responses is important for facilitating the design of personalized drugs and 
optimum dosages. One of the keys for pharmacogenetic studies is the knowledge 
about proteins responsible for the absorption, distribution, metabolism and excretion 
(ADME) of drugs. Although the original version of ADME-associated proteins 
(ADME-AP) database [245] have provided comprehensive information about all 
classes of ADME-APs described in the literature, the information about reported 
polymorphisms and pharmacogenetic effects need to be integrated into this database. 
ADME-AP database may, therefore, serve as a useful resource for understanding the 
known ADME-APs and molecular mechanism of drug responses and facilitating the 
development of personalized medicines and optimal dosages for individuals. 
In previous chapters, the strategy of database development has been discussed. 
Similar idea was used to construct ADME-AP database. Thus, this chapter has omitted 
the details of database construction and simply introduces the new version of 
ADME-AP database. More emphasis is placed on computational analysis of 
ADME-APs and applications in drug discovery. In particular, a discussion on how to 
assess the usefulness of the relevant information for facilitating pharmacogenetic 
prediction of drug responses, and how to use computational methods to predict 
individual variations of drug responses from the polymorphisms of ADME-APs is 
included.  
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6.1 ADME-associated proteins database 
Resources that provide information about ADME-APs as well as therapeutic targets 
and ADR-related proteins are useful for facilitating the study of pharmacogenetics 
[246]. To date, a number of freely accessible web-based resources have been 
developed and described in the literature [39, 40, 72, 245]. One of the most important 
web-based resources about ADME-APs is ADME-AP database, which is developed in 
2002 [245]. And its updated information is introduced in more detail below. 
The ADME-AP database [73, 245] provides comprehensive information about the 
known ADME-APs, the reported polymorphisms and pharmacogenetic effects. The 
updated database currently contains entries for 316 ADME-APs, 734 substrates and 
inhibitors, 1,337 polymorphisms in 121 proteins, and 327 reported cases of altered 
drug responses. The drug ADME-APs described in the literature are included in 
ADME-AP database. In addition, some transporter proteins and carrier proteins, not 
yet confirmed to play specific roles for drug ADME, are also included in this database. 
These proteins are capable of carrying or transporting small molecules, peptides and 
lipids and thus may potentially play a role in drug disposition [247-250]. Information 
in this database includes physiological function of each protein, site of action, tissue 
distributions, transport directions, driving force, substrates and inhibitors, and the 
potential effect on a drug in terms of ADME classes. While available, the reported 
polymorphisms and pharmacogenetic effects are provided. Cross-links to other 
databases are introduced to facilitate the access of information about the sequence, 3D 
structure, function, genetic disorder, nomenclature, ligand binding properties, and 
related literatures of each target.  
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Figure 6-1: Web-interface of a protein entry of ADME-AP database 
 
 
Figure 6-2: Web-interface of a polymorphism 
 
 
Figure 6-3: The detailed information of selected ADME-associated protein 
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Figure 6-1 shows the database entry of an ADME-AP. Information about specific 
polymorphism and pharmacogenetic effect is provided in separate pages illustrated in 
Figure 6-2 and Figure 6-3. Each of the ADME-APs can be assigned to different 
ADME classes, which are defined as: Class A - proteins involved in the absorption or 
re-absorption of drugs into systemic system, Class D1 - transporters of chemicals 
across membranes of various tissue barriers from the systemic system into the target 
sites, Class D2 - proteins responsible for transporting drugs back into the systemic 
system, Class M1 - phase I drug-metabolizing enzymes, Class M2 - phase II 
drug-metabolizing enzymes, and Class E - proteins that enable the excretion or 
presystemic elimination of drugs. The distribution of the protein entries in ADME-AP 
database with respect to ADME classes is as follows: There are 60 proteins in class A, 
which is mainly distributed in the intestine. A total of 176 proteins are found in class 
D (103 are in D1, 20 in D2, and 17 in D3 group respectively). Moreover, there are 36 
proteins that have not been reported to be involved in drug distribution by 
non-the-less might be potentially involved in drug distribution. These proteins are 
tentatively included in class D with a postfix “potential” added to their classification 
name. Class M includes 89 enzymes, including 45 in M1 and 44 in M2 group 
respectively. In addition, there are 30 proteins in class E.  
Proteins in ADME-AP database appear to be diversely distributed in almost all tissues. 
A substantial portion of these proteins can be found in intestine (53 proteins), kidney 
(94 proteins), liver (93 proteins) and brain (75 proteins) where they play important 
roles in ADME as well as normal function. Transporters and carriers make up the 
majority of ADME-APs. Overall, 142 out of 316 proteins are transporters, 
co-transporters, transporter-like proteins, transporter-associated proteins or carriers. 
These transporters and carriers are mainly involved in the absorption/re-absorption of 
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drugs (47 proteins), uptake of drugs into cells (74 proteins), efflux of drugs out of 
cells (11 proteins), and drug elimination (16 proteins). Enzymes constitute another 
major group of ADME-APs. There are 45 M1 and 44 M2 enzymes respectively. It is 
noted that 39 out of 45 M1 enzymes are oxidoreductases, and 39 out of 44 M2 
enzymes are transferases. No lyase or ligase is found in the database at present.  
6.2 ADME-associated proteins database as a resource 
for facilitating pharmacogenetics research 
A great number of freely accessible web-based resources provide plentiful 
information about studies of pharmacogenetics of drug response [251]. Up to date, 
many studies have explored the possibility of using polymorphisms as indicators of 
specific drug responses [252-256]. Computational methods have been developed for 
analyzing complex genetic, expression and environmental data to determine the 
association between drug response and the profiles of polymorphism, expression and 
environmental factors [257-259] and to derive pharmacogenetic predictors of 
individual variations of drug response [259, 260].  
6.2.1 Information sources of ADME-associated proteins 
Drug metabolism is associated with the interaction of a drug with specific 
metabolizing enzymes [261]. In certain cases, drug absorption, delivery and excretion 
is facilitated by drug binding to transporters and carriers [247]. Information about 
some of the ADME-APs can thus be obtained from specialized databases and websites 
focusing on specific class or group of transporters, carriers and metabolizing 
enzymes.  
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Table 6-1: Summary of web-resources of ADME-related proteins 
Web-Resource and URL Information 
TP-search transporter database 
(http://www.tp-search.jp) 
A database on drug transporters, which 
attract a great deal of attention in 
pharmacokinetics research field  
49 Human ATP-Binding Cassette Transporters  
(http://nutrigene.4t.com/humanabc.htm) 




Sequence, structure, and evolution of ABC 
transporters  
ABC transporters database  
(http://www.genome.ad.jp/kegg/ortholog/tab02010.html) 
Information on ABC transporter families  
ABC-Transporter Genes in HUGO Gene Nomenclature 
Committee 
(http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html) 
Nomenclature and sequence of ABC 
transporter genes  
Human Intestinal Transport System 
(http://bigfoot.med.unc.edu/watkinsLab/website/hEnt.htm) 
Information on human intestinal transport 
system proteins, substrates, and inhibitors  
Human Membrane Transporter Database (HMTD) 
(http://lab.digibench.net/transporter/) 
Information on human membrane 
transporters for drug transport studies and 
pharmacogenomics 
Transporter Classification database (TCDB) 
(http://www.tcdb.org/) 
Comprehensive info of IUBMB approved 
classification system of membrane transport 
proteins  
Human Cytochrome P450 (CYP) Alleles Database 
(http://www.imm.ki.se/CYPalleles/) 
Comprehensive info about Cytochrome 
P450 (CYP) Allele  
Chytochrome P450 Homepage of Nelson’s Lab 
(http://drnelson.utmem.edu/CytochromeP450.html) 
Integrated info of P450 enzymes (including 
animals, lower eukaryotes, plants, bacteria 
and archaebacteria)  
Cytochrome P450 family in HUGO Gene Nomenclature 
Committee 
(http://www.gene.ucl.ac.uk/nomenclature/genefamily/cyp.php) 
Nomenclature and sequence of  
Cytochrome P450 family genes  
Directory of P450-containing Systems 
(http://www.icgeb.trieste.it/~p450srv/) 




An introduction to CYP and its importance in 
clinical medicine  
UDP Glucuronosyltransferase database 
(http://som.flinders.edu.au/FUSA/ClinPharm/UGT/) 
Information on UDP 
glucuronosyltransferases  
UDP glycosyltransferases in HUGO Gene Nomenclature 
Committee 
(http://www.gene.ucl.ac.uk/nomenclature/genefamily/ugt.php) 
Nomenclature and sequence of  UDP 
glucuronosyltransferases genes 
Arylamine N-Acetyltransferase (NAT) Nomenclature 
(http://www.louisville.edu/medschool/pharmacology/NAT.html) 
Information on Arylamine N-Acyltransferase 
(NAT) polymorphisms and nomenclature 
ADME-Associated Protein database (ADME-AP) 
(http://bidd.nus.edu.sg/group/admeap/admeap.asp) 
Comprehensive info of ADME-associated 
proteins 
dbSNP at NCBI 
(http://www.ncbi.nlm.nih.gov/SNP/) 
Information on single nucleotide 
polymorphism in genes, including those of 
ADME associated proteins 
PharmGKB database 
(http://www.pharmgkb.org/index.jsp) 
Integrated data of variation in human genes 
and response to drugs, including those of 
ADME associated proteins 
GeneSNPs at the Utah Genome Center   
(http://www.genome.utah.edu/genesnps/) 
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These databases normally provide general information about sequence, structure and 
biochemical characteristics of specific classes of proteins. However, the majority of 
them are not intended for pharmacokinetic and pharmacogenetic studies, and some of 
the data relevant to the pharmacogenetic studies are not provided. Examples of these 
data are polymorphism, variants, ligands (substrates, inducers, inhibitors, etc.), related 
diseases, and related drug response. Such types of data are beginning to be added in 
existing and newly emerging databases. Table 6-1 summaries useful freely-accessible 
internet resources, which are relevant to drug ADME-APs [40, 73, 245]. 
TP-search transporter database [262] is useful resource of drug transporters, 
drug-drug interactions, gender differences, and pathophysiology. There are plans to 
add information about genetic polymorphisms and related genetic diseases into this 
database. Transporter Classification database (TCDB) is another comprehensive 
source for IUBMB approved classification system of membrane transport proteins 
[263]. The Human Intestinal Transport System website (Watkins Lab, University of 
North Carolina at Chapel Hill) provides substrates, activators and inhibitors of 
P-glycoprotein, hOATP and other transporters in epithelial cells. A website of the 49 
Human ATP-Binding Cassette (ABC) Transporters for the P-glycoprotein 
nomenclature (Allikmets R, et al, Frederick Cancer Research and Development 
Center, USA) includes 49 human ABC transporter genes with information about 
related genetic diseases, tissue distribution, and substrates. ABC transporter database 
(KEGG, Kyoto University, Japan) gives comprehensive information about ABC 
families of transporters. Other useful websites are ABC-Transporter Genes 
(University College London, UK) which gives the nomenclature and sequence of 
ABC transporter genes, and ABCISSE database (Institute Pasteur, France) which 
provides information about the sequence, structure, and evolution of ABC 
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transporters. 
The Cytochrome P450 Homepage of Nelson’s Lab (Nelson D, University of 
Tennessee, USA) includes 2,383 P450s from different species. It provides sequences, 
phylogenetic trees, and hyperlinks to other databases. The Directory of 
P450-Containing Systems (Degtyarenko KN, et al; International Centre for Genetic 
Engineering and Biotechnology, Italy) provides access to internet resources of P450 
proteins, P450-containing systems, steroid ligands known to bind to P450 and 
cross-links to a number of sequence, structure and function databases. UDP 
Glucuronosyltransferase home page (Committee for naming UDP 
Glucuronosyltransferases, Flinders University, Australia) gives detailed information 
about the sequence, multiple alignments, neighbor joining tree, and human alleles of 
UDP Glucuronosyltransferase. 
Information about polymorphism of ADME-APs and possible links to variations of 
drug responses can be obtained from general genomics databases and those 
specializing in pharmacokinetics- and ADME-APs. Home page of the Human 
Cytochrome P450 (CYP) Allele Nomenclature Committee (http://www.imm.ki.se/ 
CYPalleles/default.htm) provides comprehensive information about the genetic 
polymorphisms of 22 CYP alleles. The dbSNP database (NCBI, USA) provides 
comprehensive information about single nucleotide polymorphism (SNP) data for 29 
organisms including human. It currently contains over 20 million SNP entries and 
over 8.9 million of these have been validated. GeneSNPs (University of Utah, USA) 
is a web resource that integrates gene, sequence and polymorphism data into 
individually annotated gene models. The human genes included are related to DNA 
repair, cell cycle control, cell signaling, cell division, homeostasis and metabolism, 
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and are thought to play a role in susceptibility to environmental exposure. PharmGKB 
database [264] is a central repository for genetic and clinical information about people 
who have participated in research studies at various medical centers in the PGRN. In 
addition, genomic data, molecular and cellular phenotype data, and clinical phenotype 
data are accepted from the scientific community at large. These data are organized and 
the relationships between genes and drugs are categorized into the categories of 
clinical outcome, pharmacodynamics and drug responses, pharmacokinetics, and 
molecular and cellular functional assays.  
As indicated in previous sections, ADME-AP database [40, 73, 245] is also a useful 
resource not only for providing comprehensive information about the known 
ADME-APs, but also for obtaining pharmacogenetic data which currently contains 
information about 1,337 polymorphisms in 121 ADME- APs and 327 reported cases 
of altered drug responses. 
6.2.2 Reported polymorphisms of ADME-associated proteins 
Current progress in investigating pharmacogenomic polymorphisms of 
pharmacokinetic origin can be revealed from the analysis of the literature-reported 
polymorphisms of ADME-APs. A comprehensive search of the abstracts of Medline 
database [77] identified 1,337 SNPs in the coding regions, and a total of 13189 SNPs 
in all of the coding, non-coding and regulatory regions of 121 ADME-APs reported in 
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ber of reported 
SNPs in coding region 
Total Num
ber of 




ABCA4 D1 Transporter of retinoids 219 593 
cAMP-dependent chloride 
channel CFTR D2 Transport of chloride ions 175 503 
ATP-binding cassette 
sub-family D member 1 ABCD1 D A possible transporter 125 843 
Copper-transporting 
ATPase 2 ATP7B E Export of copper out of the cells 125 196 




ABCC6 E Transporter of glutathione conjugates and drug efflux 37 430 
ATP-binding cassette, 
sub-family A, member 1 ABCA1 D2 
Camp-dependent and sulfonylurea-sensitive transporter 
of anions 34 709 
Sulfonylurea receptor 1 ABCC8 D2 Regulator of ATP-sensitive k+ channels and insulin release 28 344 
Cytochrome P450 2D6 CYP2D6 M1 
Metabolizing enzyme for structurally unrelated 
compounds (steroids, fatty acids, and xenobiotics) and 
drugs (antiarrhythmics, antidepressants and 
beta-blockers) 
18 51 
Cytochrome P450 3A4 CYP3A4 M1 
Metabolizing enzyme for structurally unrelated 
compounds (steroids, fatty acids, and xenobiotics) and 
over 50% of drugs 
17 129 
UDP-glucuronosyl- 
transferase 1A1 UGT1A1 M2 
Enzyme responsible for conjugation and subsequent 
elimination of xenobiotics and endogenous compounds 17 65 
Copper-transporting 
ATPase 1 ATP7A D2 Transporter of copper to copper-requiring proteins 17 98 
Solute carrier family 21 
member 6 SLCO1B1 A 
Sodium-independent transporter of cystine and neutral 
and dibasic amino acids 15 418 
Neutral and basic amino 
acid transport protein 
rBAT 
SLC3A1 A; D1 
Na(+)-independent transporter of organic anions 
(pravastatin, estrone sulfate, prostaglandin e2, 
thromboxane b2, leukotriene c3, thyroxine) 
15 145 
Cytochrome P450 1B1 CYP1B1 M1 
Metabolizing enzyme for structurally unrelated 
compounds (steroids, fatty acids, and xenobiotics) and 
an unknown molecule in eye development 
14 85 
Dimethylaniline 
monooxygenase FMO3 D1 
Metabolizing enzyme of various xenobiotics such as 




SLC12A3 A Transporter mediating sodium and chloride reabsorption 13 231 
Sodium-dependent 
noradrenaline transporter SLC6A2 D1 Sodium-dependent reuptake of noradrenaline 13 219 
Antigen peptide 
transporter 1 TAP1 D2 
Transporter of antigens from cytoplasm to a 
membrane-bound compartment 10 66 
Multidrug resistance- 
associated protein 1 ABCC1 
D2;
E 
Energy-dependent efflux pump transporting drugs into 
subcellular organelles 9 807 
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Bile salt export pump 
(ATP-binding cassette, 
sub-family B, member 11) 
ABCB11 E ATP-dependent secretion of bile salts into the canaliculus of hepatocytes 9 464 
Cytochrome P450 1A1 CYP1A1 M1 Metabolizing enzyme for structurally unrelated compounds (steroids, fatty acids, and xenobiotics) 9 38 
Cytochrome P450 2C8 CYP2C8 M1 Metabolizing enzyme for structurally unrelated compounds (steroids, fatty acids, and xenobiotics) 9 208 
Arylamine 
N-acetyltransferase 1 NAT1 M2 
Enzyme catalyzing the n- or o-acetylation of various 
arylamine and heterocyclic amine substrates 9 384 
B(0,+)-type amino acid 
transporter 1 SLC7A9 A 
Transporter of cystine, and neutral and dibasic amino 
acids. 9 158 
Antigen peptide 
transporter 2 TAP2 D2 
Transporter of antigens from the cytoplasm to a 
membrane-bound compartment 8 210 
Arylamine 
N-acetyltransferase 2 NAT2 M2 
Enzyme catalyzing the n- or o-acetylation of various 




FMO2 M1 Enzyme catalyzing the n-oxidation of certain primary alkylamines to their oximes 8 214 
Sodium/iodide 
cotransporter SLC5A5 D1 Iodide uptake in the thyroid gland 8 58 
Solute carrier family 2 
(Glucose transporter type 
1, erythrocyte/ brain) 
SLC2A1 D1 Basal and growth factor-stimulated transporter of glucose and aldoses 8 167 
Multidrug resistance- 
associated protein 2 ABCC2 
D2;
E Hepatobiliary excretion of numerous organic anions 8 239 
Steroidogenic acute 
regulatory protein STAR D1 
Protein enhancing the metabolism of cholesterol into 
pregnenolone, involved in transport of cholesterol 8 212 
Multidrug resistance 
protein 1 ABCB1 
D2;
E 
Energy-dependent efflux pump transporting drugs into 
subcellular organelles 8 445 
Cytochrome P450 2B6 CYP2B6 M1 Metabolizing enzyme for structurally unrelated compounds (steroids, fatty acids, and xenobiotics) 7 162 
Dihydropyrimidine 
dehydrogenase DPYD M1 Enzyme involved in the reduction of uracil and thymine 7 1983 
Prostacyclin synthase PTGIS M1 Enzyme catalyzing the isomerization of prostaglandin h2 to prostacyclin 7 276 
Thiopurine 
S-methyltransferase TPMT M2 Enzyme catalyzing the s-methylation of thiopurine drugs 7 102 
Mitochondrial ornithine 
transporter 1 SLC25A15 D Ornithine transporter 7 88 
Organic cation/carnitine 
transporter 2 SLC22A5 A Transporter of organic cations 6 123 
Epoxide hydrolase 1 EPHX1 M1 Enzyme catalyzing the hydrolysis of arene and aliphatic epoxides 6 111 
Cytochrome P450 2C9 CYP2C9 M1 Metabolizing enzyme for structurally unrelated compounds (steroids, fatty acids, and xenobiotics) 6 248 
Prostaglandin G/H 
synthase 2 PTGS2 M1 
Likely a major mediator of inflammation and/or a role for 
prostanoid signaling 6 150 
Cytochrome P450 2A6 CYP2A6 M1 
Metabolizing enzyme for structurally unrelated 
compounds (steroids, fatty acids, and xenobiotics) and 
anti-cancer drugs (cyclophosphamide and ifosphamide) 
5 91 
Cytochrome P450 4F2 CYP4F2 M1 Metabolizing enzyme for structurally unrelated compounds (steroids, fatty acids, and xenobiotics) 5 208 
Potential phospholipid- 
transporting ATPase ATP8B1 A Transporter of aminophospholipids 5 307 
Sulfate transporter SLC26A2 A; D1 Transporter of sulfate 5 62 
Cytochrome P450 2J2 CYP2J2 M1 Metabolizing enzyme for arachidonic acid 5 193 
* Including SNPs in coding, non-coding, and regulatory regions 
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Mutations arising from coding regions may lead to altered protein structure, and 
polymorphisms in non-coding and regulatory regions such as promoters may 
influence the level of expression, inducibility, and post-transcription processing, 
thereby affecting the functional roles of these ADME-APs. Most of these proteins are 
important drug transporters such as multidrug resistance-associated proteins [265] and 
metabolizing enzymes such as cytochrome P450s [66, 266] and UDP-glucuronosyl- 
transferases [267]. 
Examples of proteins containing a higher number of reported coding region SNPs are 
retinal-specific ATP-binding cassette transporter with 219 variants, cAMP-dependent 
chloride channel with 175 variants, adrenoleukodystrophy protein with 125 variants, 
copper-transporting ATPase 2 with 125 variants, serum albumin with 64 variants, 
multidrug resistance-associated protein 6 with 37 variants, ATP-binding cassette 
sub-family A member 1 protein with 34 variants, cytochrome P450 2D6 with 18 
variants, cytochrome P450 3A4 with 17 variants, multidrug resistance-associated 
protein 1 with 17 variants, UDP-glucuronosyltransferase A with 17 variants, 
copper-transporting ATPase 1 with 17 variants, solute carrier family 21 member 6 
protein with 15 variants, neutral and basic amino acid transport protein rBAT with 15 
variants, and cytochrome P450 1B1 with 14 variants.  
Examples of proteins containing a higher number of reported SNPs in their respective 
coding, non-coding and regulatory regions are dihydropyrimidine dehydrogenase with 
1983 SNPs, ATP-binding cassette sub-family D member 1 with 843 SNPs, multidrug 
resistance-associated protein 1 with 807 SNPs, ATP-binding cassette, sub-family A 
member 1 with 709 SNPs, retinal-specific ATP-binding cassette transporter with 593 
SNPs, cAMP-dependent chloride channel with 503 SNPs, bile salt export pump 
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(ATP-binding cassette, sub-family B, member 11) with 464 SNPs, multidrug 
resistance protein 1 with 445 SNPs, multidrug resistance-associated protein 6 with 
430 SNPs, and solute carrier family 21 member 6 with 418 SNPs.  
6.2.3 ADME-associated proteins linked to reported drug 
response variations  
The role of specific ADME-APs in pharmacogenetics can be probed from its 
relationship with the reported drug response variations. Table 6-3 gives 35 
ADME-APs that have been linked to the reported variations in drug response, many 
of which are drug metabolizing enzymes [66] and multidrug resistance-associated 
proteins [265]. The altered drug responses include both altered pharmacological effect 
and altered kinetics.  
Examples of proteins linked to the reported variations in drug response are 
cytochrome P450 2D6 which are associated with variations for 61 drugs, multidrug 
resistance protein 1 for 25 drugs, cytochrome P450 2C19 for 22 drugs, cytochrome 
P450 2C9 for 22 drugs, arylamine N-acetyltransferase 2 for 17 drugs, cytochrome 
P450 3A4 for 18 drugs, sodium-dependent serotonin transporter for 9 drugs, 
cytochrome P450 1A2 for 13 drugs, cytochrome P450 2E1 for 12 drugs, thiopurine 
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Table 6-3: Examples of ADME-associated proteins linked to reported cases of 
individual variations in drug response 
Drugs with altered response*  






ber of drugs 
List of Drugs 
Cytochrome P450 2D6  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) and drugs 
(antiarrhythmics, antidepressants 
and beta-blockers) 
61 Alprenolol, Amiodarone, Amitriptyline, 
Bufuralol, Carbamazepine, Carvedilol, 
Chlorpromazine, Clarithromycin, 




Ethylmorphine, Flecainide, Fluoxetine, 
Fluvoxamine, Guanoxan, Haloperidol, 
Hydrocodone, Imipramine, Losartan, 
Maprotiline, Maprotyline, 
Methoxyamphetamine, Metoprolol, 





Phenformin, Phenformine, Phenytoin, 
Propafenone, Propranolol, 
Resperidone, Risperidone, Ritinovir, 
Simvastatin, S-Mianserin, Sparteine, 
Tamoxifen, Theophylline, Thioridazine, 
Timolol, Tramadol, Trazodon, 
Tropisetron, Venlafaxine, Venlafazine 
Multidrug resistance 
protein 1  
(ABCB1 or MDR1) 
D2;
E 
Energy-dependent efflux pump 
transporting drugs into subcellular 
organelles 
25 Amiodarone, Cefazolin, Cefotetan, 
Cis-flupenthixol, Cyclosporin A, 
Cyclosporine, Digoxin, Diltiazem, 
Efavirenz, Fexofenadine, Indinavir, 
Irinotecan,  Mitoxantrone, Morphine, 
Nelfinavir, Nicardipine, Nortriptyline, 
Ondansetron, Phenytoin, Quinidine, 
Tacrolimus, Tamoxifen, Topotecan, 
Trifluperazine, Verapamil   
Cytochrome P450 
2C19  
M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) and 
anticonvulsant drugs 
22 Citalopram, Clarithromycin, Diazepam, 
Difebarbamate, Febarbamate, 




Phenytoin, Proguanil, Propranolol, 
Rifampin, Sertraline, Valproate, 
Warfarin, Zonisamide 
Cytochrome P450 2C9  M1 Matabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) and many 
polar drugs (ibuprofen, naproxen, 
diclofenac and sulphaphenazole) 
22 Diclofenac, Fluoxetine, Glibenclamide, 
Glimepiride, Glipazide, Glipizide, 
Glyburide, Ibuprofen, Imipramine, 
Irbesartan, Isoniazid, Lornoxicam , 
Losartan, Naproxen, Nateglinide , 
Phenytoin, Piroxicam, Rifampin, 
Tenoxicam, Tolbutamide, Verapamil, 
Warfarin 
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Cytochrome P450 3A4  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) and over 
50% of drugs. 
18 Carbamazepine, Cisapride, 
Clonazepam, Cyclophosphamide, 
Cyclosporin A, Ethosuximide, 
Etoposide, Ganaxolone, Ifosphamide, 
Midazolam, Paclitaxel, Phenytoin, 
Tacrolimus, Teniposide, Tiagabine, 




M2 Enzyme catalyzing the n- or 
o-acetylation of various arylamine 
and heterocyclic amine substrates.  
17 Amonafide, Amonifide, Amrinone, 
Caffeine, Dapson, Dapsone, 
DiHydralazine, Hydralazine, Isoniazid, 





Cytochrome P450 1A2  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) 
13 Amonafide, Carbamazepine, Diltiazem, 
Erythromycin, Fluoxetine, Imipramine, 
Isoniazid, Naproxen, Nortriptyline 
hydrochloride, Phenytoin, Rifampin, 
Theophylline, Verapamil 
Cytochrome P450 2E1  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics), and certain 
precarcinogens, drugs and solvents. 
12 Alcohol, Diepoxybutane, Ethanol, 





serotonin transporter  
(5-HTT) 
D1 Sodium-dependent reuptake of 
serotonine into presynaptic terminals. 
9 Citalopram, Clomipramine, 
Fenfluramine, Fluoxetine, 
Fluvoxamine, Lithium, Nortriptyline, 
Paroxetine, Sertraline 
UDP-glucuronosyl-tran
sferase 1A1 (UGT1A1)  
M2 Enzyme responsible for conjugation 
and elimination of xenobiotics and 
endogenous compounds.  
7 Bilirubin (endogenous), Irinotecan, 
Estradiol, Tranilast, Etoposide, 
Atazanavir, Indinavir 
Glutathione 
S-transferase Mu 1 
(GSTM1) 
M2 Enzyme responsible for conjugation 
of reduced glutathione to exogenous 
and endogenous hydrophobic 
electrophiles. 
6 5-fluorouracil, Cyclophosphamide, 
Doxorubicin, D-penicillamine, Platinum, 
Tacrine 
Glutathione 
S-transferase theta 1  
(GSTT1) 
M2 Enzyme responsible for conjugation 
of reduced glutathione to exogenous 
and endogenous hydrophobic 
electrophiles. 
6 5-fluorouracil, Cyclophosphamide, 
Doxorubicin, Diepoxybutane, Platinum, 
Tacrine 
Cytochrome P450 2A6  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) and 
anti-cancer drugs 
(cyclophosphamide and ifosphamide) 
6 Carbamazepine, Coumarin, 





M2 Enzyme for o-methylating and 
inactivating catecholamine 
neurotransmitters and catechol 
hormones 





M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) 





M2 Enzyme catalyzing the s-methylation 
of thiopurine drugs such as 
6-mercaptopurine. 
4 Azathioprine, Azathiopurin, 
Thioguanine (6-Thioguanine), 
Mercaptopurine (6-Mercaptopurine) 
Cytochrome P450 2C8  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics), arachidonic 
acid, and anti-cancer drug paclitaxel 
4 Carbamazepine, Paclitaxel, Phenytoin, 
Trimethadione 
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(taxol)] 
Cytochrome P450 3A5  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) 
4 Cyclosporine, Tacrolimus, Phenytoin, 
Zonisamide 
Cytochrome P450 2B6  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics)  
4 Cyclophosphamide, Mephobarbital, 
Phenytoin, Valproate 
ATP-binding cassette 
sub-family G member 
2 (ABCG2 or BCRP) 
D2;
E 
Xenobiotic transporter involved in the 
multidrug resistance phenotype of a 
specific mcf-7 breast cancer cell line 
4 Diflomotecan, Irinotecan, mitoxantrone, 
topotecan 
UDP-glucuronosyl-tran
sferase 2B7  
(UGT2B7) 
M2 Enzyme responsible for conjugation 
and elimination of xenobiotics and 
endogenous compounds. 
2 Epirubicin, Irinotecan 
Amine oxidase 
[flavin-containing] A  
(MAOA)  
M1 Enzyme catalyzing the oxidative 
deamination of biogenic and 
xenobiotic amines 
2 Fluvoxamine, Moclobemide 
Arylamine 
N-acetyl-transferase 1  
(NAT1) 
M2 Enzyme catalyzing the n- or 
o-acetylation of various arylamine 
and heterocyclic amine substrates 





M1 Enzyme catalyzing the reduction of 
uracil and thymine 
1 Fluorouracil (5-Fluorouracil)  
Sulfonylurea receptor 
1 
D2 Regulator of ATP-sensitive k+ 
channels and insulin release. 
1 Tolbutamide 
Cytochrome P450 3A7  M1 Metabolizing enzyme for structurally 
unrelated compounds (steroids, fatty 
acids, and xenobiotics) 
1 Phenytoin 
ATP-binding cassette, 
sub-family A, member 
1 (ABCA1) 
D2 Camp-dependent and 
sulfonylurea-sensitive transportor of 
anions. 
1 Fluvastatin 
Epoxide hydrolase 1 
(EH) 
M1 Enzyme catalyzing the hydrolysis of 
arene and aliphatic epoxides to less 






D1 Sodium-dependent reuptake of 








Energy-dependent efflux pump 
transporting drugs into subcellular 
organelles 
1 Doxorubicin 
Liver carboxylesterase  M1 Enzyme hydrolyzing aromatic and 
aliphatic esters 
1 SN-38 (from the prodrug irinotecan) 
NAD(P)H 
dehydrogenase 
[quinone] 1 (NQO1 or 
DT-diaphorase) 
M1 Enzyme responsible for conjugation 




[NADPH] 1 (Carbonyl 
reductase 1) 
M1 Enzyme catalyzing the reduction of 








Transporter acting as an organic 
anion pump 
1 Azidothymidine 
Excitatory amino acid 
transporter 2 (EAAT2) 
D1 Transporter of l-glutamate and also l- 
and d-aspartate 
1 3-Nitropropionic acid 
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Cytochrome P450 2D6 is responsible for the metabolism of most psychoactive drugs 
and it accounts for 20-30% of drugs metabolized by all cytochrome P450 enzymes 
[266]. It metabolizes drugs for several diseases including depression, psychosis, 
cancer, and pain. Changes in the metabolism of these drugs are expected to have a 
significant impact on the level of toxic effects as well as therapeutic effects induced 
by these drugs. Thus it is not surprising that this enzyme affects the response of a 
large number of drugs. Examples of other cytochrome P450 enzymes affecting a wide 
spectrum of drugs are CYP2C9 [268], which metabolizes 10% drugs and affects drugs 
for depression, cardiovascular, and epilepsy, and CYP2C19, which metabolizes 5% 
drugs and affects drugs for depression and ulcer [268]. Although CYP3A4 is known 
to metabolize 40-45% of drugs, there has been insufficient study about the clinical 
effects of the polymorphisms of this enzyme [266]. 
Multidrug resistance protein 1, which affects the response to the second largest 
number of drugs, is an energy-dependent cellular efflux protein responsible for the 
efflux of a wide spectrum of drugs including bilirubin, some anticancer agents, 
cardiac glycosides, immunosuppressive agents, glucocorticoids, HIV-1 protease 
inhibitors [269-271]. It plays important roles in the excretion of xenobiotics and 
metabolites into urine, bile, and intestine lumen [272, 273]. It also limits the 
accumulation of many drugs in the brain including digoxin, ivermectin, vinblastine, 
dexamethasone, cyclosporine, domperidone, and loperamide [272-274]. 
6.2.4 Development of rule-based prediction system 
Established links between polymorphisms of ADME-APs and individual drug 
responses have been used in combination with genetic studies as indicators for 
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predicting individual variations of drug response [252-256]. Based on the analysis of 
clinical samples of the variation of drug response and the results of genetic analysis of 
the participating patients, simple rules can be derived for the prediction of individual 
variations of drug response from the polymorphism of specific protein [252, 253, 255] 
or combination of polymorphisms of multiple proteins [275, 276]. Experimental 
techniques capable of differentiating between a single wild-type sequence and mutant 
sequences can then be used to detect these polymorphisms and predict drug response. 
 
Figure 6-4: The flow chart of development of rule-based prediction system  
 
 
Figure 6-4 describes the process of developing rule-based prediction system. Firstly, a 
sample sequence is conducted to do sequence similarity search by using BLAST [240]. 
The searched results are then introduced to compare with mutation information 
collected in ADME-APs database. Several mutations occurring in sample sequence 
are confirmed and they are searched in pharmacogenetic effects library integrated in 
ADME-APs database. Based on the rules generated in advance, the matched mutation 
can be used to predict possible drug responses. In this flow chart, there are two key 
components in this process. One is about database construction, which has been 
discussed in previous sections. The other is about rules generation. Generally, the 









Mutation c … 
Comparing with 










Comparing with mutation 
information 
Chapter 6                          Computational analysis of Drug ADME-Associated Proteins 
 
 - 155 - 
rules can also be some numeric profiles generated by computational methods and 
interpreted by computer. 
6.2.4.1 Rule-based prediction of drug responses from the 
polymorphisms of ADME-associated proteins 
Established links between polymorphisms of ADME-APs and individual drug 
responses have been used in combination with genetic studies as indicators for 
predicting individual variations of drug response [252-256]. Based on the analysis of 
clinical samples of the variation of drug response and the results of genetic analysis of 
the participating patients, simple rules can be derived for the prediction of individual 
variations of drug response from the polymorphism of specific protein [252, 253, 255] 
or combination of polymorphisms of multiple proteins [275, 276]. Experimental 
techniques capable of differentiating between a single wild-type sequence and mutant 
sequences can then be used to detect these polymorphisms and predict drug response. 
The simple rules generated and applied in these studies may be collected and used for 
developing a computer prediction system in a similar fashion like that of the HIV drug 
resistant genotype interpretation systems [277]. Table 6-4 gives examples of the 
ADME-APs with a known pharmacogenetic polymorphism and a reasonably accurate 
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Table 6-4: Prediction of specific drug responses from the polymorphisms of ADME 
associated proteins by using simple rules 




Polymorphism Rules and 















polymorphism in CYP1A2 
gene, 2000 [278] 
85 69% 
CYP2C9*2 genotype, 2004 
[279] 
61 26% Cytochrome 
P450 2C9 
Anticoagulant 
agents for the 

























drug side effects 













2005 [256]  

























Homozygosity for a 
(TA)7-repeat element 
within the promotor region 
of UGT1A1 gene, 2004 
[252] 
146 40% 
NAT2*5A allele, 1997 [283] 18 89% 





the treatment of 
infections in infants 
Idiosyncratic 
reactions such 














NAT2*4 allele, 2000 [284] 76 53% 
N-acetyl-tran
sferase 2 









SA type (NAT2*6/*6, 
NAT2*6/*7, and 
NAT2*7/*7), 2002 [254] 
6 83% 
A218C A/C phenotypes, 
2001 [285] 
107 76% 





















T allele of the NET T182C 





inhibitors for the 
Antidepressant 
response 
s/s genotype of serotonin 
transporter gene promoter 
11-72 54% at 6th 
week 
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region, 2000-2004 [59, 60, 
282, 286] 
s/l genotype of serotonin 
transporter gene promoter 
region, 2000-2004 [59, 60, 
282, 286]  




l/l genotype of serotonin 
transporter gene promoter 
region, 2000-2004 [59, 60, 
282, 286]  
4-16 48% at 6th 
week 
ABCB1 C3435T C/C 
genotype, 2003 [287] 
73 75% 
ABCB1 C3435T C/T 






Epileptic drugs for 




ABCB1 C3435T T/T 
genotype, 2003 [287] 
73 53% 
MDR1 C3435T C/C 
genotype, 2005 [288] 














week 8 MDR1 C3435T C/T 
genotype, 2005 [288] 
33 91% 
 
The reported prediction accuracy for the patients with specific polymorphism reported 
in the literature is also given. Based on the test of the patients described in these 
reports, most of these rules are capable of predicting drug responses at accuracies of 
50%~100%, which are not too much lower than and in many cases comparable to the 
accuracies of 81%~97% for predicting HIV drug resistance mutations from the HIV 
resistant genotype interpretation systems [277]. This suggests that these simple rules 
have certain level of capacity for facilitating pharmacogenetic prediction of drug 
response and they may be used as the basis for developing more sophisticated 
interpretation systems like those of HIV resistant genotype interpretation systems 
[277].   
Variation of response to some drugs is known to be associated with interactions 
between genetic polymorphisms in more than one protein [275, 276]. For instance, 
specific polymorphisms in cytochrome P450 7A1 (CYP7A1) and ATP-binding 
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cassette transporters G5 and G6 (ABCG5/G6) are known to affect LDL 
cholesterol-lowering response to atorvastatin. The combination of the polymorphisms 
in CYP7A1 and ABCG5/G6 explained a greater percentage of response variations 
(8.5%) than the single polymorphism in each of these proteins (4.2% in CYP7A1 and 
3.0% in ABCG5/G6) [276]. Therefore, in such cases, simple rules based on single 
polymorphism in one protein are insufficient for predicting individual variations of 
drug responses. Rules that take into consideration of complex interaction of 
polymorphisms in multiple proteins [275, 276], gene expression patterns [258], and 
environmental factors [259] likely give more accurate prediction ranges and accuracy. 
Some of the pharmacogenetic studies have been based on a limited number of 
samples and the derived data may show various degrees of deviations. For instance, in 
a systematic review of the literature on the influence of polymorphisms in the 
serotonin transporter gene on SSRI response, it was found that both the investigation 
methodologies and research outcomes showed large heterogeneity, which led to the 
conclusion that the current information is insufficiently reliable as a basis for 
implementing pharmacogenetic testing of depressive patients [59, 60, 282, 286]. This 
is not surprising when the neurochemistry of the drugs is considered. Increased 
synaptic availability of serotonin is known to stimulate a large number of 
post-synaptic receptors yet down-regulate others. Therefore, the relevant data may 
need to be interpreted cautiously [289] particularly in applying them for 
pharmacogenetic prediction of individual variation of drug response. 
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6.2.4.2 Computational methods for analysis and prediction of 
pharmacogenetics of drug responses from the polymorphisms 
of ADME-associated proteins 
The complex pharmacogenetic interactions of proteins [275, 276], complicated 
microarray-based gene expression profiles [258], and multitude of patient data 
(physical conditions, medications, food consumptions, outdoor activities etc.) [259] 
used in pharmacogenetic analysis and prediction of drug responses require the 
application of more sophisticated statistical analysis and statistical learning methods 
than those of simple rule-based and linear methods [257-260]. Table 6-5 summarizes 
the computational methods recently explored for pharmacogenetic prediction of drug 
responses. These methods include discriminant analysis (DA) [259], unconditional 
logistic regression [284], random regression model [290], conditional logistic 
regression, 2004 [260], artificial neural networks (ANN) [257, 259], and maximum 
likelihood context model from haplotype structure provided by HapMap [291]. 
Table 6-5: Statistical analysis and statistical learning methods used for 
pharmacogenetic prediction of drug responses 
Method and 
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DA determines a linear combination of input feature variables and forms a linear 
discriminate function which could provide the maximum degree of distinction among 
the different drug response groups [259]. RRM attempts to explain the relationship 
between the drug responses and their pharmacogenetic origins by constructing a 
statistical model that fits to the multi-variable data [290]. Logistic regression 
(conditional and unconditional) produces a prediction equation by determining 
regression coefficients which measure the predictive capability of the input 
independent variables [260, 284]. It predicts the occurrence possibility of an event 
which could be interpreted as the ratio of the probability of the occurrence of a 
particular pharmacogenetic event to that without the event. 
ANN trains a hidden-layer-containing network and uses its outcomes for pattern 
recognition and classification of the input feature vectors [292, 293], with each vector 
representing various data of a patient. A classifier for ANN is ∑=
j
jj hwgy 0 , where 
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jw0  is the output weight of a hidden node j  to an output node, g  is the output 
function, jh  is the value of a hidden layer node: )(∑ +=
j
jjjij wxwh δ , jiw  is the 
input weight from an input node i  to a hidden node j , jw  is the threshold weight 
from an input node of value 1 to a hidden node j , and δ  is a sigmoid function. 
Known resistance and non-resistance samples are used for training an ANN such that 
all the weights are determined, and the resulting classifier can be used for determining 
whether or not a new input data of a patient responds to a drug. 
The haplotype structures of HapMap reveal variation patterns in DNA sequences, 
from which a statistical model can be developed to directly characterize specific DNA 
sequence variants responsible for drug response [291]. One such model has been 
developed in the maximum likelihood context, which is represented by clinically 
meaningful mathematical functions modeling drug response and is implemented by an 
integrative EM algorithm.  
The application and performance of statistical analysis and statistical learning 
methods depends on several factors including knowledge of related proteins, 
availability of sequence and polymorphism data, establishment of quantitative 
relationship between polymorphism and drug response from sufficient number of 
patients, and appropriate representation of genetic polymorphisms and other 
properties such as expression profiles and environmental factors. For instance, a 
sufficiently diverse set of response and non-response samples is needed for training a 
sophisticated statistical learning system such as ANN and SVMs which have been 
successfully applied for predicting drug resistance mutations directly from protein 
sequence [251]. Thus these methods are not applicable for proteins and drugs with 
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little or no polymorphism and drug response data. Mining of polymorphism and drug 
response data from the literature [294-296] and other sources [73, 245, 264], is a key 
to more extensive exploration of statistical learning methods as well as rule-based 
methods for pharmacogenetic prediction of individual variations of drug responses. 
6.3 Conclusion  
Knowledge about ADME-APs, polymorphisms and drug responses appears to have 
reached a meaningful level to facilitate pharmacogenetic prediction of various types 
of individual variations of drug responses. Internet sites such as the ADME-AP 
database and PharmGKB database serve as convenient resources for obtaining the 
relevant information. With the rapid development of genomics [32], pharmacokinetics 
[297-300], and pharmacogenomics [64, 66, 67], more information about ADME-APs, 
polymorphisms and variations of drug responses are expected to become available. 
Moreover, progress in the study of proteomics [31] and pathways [301] related to 
drug ADME-APs is expected to further facilitate our understanding of the mechanism 
of drug disposition and their possible contribution to individual variations in drug 
response.  
Both rule-based methods and statistical learning methods have consistently shown a 
promising capability for predicting individual variations of drug responses from 
polymorphisms of ADME-APs as well as those of therapeutic targets and 
ADR-related proteins. The availability of more comprehensive information about 
ADME-APs, polymorphisms and variations of drug responses will further extend the 
range of the application of these methods. It is expected that rules and methods that 
predict individual variations of drug responses on the basis of complex 
pharmacogenetic interactions will be more extensively explored. Methods that 
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improve the prediction accuracy in cases of imbalanced datasets, such as those with 
too small number of drug respondents, are being developed [302] and these may be 
applied to further improve the accuracy of drug responses.
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7 Conclusion 
In the post-genomic age, multi-disciplinary bioinformatics approaches are widely used 
to advance drug discovery. In this regard, the objective of this study were to develop 
and update three related pharmainformatics databases, namely, TTD, TRMP database, 
and ADME-AP database.  
In the new version of TTD, the number of reported targets was increased to 1,535. Not 
only much additional relevant information has been included in the database to provide 
more comprehensive knowledge about the therapeutic targets, but also the data 
structure has been rearranged and the web interface has been rewritten to facilitate the 
better search of targets and corresponding drug/ligand, and disease information. 
Likewise, TRMP database has been developed to understand comprehensively the 
relationship between different targets of the same disease and facilitate mechanistic 
study of drug actions. It contains 11 entries of multiple pathways, 97 entries of 
individual pathways, 120 targets covering 72 disease conditions together with 120 sets 
of drugs directed at each of these targets. Also, information about 1,337 polymorphisms 
in 121 proteins, and 327 drugs with altered responses linked to ADME-APs has been 
added into the new version of ADME-AP database. By studying pharmacogenetic data, 
we find it could be feasible to do pharmacogenetic prediction of drug responses and 
individual variations from the polymorphisms of ADME-APs.  
Consequently, these databases provide comprehensive information of known 
therapeutic targets, pathways, and ADME-APs and can serve as platforms to the 
scientific understanding of therapeutically relevant events. Particularly, knowledge of 
targets is helpful for molecular dissection of the mechanism of action of drugs, and for 
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predicting features that guide new drug design and the search for new targets. Based on 
therapeutic targets relevant profiles and their characteristics described in earlier 
investigations [37, 195], the following simple rules were derived for characterizing 
druggable proteins: 
z The druggable protein is from one of the target-representing protein families. 
z Sequence variation between the drug-binding domain of a druggable protein and 
those of the other human members of its protein family needs to allow sufficient 
degree of differential binding of a “rule-of-five” molecule to the common binding 
site. 
z The druggable protein is preferable to have less than 15 human similarity proteins 
outside its family (HSP).  
z The druggable protein is preferable to be involved in no more than 3 pathways in 
human (HP). 
z For organ or tissue specific diseases, the druggable protein is preferable to be 
distributed in no more than 5 tissues in human (HT).  
z A higher number of HSP, HP and HT does not preclude the protein as a potential 
target, it statistically increase the chance of unwanted interferences and the level of 
difficulty for finding viable drugs. 
Furthermore, a SVM prediction system, which was developed by using 1,174 targets 
and 12,956 non-druggable proteins from 6,856 non-target families, was constructed to 
predict possible therapeutic targets. Its estimated prediction accuracy was 69.8% and 
99.3% for druggable and non-druggable proteins respectively, based on a 5-fold cross 
validation study. In addition, to test its potential for practical applications, the 
constructed SVM prediction system was used to scan the human, yeast, and HIV 
genomes to identify potential druggable proteins that were not in the training and 
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testing sets. The results suggested that statistical learning methods such as SVM would 
be potentially useful for facilitating genome search for druggable proteins.  
In conclusion, this study provided knowledge platforms to facilitate pharmaceutical 
research by developing several useful databases, studied the possibilities of predicting 
pharmacogenetic effects from the polymorphisms of ADME-APs, and constructed a 
feasible prediction system to search potential candidates for therapeutic targets. Also, 
some limitations about the research are discussed here. According to the generated 
“rules” in the previous section, several limitations are listed as follows: 
z The rules are generated from the statistics of the 1,535 currently known targets. 
z The number of known successful targets is limited. 
z The research targets need to be proved as successful targets in further clinical 
experiments. 
z The annotation of many protein targets needs to be completed.   
Therefore, the “rules” listed here are rough rules, which can be considered as a 
flexible profile to facilitate the search of druggable proteins. The feasibility of these 
rules is still waiting to be proven. Furthermore, with the development of modern 
biological technologies, more and more targets discovered by experiments will be 
added into the database, which would require generation of more elaborate rules from 
more comprehensive data. Eventually, the rules will play an important role in 
shortening the procedure of target discovery and speeding up the whole drug 
discovery. In addition, the prediction accuracy for druggable proteins needs to be 
improved. One reason for the lower accuracy of druggable proteins is the large 
imbalance between the number of druggable and non-druggable proteins. Such a large 
imbalance is known to affect the accuracy of a SVM prediction system.  
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In future research, there are several aspects that can be studied. Firstly, reliable data is 
the key to successful prediction. Thus, targets and non-targets should be chosen more 
strictly from the clinical experiment reports according to their different 
pharmacological properties, physical and chemical properties. Besides, since drug 
discovery is a fast growing area with many different communities internationally. The 
standards of America for drug designs and trials, or drug patents can be rather 
different from those of Europe and Asia. As a result, future work should be extended 
to study those marketed drug approved by other communities. Secondly, knowledge 
about therapeutic pathways as well as that of drug targets and ADME-APs should be 
used in analysis of mechanism of drug action and disease relevant events, especially 
on the aspect of relationships between drugs, targets and diseases. As a result, future 
work should pay more attention to understand the therapeutic targets and ADME-APs 
in overall views. That is to say, it would be better put them into a specific pathologic 
context for study, rather than consider them individually. Thirdly, regarding database 
development, an open architecture with the databases should be added to facilitate 
public to submit entries missed by our databases. The new submitted data can be 
manually checked in further and filled into the databases. Moreover, effective text 
mining technique also needs to be explored to facilitate information collection. 
Fourthly, the kernel function plays an important role in SVM prediction. Therefore, in 
order to effectively improve the prediction accuracy, the SVM kernel function, kernel 
KBF, should be further modified to address specified problem, druggable proteins 
prediction. In addition, other kernels, such as kernel PCA, kernel ICA, or introducing 
text kernel, should be explored in future research. Finally, although Support Vector 
Machine (SVM) methods have many advantages in huge data classification, they have 
a few disadvantages inherently, such as inability to handle the imbalance data properly, 
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inability to distinguish the predominant features, and working as a black box. As a 
consequence, other effective prediction systems (neural networks, consensus model, 
QSAR, etc.) should be explored as complements to SVM for classifying imbalance 
data. 
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APPENDIX A 
Some examples of druggable proteins selected by human genome screening: 
 
2',3'-cyclic nucleotide 3'-phosphodiesterase Immunoglobulin alpha Fc receptor 
40S ribosomal protein S12 Intercellular adhesion molecule-1 
40 kDa peptidyl-prolyl cis-trans isomerase Inositol polyphosphate 1-phosphatase 
5-hydroxytryptamine 5A receptor Inositol-1(or 4)-monophosphatase 
5-hydroxytryptamine 6 receptor Insulin receptor substrate-1 
69 kDa islet cell autoantigen Insulin-like growth factor binding protein 1 
72 kDa type IV collagenase Integrin-linked protein kinase 1 
92 kDa type IV collagenase Interferon regulatory factor 1 
Acetyl-CoA carboxylase 1 Interleukin-1 beta convertase 
Aconitate hydratase, mitochondrial Junction plakoglobin 
Acylamino-acid-releasing enzyme Kallikrein 6 
Adenosine kinase Kallikrein 7 
Adenosylhomocysteinase Keratin, type I cytoskeletal 19 
Adenylate cyclase, type II Kinesin-like protein KIF11 
Adipocyte-derived leucine aminopeptidase Kininogen 
Adiponectin Kynureninase 
Adrenocorticotropic hormone receptor Lactadherin 
Adenosine A3 receptor Lactase-phlorizin hydrolase 
Bile acid receptor Lactosylceramide alpha-2,3-sialyltransferase 
B1 bradykinin receptor Melanoma-associated antigen 4 
B2 bradykinin receptor Membrane copper amine oxidase 
Baculoviral IAP repeat-containing protein 4 Metabotropic glutamate receptor 1 
Baculoviral IAP repeat-containing protein 5 Myeloperoxidase 
Bax inhibitor-1 Myotubularin-related protein 1 
Beta crystallin B1 NAD(P)H dehydrogenase [quinone] 1 
Beta platelet-derived growth factor receptor Neprilysin 
Beta-3 adrenergic receptor Neural-cadherin 
Beta-adrenergic receptor kinase 1 Neuroendocrine convertase 1 
Beta-catenin Neuroendocrine convertase 2 
Calgranulin D Neurogenic locus notch homolog protein 1 
Calmodulin Nigral tachykinin NK(3) receptor 
cAMP response element binding protein Oncostatin M 
Cell division protein kinase 9 Orexin 
cathepsin B Orexin receptor type 1 
multidrug resistance-associated protein 2 Ornithine aminotransferase, mitochondrial 
Cannabinoid receptor 1 Orphan nuclear receptor DAX-1 
Delta-aminolevulinic acid dehydratase P2Y purinoceptor 6 
Delta-type opioid receptor Paired box protein Pax-5 
Deoxyhypusine synthase Presenilin 2 
Early activation antigen CD69 Prostacyclin receptor 
Ets-domain protein elk-3 Proto-oncogene C-crk 
Endothelin-converting enzyme 1 Peripheral-type benzodiazepine receptor 
Elastase 1 Phosphatidylethanolamine N-methyltransferase 
Elav-like protein 1 Prostaglandin E synthase 
Elongation factor 2 Placenta growth factor 
Endoglin Plasminogen activator inhibitor-1 
Endothelin-1 Platelet endothelial cell adhesion molecule 
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Eosinophil peroxidase Renin, renal 
Ephrin type-A receptor 2 Reticulon 4 receptor 
Fanconi anemia group F protein Retinoic acid receptor alpha 
Farnesyl-diphosphate farnesyltransferase Rhodopsin 
Fascin Rhombotin-2 
Ferrochelatase Ribosomal protein S6 kinase 
Fibroblast growth factor receptor 3 Ryanodine receptor 2 
fibroleukin Somatostatin receptor type 1 
Filamin A Steroid hormone receptor ERR1 
FL cytokine receptor Small inducible cytokine A2 
Folate receptor alpha Serum paraoxonase/arylesterase 1 
G2/mitotic-specific cyclin B1 Seprase 
Galanin receptor type 1 Serine protease hepsin 
Gamma-synuclein Suppressor of tumorigenicity 14 
Gap junction alpha-1 protein Synaptosomal-associated protein 25 
Gastric inhibitory polypeptide T-box transcription factor TBX21 
Gastrin/cholecystokinin type B receptor T-cell-specific surface glycoprotein CD28 
Gastrin-releasing peptide receptor Telomerase reverse transcriptase 
Glucagon receptor Tenascin 
Glucagon-like peptide 1 receptor Thioredoxin 
Glucose-6-phosphatase Ubiquitin-protein ligase E3A 
Heat shock 27 kDa protein UDP-glucose 4-epimerase 
Heat shock factor protein 1 Urotensin II receptor 
Guanylyl cyclase C vascular endothelial growth factor B 
Heme oxygenase 1 Vascular endothelial growth factor receptor 2 
Heparin cofactor II Vascular endothelial-cadherin 
Heparin-binding growth factor 1 Vasoactive intestinal polypeptide receptor 1 
Heparin-binding growth factor 2 Vasopressin V1a receptor 
Hepatocyte growth factor Wilms' tumor protein 
Hepatocyte growth factor receptor Xaa-Pro dipeptidase 
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